CA2529729A1 - New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions - Google Patents
New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions Download PDFInfo
- Publication number
- CA2529729A1 CA2529729A1 CA002529729A CA2529729A CA2529729A1 CA 2529729 A1 CA2529729 A1 CA 2529729A1 CA 002529729 A CA002529729 A CA 002529729A CA 2529729 A CA2529729 A CA 2529729A CA 2529729 A1 CA2529729 A1 CA 2529729A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- alkyl
- amino
- benzo
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- JXXWJMUPNZDILL-UHFFFAOYSA-N imidazo[4,5-b]pyridin-2-one Chemical class C1=CC=NC2=NC(=O)N=C21 JXXWJMUPNZDILL-UHFFFAOYSA-N 0.000 title abstract description 4
- HCYYBBFWNWACCL-UHFFFAOYSA-N imidazo[4,5-c]pyridazin-3-one Chemical compound N1=NC(=O)C=C2N=CN=C21 HCYYBBFWNWACCL-UHFFFAOYSA-N 0.000 title abstract description 4
- 238000002360 preparation method Methods 0.000 title description 16
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 16
- -1 piperidin-1-yl-carbonylamino, morpholin-4-yl-carbonylamino, piperazin-1-yl-carbonylamino Chemical group 0.000 claims description 507
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 148
- 150000001875 compounds Chemical class 0.000 claims description 53
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 40
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 37
- 125000005605 benzo group Chemical group 0.000 claims description 35
- 229910052757 nitrogen Inorganic materials 0.000 claims description 29
- 125000004432 carbon atom Chemical group C* 0.000 claims description 27
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 26
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 claims description 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 23
- 229910052731 fluorine Inorganic materials 0.000 claims description 23
- 239000011737 fluorine Substances 0.000 claims description 23
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 22
- 229910052801 chlorine Inorganic materials 0.000 claims description 22
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 22
- 239000000460 chlorine Substances 0.000 claims description 20
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 19
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 18
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 17
- 229910052794 bromium Inorganic materials 0.000 claims description 15
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 14
- 125000003277 amino group Chemical group 0.000 claims description 13
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 12
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 11
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 11
- 229910052740 iodine Inorganic materials 0.000 claims description 11
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 125000000623 heterocyclic group Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 claims description 7
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical class 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 6
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 claims description 4
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- KPZJECGHVCREDA-UHFFFAOYSA-N 2-(3-aminopiperidin-1-yl)-3-but-2-ynyl-5-(phenanthren-9-ylmethyl)imidazo[4,5-d]pyridazin-4-one Chemical compound N=1C=2C=NN(CC=3C4=CC=CC=C4C4=CC=CC=C4C=3)C(=O)C=2N(CC#CC)C=1N1CCCC(N)C1 KPZJECGHVCREDA-UHFFFAOYSA-N 0.000 claims description 3
- ZLDCNHMFWIWKSR-UHFFFAOYSA-N 2-(3-aminopiperidin-1-yl)-3-but-2-ynyl-5-(phenanthridin-6-ylmethyl)imidazo[4,5-d]pyridazin-4-one Chemical compound N=1C=2C=NN(CC=3C4=CC=CC=C4C4=CC=CC=C4N=3)C(=O)C=2N(CC#CC)C=1N1CCCC(N)C1 ZLDCNHMFWIWKSR-UHFFFAOYSA-N 0.000 claims description 3
- FULFHYLXDHXRPI-HXUWFJFHSA-N 2-[(3r)-3-aminopiperidin-1-yl]-3-but-2-ynyl-7-methyl-5-(phenanthridin-6-ylmethyl)imidazo[4,5-d]pyridazin-4-one Chemical compound N=1C=2C(C)=NN(CC=3C4=CC=CC=C4C4=CC=CC=C4N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 FULFHYLXDHXRPI-HXUWFJFHSA-N 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 claims description 3
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 claims description 3
- XVYVYYCBAYMRDS-OAHLLOKOSA-N 2-[[2-[(3r)-3-aminopiperidin-1-yl]-3-but-2-ynyl-4-oxoimidazo[4,5-d]pyridazin-5-yl]methyl]-1h-quinazolin-4-one Chemical compound N=1C=2C=NN(CC=3NC(=O)C4=CC=CC=C4N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 XVYVYYCBAYMRDS-OAHLLOKOSA-N 0.000 claims description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 102000055006 Calcitonin Human genes 0.000 claims description 2
- 108060001064 Calcitonin Proteins 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 125000003342 alkenyl group Chemical class 0.000 claims description 2
- 125000000304 alkynyl group Chemical class 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
- 229960004015 calcitonin Drugs 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000006223 tetrahydrofuranylmethyl group Chemical group 0.000 claims description 2
- 125000006173 tetrahydropyranylmethyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 71
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 14
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 13
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims 13
- 125000006576 di-(C1-C3-alkyl)-aminocarbonyl group Chemical group 0.000 claims 4
- 125000006563 (C1-3) alkylaminocarbonyl group Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 125000006602 (C1-C3) alkylsulfonylamino group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- YHLSSNDCCKCCDZ-HXUWFJFHSA-N 2-[(3r)-3-aminopiperidin-1-yl]-5-(benzo[b][1,4]benzoxazepin-6-ylmethyl)-3-but-2-ynyl-7-methylimidazo[4,5-d]pyridazin-4-one Chemical compound N=1C=2C(C)=NN(CC=3C4=CC=CC=C4OC4=CC=CC=C4N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 YHLSSNDCCKCCDZ-HXUWFJFHSA-N 0.000 claims 2
- ZEPKFVIFLHUZKL-LJQANCHMSA-N 2-[(3r)-3-aminopiperidin-1-yl]-5-(benzo[b][1,4]benzoxazepin-6-ylmethyl)-3-but-2-ynylimidazo[4,5-d]pyridazin-4-one Chemical compound N=1C=2C=NN(CC=3C4=CC=CC=C4OC4=CC=CC=C4N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 ZEPKFVIFLHUZKL-LJQANCHMSA-N 0.000 claims 2
- TUCKVYWUWFIYEG-GOSISDBHSA-N 2-[(3r)-3-aminopiperidin-1-yl]-5-(benzo[e][1,3]benzoxazol-2-ylmethyl)-3-but-2-ynylimidazo[4,5-d]pyridazin-4-one Chemical compound N=1C=2C=NN(CC=3OC4=C(C5=CC=CC=C5C=C4)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 TUCKVYWUWFIYEG-GOSISDBHSA-N 0.000 claims 2
- WXOVMIAWNIFSGN-GOSISDBHSA-N 2-[(3r)-3-aminopiperidin-1-yl]-5-(benzo[g][1,3]benzoxazol-2-ylmethyl)-3-but-2-ynylimidazo[4,5-d]pyridazin-4-one Chemical compound N=1C=2C=NN(CC=3OC4=C5C=CC=CC5=CC=C4N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 WXOVMIAWNIFSGN-GOSISDBHSA-N 0.000 claims 2
- ZEPKFVIFLHUZKL-IBGZPJMESA-N 2-[(3s)-3-aminopiperidin-1-yl]-5-(benzo[b][1,4]benzoxazepin-6-ylmethyl)-3-but-2-ynylimidazo[4,5-d]pyridazin-4-one Chemical compound N=1C=2C=NN(CC=3C4=CC=CC=C4OC4=CC=CC=C4N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@H](N)C1 ZEPKFVIFLHUZKL-IBGZPJMESA-N 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000006597 (C1-C3) alkylcarbonylamino group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 13
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 238000001819 mass spectrum Methods 0.000 description 38
- 239000013543 active substance Substances 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- CICPLKAJEGYYGM-UHFFFAOYSA-N 3h-pyridazin-4-one Chemical compound O=C1CN=NC=C1 CICPLKAJEGYYGM-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 235000002639 sodium chloride Nutrition 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 10
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 125000004430 oxygen atom Chemical group O* 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 229920002261 Corn starch Polymers 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 229960004132 diethyl ether Drugs 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- PPNFWYUJXHAZIN-UHFFFAOYSA-N imidazo[4,5-c]pyridin-4-one Chemical compound O=C1N=CC=C2N=CN=C12 PPNFWYUJXHAZIN-UHFFFAOYSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102100040918 Pro-glucagon Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LNNXOEHOXSYWLD-UHFFFAOYSA-N 1-bromobut-2-yne Chemical compound CC#CCBr LNNXOEHOXSYWLD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NBUVTNBHLKLAGN-UHFFFAOYSA-N 5-acetyl-1h-imidazole-4-carbonitrile Chemical compound CC(=O)C=1N=CNC=1C#N NBUVTNBHLKLAGN-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 125000002785 azepinyl group Chemical group 0.000 description 2
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- JMXUWJPKHDKROF-UHFFFAOYSA-N dimethyl 2-bromo-1h-imidazole-4,5-dicarboxylate Chemical compound COC(=O)C=1N=C(Br)NC=1C(=O)OC JMXUWJPKHDKROF-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- KVOVCEPPQJRTOB-UHFFFAOYSA-N imidazo[4,5-d]pyridazin-4-one Chemical compound O=C1N=NC=C2N=CN=C12 KVOVCEPPQJRTOB-UHFFFAOYSA-N 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 210000002660 insulin-secreting cell Anatomy 0.000 description 2
- 125000004254 isoquinolin-1-yl group Chemical group [H]C1=C([H])C2=C([H])C([H])=C([H])C([H])=C2C(*)=N1 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- ZWYGMXZYHYANIY-UHFFFAOYSA-N methyl 2-bromo-5-(1-hydroxy-2-nitroethyl)-3-(3-methylbut-2-enyl)imidazole-4-carboxylate Chemical compound COC(=O)C1=C(C(O)C[N+]([O-])=O)N=C(Br)N1CC=C(C)C ZWYGMXZYHYANIY-UHFFFAOYSA-N 0.000 description 2
- DGGMIKCBWOJCTC-UHFFFAOYSA-N methyl 2-bromo-5-formyl-3-(3-methylbut-2-enyl)imidazole-4-carboxylate Chemical compound COC(=O)C1=C(C=O)N=C(Br)N1CC=C(C)C DGGMIKCBWOJCTC-UHFFFAOYSA-N 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229940075966 (+)- menthol Drugs 0.000 description 1
- NOOLISFMXDJSKH-AEJSXWLSSA-N (+)-menthol Chemical compound CC(C)[C@H]1CC[C@H](C)C[C@@H]1O NOOLISFMXDJSKH-AEJSXWLSSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- XGDRLCRGKUCBQL-UHFFFAOYSA-N 1h-imidazole-4,5-dicarbonitrile Chemical compound N#CC=1N=CNC=1C#N XGDRLCRGKUCBQL-UHFFFAOYSA-N 0.000 description 1
- OLEGUVZMYFIHMO-UHFFFAOYSA-N 2,3-dihydro-1,5-benzothiazepine Chemical compound S1CCC=NC2=CC=CC=C21 OLEGUVZMYFIHMO-UHFFFAOYSA-N 0.000 description 1
- FFFBNHHENIOTBP-UHFFFAOYSA-N 2,3-dihydro-1,5-benzoxazepine Chemical compound O1CCC=NC2=CC=CC=C21 FFFBNHHENIOTBP-UHFFFAOYSA-N 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- QPKNFEVLZVJGBM-UHFFFAOYSA-N 2-aminonaphthalen-1-ol Chemical compound C1=CC=CC2=C(O)C(N)=CC=C21 QPKNFEVLZVJGBM-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- WZGLJVVIKYVQLG-UHFFFAOYSA-N 2-bromo-7-hydroxy-3-(3-methylbut-2-enyl)-6,7-dihydro-5h-imidazo[4,5-c]pyridin-4-one Chemical compound OC1CNC(=O)C2=C1N=C(Br)N2CC=C(C)C WZGLJVVIKYVQLG-UHFFFAOYSA-N 0.000 description 1
- URFKLQSFBXBOQU-UHFFFAOYSA-N 2-chloro-1,1,1-triethoxyethane Chemical compound CCOC(CCl)(OCC)OCC URFKLQSFBXBOQU-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- DSZCQHJBMSIMNX-UHFFFAOYSA-N 3,6-dihydroimidazo[4,5-d]pyridazin-7-one Chemical compound O=C1NN=CC2=C1N=CN2 DSZCQHJBMSIMNX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- SSPYBJYEUFNDGW-UHFFFAOYSA-N 5-formyl-1h-imidazole-4-carboxylic acid Chemical compound OC(=O)C=1NC=NC=1C=O SSPYBJYEUFNDGW-UHFFFAOYSA-N 0.000 description 1
- USJALFVAJSYMSN-UHFFFAOYSA-N 5h-benzo[c][1]benzazepine-6,11-dione Chemical compound O=C1NC2=CC=CC=C2C(=O)C2=CC=CC=C12 USJALFVAJSYMSN-UHFFFAOYSA-N 0.000 description 1
- ZKZWBESHZSNYRI-UHFFFAOYSA-N 6-(chloromethyl)benzo[b][1,4]benzoxazepine Chemical compound ClCC1=NC2=CC=CC=C2OC2=CC=CC=C12 ZKZWBESHZSNYRI-UHFFFAOYSA-N 0.000 description 1
- ARZPFOVROXWUDU-UHFFFAOYSA-N 7-methyl-3h-imidazo[4,5-d]pyridazin-4-amine Chemical compound CC1=NN=C(N)C2=C1N=CN2 ARZPFOVROXWUDU-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007733 Catabolic state Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
- 108091007911 GSKs Proteins 0.000 description 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100030488 HEAT repeat-containing protein 6 Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 1
- 101000990566 Homo sapiens HEAT repeat-containing protein 6 Proteins 0.000 description 1
- 101000801684 Homo sapiens Phospholipid-transporting ATPase ABCA1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 101710204865 Tyrosine-protein phosphatase 1 Proteins 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- VWFLSBXIOIZAFT-UHFFFAOYSA-N chembl2029512 Chemical compound CC1=NNC(=O)C2=C1N=CN2 VWFLSBXIOIZAFT-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 125000004145 cyclopenten-1-yl group Chemical group [H]C1=C(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- CUIWFAXEALIQJS-UHFFFAOYSA-N dimethyl 1h-imidazole-4,5-dicarboxylate Chemical compound COC(=O)C=1N=CNC=1C(=O)OC CUIWFAXEALIQJS-UHFFFAOYSA-N 0.000 description 1
- CWMHVLJIBJQGBT-UHFFFAOYSA-N dimethyl 2-bromo-3-(3-methylbut-2-enyl)-1,2-dihydroimidazole-4,5-dicarboxylate Chemical compound COC(=O)C1=C(C(=O)OC)N(CC=C(C)C)C(Br)N1 CWMHVLJIBJQGBT-UHFFFAOYSA-N 0.000 description 1
- MMXSXXFZAMURGQ-UHFFFAOYSA-N dimethyl 2-bromo-3-but-2-ynyl-1,2-dihydroimidazole-4,5-dicarboxylate Chemical compound COC(=O)C1=C(C(=O)OC)N(CC#CC)C(Br)N1 MMXSXXFZAMURGQ-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- YHTGVGXZFPGAFZ-UHFFFAOYSA-N methyl 2-bromo-3-but-2-ynyl-5-formylimidazole-4-carboxylate Chemical compound COC(=O)C1=C(C=O)N=C(Br)N1CC#CC YHTGVGXZFPGAFZ-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- JKNKNWJNCOJPLI-UHFFFAOYSA-N o-phthalaldehydic acid Chemical compound C1=CC=C2C(O)OC(=O)C2=C1 JKNKNWJNCOJPLI-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004260 quinazolin-2-yl group Chemical group [H]C1=NC(*)=NC2=C1C([H])=C([H])C([H])=C2[H] 0.000 description 1
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- WUOQXNWMYLFAHT-UHFFFAOYSA-N tert-butyl n-piperidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCCNC1 WUOQXNWMYLFAHT-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula (I), wherein Y and R1 to R4 are defined as indicated in claim 1, the tautomers, enantiomers, diastereomers, mixtures, and salts thereof that have valuable pharmacological properties, especially an inhibiting effect on the activity of the dipeptidyl peptidase IV (DPP-IV) enzyme.
Description
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 8431 Offt New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions The present invention relates to new substituted imidazopyridazinones and imidazopyridones of general formula Rs R1~N N
I I ~ R4 N
the tautomers, the enantiomers, the diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV), the preparation thereof, the use thereof for the prevention or treatment of diseases or conditions associated with an increased DPP-IV activity or capable of being prevented or alleviated by reducing the DPP-IV
activity, particularly type I or type II diabetes mellitus, the pharmaceutical compositions containing a compound of general formula (I) or a physiologically acceptable salt thereof as well as processes for the preparation thereof.
The present invention thus relates to the above compounds of general formula I
which have valuable pharmacological properties, the pharmaceutical compositions containing the pharmacologically effective compounds, the use thereof and processes for the preparation thereof.
In the above general formula I
R' denotes a C~_3-alkyl group substituted by a group Ra, where Boehringer Ingelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text Ra denotes a 3,4-dihydro-quinolinyl, 3,4-dihydro-isoquinolinyl, 1,4-dihydro-quinazolinyl, 3,4-dihydro-quinazolinyl, 1H-benzo[dJ[1,2]oxazinyl, 4H-benzo[e][1,3]oxazinyl, 4H-benzo[off[1,3]oxazinyl or 2H-benzo[1,4]oxazinyl group, wherein in each case in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocyclyl moiety a methylene group may be replaced by a carbonyl group, a 4H-benzo[e][1,3]thiazinyl, 4H-benzo[d][1,3]thiazinyl or 2H-benzo [1,4]thia-zinyl group wherein in each case in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocyclyl moiety a methylene group may be replaced by a carbonyl group and the sulphur atom may be replaced by a sulphinyl or sulphonyl group, a 2-oxo-2H-benzo[e][1,3]oxazinyl or 2,2-dioxo-1H-benzo[c][1,2]thiazinyl group wherein in each case in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom, a 2,3-dihydro-1H-benzo[e][1,4]diazepinyl, 4,5-dihydro-3H-benzo[bJ[1,4]diaze-piny! or 5-oxo-4,5-dihydro-3H-benzo[e][1,4]diazepinyl group wherein in each case in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocyclyl moiety a methylene group may be replaced by a carbonyl group, a 2,3-dihydro-benzo[~[1,4]oxazepinyl or 2,3-dihydro-benzo[b][1,4]oxazepinyl group wherein in each case Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocyclyl moiety a methylene group may be replaced by a carbonyl group, a 2,3-dihydro-benzo[b][1,4]thiazepinyl or 2,3-dihydro-benzo[tj[1,4]thiazepinyl group wherein in each case in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocyclyl moiety a methylene group may be replaced by a carbonyl group and the sulphur atom may be replaced by a sulphinyl or sulphonyl group, a 5-oxo-4,5-dihydro-benzo[t][1,3,4]oxadiazepinyl group wherein in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom, a 11H-dibenzo[b,e]azepinyl or 5H-dibenzo[a,d]cycloheptenyl group wherein in each case in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and the methylene group in the heterocyclyl moiety may be replaced by an oxygen or sulphur atom, a carbonyl, sulphinyl or sulphonyl group or by an imino group substituted by RX, where RX denotes a hydrogen atom or a C~~-alkyl, C2_4-alkenyl, C2_a-alkynyl, C~s-cycloalkyl, C~s-cycloalkyl-C~_3-alkyl, aryl, aryl-C~_3-alkyl, hydroxy-C2~-alkyl, C~_3-alkyloxy-C2_4-alkyl, C~s-cycfoalkyloxy-C2_4-alkyl, amino-C2~-alkyl, C~_3-alkylamino-C2~-alkyl, di-(C,_3-alkyl)-amino-C2~-alkyl, C~_3-alkyl-carbonyl, C,_3-alkyloxy-carbonyl, C~_3-alkyloxy-carbonyl-C~_3-alkyl, aryl-carbonyl, C,_3-alkyl-sulphonyl or aryl-sulphonyl group, a phenanthridinyl group wherein Boehringer Ingelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom, and a 1,2,3,4-tetrahydro-phenanthridinyl, 1,2,3,4,4a,10b-hexahydro-phenan-thridinyl, 2,3-dihydro-1 H-4-aza-cyclopenta[a]naphthyl or a 8,9,10,11-tetrahydro-7H-6-aza-cyclohepta[a]naphthyl group wherein in each case in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and one or two methylene groups may each be replaced by an oxygen atom or a carbonyl group, while, if two methylene groups are each replaced by an oxygen atom, the oxygen atoms must be separated from one another by at least two methylene units, a phenanthrenyl group wherein in each case one to three of the methyne groups in position 1 to 4 and 5 to 8 may each be replaced by a nitrogen atom, a 1,2,3,4-tetrahydro-phenanthrenyl or a 1,2,3,4,5,6,7,8-octahydro-phenanthrenyl group wherein in each case one or two of the methylene groups in position 1 to 4 and 5 to 8 may each be replaced by an oxygen atom or a carbonyl group, while, if two methylene groups are each replaced by an oxygen atom, the oxygen atoms must be separated from one another by at least two methylene units, a 5H-benza[a]pyrrolo[1,2-a][1,4]diazepinyl, thieno[3,2-b][1,4]benzoxazepinyl, 5H-dibenzo[d,t][1,3]diazepinyl or a 5-oxa-7-aza-dibenzo[a,c]cycloheptenyl group wherein in each case Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom, a naphtho[1,2-djoxazolyl, naphtho[2,1-dJoxazolyl , naphtho[1,2-dJthiazolyl, 5 naphtho[2,1-dJthiazolyl, naphtho[1,2-dJimidazolyl, naphtho[1,2-b]furanyl or naphtho[2,1-b]furanyl group wherein in each case in the naphthyl moiety one to three methyne groups may each be replaced by a nitrogen atom, or a furo[3,2-c]isoquinolinyl, pyrazolo[1,5-c]quinazolinyl or 1H-perimidinyl group, while the methylene and methyne groups of the above mentioned radicals Ra may be substituted by the groups R'° to R'3 and additionally by a Ci_3-alkyl group and the imino groups of the above mentioned radicals Ra may be substituted by the groups RX as hereinbefore defined and R'° denotes a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, a C,~-alkyl, hydroxy, or C~_4-alkyloxy group, a nitro, amino, C,_3-alkylamino, di-(C,_3-alkyl)amino, cyano-C,_3-alkylamino, N-(cyano-C~_3-alkyl)-N-(C~_3-alkyl)-amino, C~_3-alkyloxy-carbonyl-C,_3-alkylamino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, or 4-(C~_3-alkyl)-piperazin-1-yl group, a C~_3-alkyl-carbonylamino, arylcarbonylamino, aryl-C~_3-alkyl-carbonylamino, C,_3-alkyloxy-carbonylamino, aminocarbonylamino, C~_3-alkylaminocarbonylamino, di-(C,_3-alkyl)aminocarbonylamino, pyrrolidin-1-yl-carbonylamino, piperidin-1-yl-carbonylamino, morpholin-4-yl-carbonylamino, piperazin-1-yl-carbonylamino or 4-(C1_3-alkyl)-piperazin-Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 1-yl-carbonyfamino, C~_3-alkyl-sulphonylamino, bis-(C~_3-alkylsulphonyl)-amino, aminosulphonylamino, C~_3-alkylamino-sulphonylamino, di-(C~_3-alkyl)amino-sulphonylamino, pyrrolidin-1-yl-sulphonylamino, piperidin-1-yl-sulphonylamino, morpholin-4-yl-sulphonylamino, piperazin-1-yl-sulphonylamino or 4-(C~_3-alkyl)-piperazin-1-yl-sulphonylamino, (C~_3-alkylamino)thiocarbonylamino, (C~_3-alkyloxy-carbonyl-amino)carbonylamino, arylsulphonylamino or aryl-C~_3-alkyl-sulphonyl-amino group, an N-(C~_3-alkyl)-C~_3-alkyl-carbonylamino, N-(C~_3-alkyl)-arylcarbonyl-amino, N-(C~_3-alkyl)-aryl-C~_3-alkyl-carbonylamino, N-(C~_3-alkyl)-C~_3-alkyloxy-carbonylamino, N-(aminocarbonyl)-C~_3-alkylamino, N-(C~_3-alkyl-aminocarbonyl)-C~_3-alkylamino , N-[di-(C~_3-aikyl)aminocarbonyl]-C~_3-alkylamino, N-(C~_3-alkyl)-C~_3-alkyl-sulphonylamino, N-(C~_3-alkyl)-arylsulphonylamino, or N-(C~_3-alkyl)-aryl-C~_3-alkyl-sulphonylamino group, a 2-oxo-imidazolidin-1-yf, 2,4-dioxo-imidazolidin-1-yl, 2,5-dioxo-imidazolidin-1-yl or 2-oxo-hexahydropyrimidin-1-yl group wherein the nitrogen atom in the 3 position may be substituted in each case by a methyl or ethyl group, a cyano, carboxy, C~_3-alkyloxy-carbonyl, aminocarbonyl, C~_3-alkyl-aminocarbonyl, di-(C~_3-alkyl)-aminocarbonyl, pyrrolidin-1-yl-carbonyl, piperidin-1-yl-carbonyl, morpholin-4-yl-carbonyl, piperazin-1-yl-carbonyl or 4-(C~_3-alkyl)-piperazin-1-yl-carbonyl group, a C~_3-alkyl-carbonyl or an arylcarbonyl group, a carboxy-Cy_3-alkyl, C~_3-alkyloxy-carbonyl-C,_3-alkyl, cyano-C,-3-alkyl, aminocarbonyl-C~_3-alkyl, C~_3-alkyl-aminocarbonyl-C,_3-alkyl, di-(C~_3-alkyl)-aminocarbonyl-C~_3-alkyl, pyrrolidin-1-yl-carbonyl-C~_3-alkyl, piperidin-1-yl-carbonyl-C~_3-alkyl, morpholin-4-yl-carbonyl-C~_3-alkyl, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text piperazin-1-yl-carbonyl-C~_3-alkyl or 4-(C~_3-alkyl)-piperazin-1-yl-carbonyl-C~_3-alkyl group, a carboxy-C~_3-alkyloxy, C~_3-alkyloxy-carbonyl-C~_3-alkyloxy, cyano-C~_3-alkyloxy, aminocarbonyl-C~_3-alkyloxy, C~_3-alkyl-aminocarbonyl-C~_3-alkyloxy, di-(C~-3-alkyl)-aminocarbonyl-C~_3-alkyloxy, pyrrolidin-1-yl-carbonyl-C~_3-alkyloxy, piperidin-1-yl-carbonyl-C~_3-alkyloxy, morpholin-4-yl-carbonyl-C~_3-alkyloxy, piperazin-1-yl-carbonyl-C~_3-alkyloxy or 4-(C~_3-alkyl)-piperazin-1-yl-carbonyl-C~_3-alkyloxy group, a hydroxy-C~_3-alkyl, C~_3-alkyloxy-C,_3-alkyl, amino-G~_3-alkyl, C~_3-alkylamino-C~_3-alkyl, di-(C~_3-alkyl)-amino-C~_3-alkyl, pyrrolidin-1-yl-C1_3-alkyl, piperidin-1-yl-C~-3-alkyl, morpholin-4-yl-C~_3-alkyl, piperazin-1-yl-C~_3-alkyl or 4-(C~_3-alkyl)-piperazin-1-yl-C~_3-alkyl group, a hydroxy-C~_3-alkyloxy, C~_3-alkyloxy-C~_3-alkyloxy, C~_3-alkylsulphanyl-C~_3-alkyloxy, C~_3-alkylsulphinyl-C~_3-alkyloxy, C~_3-alkylsufphonyl-C~_3-alkyloxy, amino-C~_3-alkyloxy, C~_3-alkylamino-C~_3-alkyloxy, di-(C~_3-alkyl)-amino-C~_3-alkyloxy, pyrrolidin-1-yl-C~_3-alkyloxy, piperidin-1-yl-C~_3-alkyloxy, morpholin-4-yl-C~_3-alkyloxy, piperazin-1-yl-C~_3-alkyloxy or 4-(C~_3-alkyl)-piperazin-1-yl-C~_3-alkyloxy group, a mercapto, C~_3-alkylsulphanyl, C~_3-alkysulphinyl, C~_3-alkylsulphonyl, C~_3-alkylsulphonyloxy, arylsulphonyloxy, trifluoromethylsulphanyl, trifluoromethylsulphinyl or trifluoromethylsulphonyl group, a sulpho, aminosulphonyl, C~_3-alkyl-aminosulphonyl, di-(C~_3-alkyl)-aminosulphonyl, pyrrolidin-1-yl-sulphonyl, piperidin-1-yl-sulphonyl, morpholin-4-yl-sulphonyl, piperazin-1-yl-sulphonyl or 4-(C1_3-alkyl)-piperazin-1-yl-sulphonyl group, a methyl or methoxy group substituted by 1 to 3 fluorine atoms, an ethyl or ethoxy group substituted by 1 to 5 fluorine atoms, Boehringer Ingelheim International GmbH Case 1/1502 55216 ingelheim foreign filing text a C2~-alkenyl or Cz_4-alkynyl group, a C3~-alkenyloxy or C3_4-alkynyloxy group, a C3~-cycloalkyl or C~.6-cycloalkyloxy group, a C3~-cycloalkyl-C~_3-alkyl or C3_s-cycloalkyl-C~_3-alkyloxy group or an aryl, aryloxy, aryl-C~.3-alkyl or aryl-C~_3-alkyloxy group, R" and R'2, which may be identical or different, in each case represent a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, a C~_3-alkyl, trifluoromethyl, hydroxy, C~_3-alkyloxy or cyano group, or R" together with R'2, if these are bound to adjacent carbon atoms, also denotes a methylenedioxy, difluoromethylenedioxy, ethylenedioxy or a straight-chain C3_5-alkylene group and R'3 denotes a hydrogen atom, a fluorine, chlorine or bromine atom, a trifluoromethyl, C~_3-alkyl or C~_3-alkyloxy group, R2 denotes a hydrogen, fluorine or chlorine atom, a C~~-alkyl group, a C2_4-alkenyl group, a C3~,-alkynyl group, a C3_6-cycloalkyl group, a C3~-cycloalkyl-C~_3-alkyl group, 8oehringer lngelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydro-furanylmethyl or tetrahydropyranylmethyl group, an aryl group, an aryl-C~_4-alkyl group, an aryl-CZ_3-alkenyl group, an arylcarbonyl group, an arylcarbonyl-C~_2-alkyl group, a heteroaryl group, a heteroaryl-C~_3-alkyl group, a furanylcarbonyl, thienylcarbonyl, thiazolyicarbonyl or pyridylcarbonyl group, a furanylcarbonylmethyl, thienylcarbonylmethyl, thiazolylcarbonylmethyl or pyridylcarbonylmethyl group, a C~_4-alkyl-carbonyl group, a C~_4-alkyl-carbonyl-C~_2-alkyl group, a C3~-cycloalkyl-carbonyl group, a C3_fi-cycloalkyl-carbonyl-C~_2-alkyl group, an aryl-A or aryl-A-C~_3-alkyl group, where A denotes an oxygen or sulphur atom, an imino, C~_3-alkylimino, sulphinyl or sulphonyl group, a group Rb, where Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Rb denotes a cyano, carboxy, C~_3-alkyloxy-carbonyl, aminocarbonyl, C~_3-alkylamino-carbonyl, di-(C~_3-alkyl)-amino-carbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4-5 methylpiperazin-1-ylcarbonyl, 4-ethylpiperazin-1-ylcarbonyl, hydroxy, mercapto, C~_3-alkyloxy, C~_3-alkylsulphenyl, C~_3-alkylsulphinyl, C~_3-alkyl-sulphonyl, amino, C~_3-alkylamino, di-(C~_3-alkyl)-amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl or 4-ethyl-piperazin-1-yl group, or a C~_4-alkyl group substituted by a group Rb, where Rb is as hereinbefore defined, Y denotes a nitrogen atom or a group of formula C-R5, while RS is defined like R2 and in each case one of the two groups R2 and RS
must be a hydrogen atom or a C~_3-alkyl group, R3 denotes a C3_$-alkyl group, a C~_3-alkyl group substituted by a group R~, where R~ denotes a C~~-cycloalkyl group optionally substituted by one or two C~_3-alkyl groups, a C5_~-cycloalkenyl group optionally substituted by one or two C~_3-alkyl groups, an aryl group or a furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidyl or pyrazinyl group, while the above mentioned heterocyclic groups may each be substituted by one or two C~-3-alkyl groups or by a fluorine, chlorine, bromine or iodine atom or by a trifluoromethyl, cyano or C~_3-alkyloxy group, Boehringer Ingelheim International GmbH Case 111502 55216 Ingelheim foreign filing text a C3_$-alkenyl group, a C3_s-alkenyl group substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl group, a C3_$-alkynyl group, an aryl group or an aryl-C2_4-alkenyl group, and R4 denotes an azetidin-1-yl or pyrrolidin-1-yl group which is substituted in the 3 position by an amino, C~_3-alkylamino or a di-(C,_3-alkyl)amino group and may additionally be substituted by one or two C~_3-alkyl groups, a piperidin-1-yl or hexahydroazepin-1-yl group which is substituted in the 3 position or in the 4 position by an amino, C~_3-alkylamino or a di-(C~_3-alkyl)amino group and may additionally be substituted by one or two C~_3-alkyl groups, a 3-amino-piperidin-1-yl group wherein the piperidin-1-yl moiety is additionally substituted by an aminocarbonyl, C~_2-alkyl-aminocarbonyl, di-(C~_2-alkyl)aminocarbonyl, pyrrolidin-1-yl-carbonyl, (2-cyano-pyrrolidin-1-yl-)carbonyl, thiazolidin-3-yl-carbonyl, (4-cyano-thiazolidin-3-yl)carbonyl, piperidin-1-ylcarbonyl or morpholin-4-ylcarbonyl group, a 3-amino-piperidin-1-yl group wherein the piperidin-1-yl moiety in the 4 position or in the 5 position is additionally substituted by a hydroxy or methoxy group, a 3-amino-piperidin-1-yl group wherein the methylene group in the 2 position or in the 6 position is replaced by a carbonyl group, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text a piperidin-1-yl or hexahydroazepin-1-yl group substituted in the 3 position by an amino, C~_3-alkylamino or di-(C~_3-alkyl)-amino- group, wherein in each case two hydrogen atoms on the carbon skeleton of the piperidin-1-yl or hexahydroazepin-1-yl-group are replaced by a straight-chain alkylene bridge, this bridge containing 2 to 5 carbon atoms if the two hydrogen atoms are located on the same carbon atom, or to 4 carbon atoms, if the hydrogen atoms are located on adjacent carbon atoms, or 1 to 4 carbon atoms, if the hydrogen atoms are located on carbon atoms which are separated by one atom, or 1 to 3 carbon atoms if the two hydrogen atoms are located on carbon atoms separated by two atoms, an azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl or hexahydroazepin-1-yl group which is substituted by an amino-C~_3-alkyl, C~-3-alkylamino-C~_3-alkyl or a di-(C~_3-alkyl)-amino-C,_3-alkyl group, a piperazin-1-yl or [1,4]diazepan-1-yl group optionally substituted at the carbon skeleton by one or two C~_3-alkyl groups, a 3-imino-piperazin-1-yl, 3-imino-[1,4]diazepan-1-yl or 5-imino-[1,4]diazepan-1-yl group optionally substituted at the carbon skeleton by one or two C~_3-alkyl groups, a [1,4)diazepan-1-yl group optionally substituted by one or two C~_3-alkyl groups, which is substituted in the 6 position by an amino group, a C3_~-cycloalkyl group which is substituted by an amino, C~_3-alkylamino or di-(C~_3-alkyl)-amino group, a C3_~-cycloalkyl group which is substituted by an amino-C~_3-alkyl, C~_3-alkylamino-C,_3-alkyl or a di-(C~_3-alkyl)amino-C~_3-alkyl group, a C3_~-cycloalkyl-C~_2-alkyl group wherein the cycloalkyl moiety is substituted by an amino, C,_3-alkylamino or di-(C~_3-alkyl)-amino group, a C3_~-cycloalkyl-C~_2-alkyl group wherein the cycloalkyl moiety is substituted by an amino-C~_3-alkyl, C~_3-alkylamino-C~_3-alkyl or a di-(C~_3-alkyl)amino-C,_3-alkyl group, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text a C3_~-cycloalkylamino group wherein the cycloalkyl moiety is substituted by an amino, C~_3-alkylamino or di-(C,_3-alkyl)-amino group, while the two nitrogen atoms at the cycloalkyl moiety are separated from one another by at least two carbon atoms, an N-(C3_~-cycloalkyl)-N-(C~-3-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino, C~_3-alkylamino or di-(C~_3-alkyl)-amino group, while the two nitrogen atoms at the cycloalkyl moiety are separated from one another by at least two carbon atoms, a C3_~-cycloalkylamino group wherein the cycloalkyl moiety is substituted by an amino-C~-3-alkyl, C~_3-alkylamino-C~_3-alkyl or a di-(C~_3-alkyl)amino-C~_3-alkyl group, an N-(C3_~-cycloalkyl)-N-(C~_3-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino-C~_3-alkyl, C,_3-alkylamino-C~_3-alkyl or a di-(C~_3-alkyl)amino-C~_3-alkyl group, a C3_~-cycloalkyl-C~_2-alkyl-amino group wherein the cycfoalkyl moiety is substituted by an amino, C~_3-alkylamino or di-(C~_3-alkyl)-amino group, an N-(C3_~-cycloalkyl-C~_2-alkyl)-N-(C~_2-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino, C~_3-alkylamino or di-(C~_3-alkyl)-amino group, a C3_~-cycloalkyl-C,_2-alkyl-amino group wherein the cycloalkyl moiety is substituted by an amino-C~_3-alkyl, C~_3-alkylamino-C~_3-alkyl or a di-(C~_3-alkyl)amino-C~_3-alkyl group, an N-(C3_~-cycloalkyl-C~-2-alkyl)-N-(C~_2-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino-C~_3-alkyl, C~_3-alkylamino-C~_3-alkyl or a di-(C~_3 alkyl)amino-C~_3-alkyl group, a R'9-C2_4-alkylamino group wherein R'9 is separated from the nitrogen atom of the C2_4-alkylamino moiety by at least two carbon atoms and Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text R'9 denotes an amino, C~_3-alkylamino or di-(C~_3-alkyl)-amino group, an R'9-C2_4-alkylamino group wherein the nitrogen atom of the C2_4-alkylamino moiety is substituted by a C~_3-alkyl group and R'9 is separated from the nitrogen atom of the C2_4-alkylamino moiety by at least two carbon atoms, while R'9 is as hereinbefore defined, an amino group substituted by the group R2° wherein R2° denotes an azetidin-3-yl, azetidin-2-ylmethyl, azetidin-3-ylmethyl, pyrrolidin-3-yl, pyrrolidin-2-ylmethyl, pyrrolidin-3-ylmethyl, piperidin-3-yl, piperidin-4-yl, piperidin-2-ylmethyl, piperidin-3-ylmethyl or piperidin-4-yfmethyl group, while the groups mentioned for R2° may each be substituted by one or two C~_3-alkyl groups, an amino group substituted by the group R2° and a C~_3-alkyl group wherein R2° is as hereinbefore defined, white the groups mentioned for R2° may each be substituted by one or two C~_3-alkyl groups, an R'9-C3_4-alkyl group wherein the C3_4-alkyl moiety is straight-chained and may additionally be substituted by one or two C~_3-alkyl groups, while R'9 is as hereinbefore defined, a 3-amino-2-oxo-piperidin-5-yl or 3-amino-2-oxo-1-methyl-piperidin-5-yl group, a pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, hexahydroazepin-3-yl or hexahydroazepin-4-yl group which is substituted in the 1 position by an amino, C~_3-alkylamino or di-(C~_3-alkyl)amino group, or an azetidin-2-yl-C~_2-alkyl, azetidin-3-yl-C~_2-alkyl, pyrrolidin-2-yl-C~_2-alkyl, pyrrolidin-3-yl, pyrrolidin-3-yl-C~_2-alkyl, piperidin-2-yl-C~_2-alkyl, piperidin-3-yl, piperidin-3-yl-C~_2-alkyl, piperidin-4-yl or piperidin-4-yl-C~_2-alkyl group, while the above mentioned groups may each be substituted by one or two C~_3-alkyl groups, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filin4 text while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups which may be mono- or disubstituted by Rh, while the substituents may be identical or different and R,, denotes a fluorine, chlorine, bromine or iodine atom, a trifluoromethyl, cyano, nitro, amino, aminocarbonyl, 5 aminosulphonyl, methylsulphonyl, acetylamino, methylsulphonylamino, C~_3-alkyl, cyclopropyf, ethenyl, ethynyl, hydroxy, C~_3-alkyloxy, difluoromethoxy or trifluoromethoxy group, by the heteroaryl groups mentioned in the definition of the above groups are meant a 10 pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl or isoquinolinyl group, or a pyrrolyl, furanyl, thienyl or pyridyl group, wherein one or two methyne groups are replaced by nitrogen atoms, or an indolyl, benzofuranyl, benzothiophenyl, quinolinyl or isoquinolinyl group, wherein one to three methyne groups are replaced by nitrogen atoms, and the above mentioned heteroaryl groups may be mono- or disubstituted by Rh, while the substituents may be identical or different and R,, is as hereinbefore defined, while, unless otherwise stated, the above mentioned alkyl, alkenyl and alkynyl groups may be straight-chain or branched, and the hydrogen atoms of the methyl or ethyl groups contained in the definitions may be wholly or partly replaced by fluorine atoms, the tautomers, enantiomers, diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof.
Compounds of the above general formula I which contain one or more groups that can be cleaved in vivo are so-called prodrugs.
Boehringer Ingelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text The carboxy groups mentioned in the definition of the above mentioned groups may be replaced by a group which can be converted into a carboxy group in vivo or by a group which is negatively charged under physiological conditions, and furthermore the amino and imino groups mentioned in the definition of the above mentioned groups may be substituted by a group which can be cleaved in vivo.
Such groups are described for example in WO 98!46576 and by N.M. Nielsen ef al. in International Journal of Pharmaceutics 39, 75-85 (1987).
By a group which can be converted in vivo into a carboxy group is meant, for example, a hydroxymethyl group, a carboxy group esterified with an alcohol wherein the alcohol moiety is preferably a C~_6-alkanol, a phenyl-C~_3-alkanol, a C3_9-cycloalkanol, while a C5_s-cycloaikanol may additionally be substituted by one or two C~_3-alkyl groups, a CS_s-cycloalkanol wherein a methylene group in the 3 or 4 position is replaced by an oxygen atom or by an imino group optionally substituted by a C,_3-alkyl, phenyl-C~_3-alkyl, phenyl-C~_3-alkyloxycarbonyl or C2~-alkanoyl group and the cycloalkanol moiety may additionally be substituted by one or two C~_3-alkyl groups, a C4_~-cycloalkenol, a C3_5-alkenol, a phenyl-C3_5-alkenol, a C3_5-alkynol or phenyl-C3_5-alkynol with the proviso that no bonds to the oxygen atom start from a carbon atom which carries a double or triple bond, a C3_$-cycloalkyl-C~_3-alkanol, a bicycloalkanol with a total of 8 to 10 carbon atoms which may additionally be substituted in the bicycloalkyl moiety by one or two C~_3-alkyl groups, a 1,3-dihydro-3-oxo-1-isobenzofuranol or an alcohol of formula Rp-CO-O-(RqCR~)-OH, wherein Rp denotes a C~_s-alkyl, C~~-cycloalkyl, C,_s-alkyloxy, C5_~-cycloalkyloxy, phenyl or phenyl-C,_3-alkyl group, Rq denotes a hydrogen atom, a C~_3-alkyl, C5_~-cycloalkyl or phenyl group and R~ denotes a hydrogen atom or a C~_3-alkyl group, Boehringer Ingelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text by a group which is negatively charged under physiological conditions is meant, for example, a tetrazol-5-yl, phenylcarbonylaminocarbonyl, trifluoromethylcarbonylaminocarbonyl, C~_6-alkylsulphonylamino, phenylsulphonylamino, benzylsulphonylamino, trifluoromethylsulphonylamino, C~_6-alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, benzylsulphonylaminocarbonyl or periluoro-C~_6-alkylsulphonylaminocarbonyl group and by a group which can be cleaved in vivo from an imino or amino group is meant, for example, a hydroxy group, an acyl group such as a phenylcarbonyl group optionally mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C,_3-alkyl or C~_3-alkyloxy groups, while the substituents may be identical or different, a pyridinoyl group or a C~_~s-alkanoyl group such as the formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, a 3,3,3-trichloropropionyl or allyloxycarbonyl group, a C~_~s-alkyloxycarbonyl or C~_~s-alkylcarbonyloxy group, wherein hydrogen atoms may be wholly or partially replaced by fluorine or chlorine atoms such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert.butoxycarbonyl, pentoxycarbonyl, hexoxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, hexadecyloxycarbonyl, methylcarbonyloxy, ethylcarbonyloxy, 2,2,2-trichloroethylcarbonyloxy, propylcarbonyloxy, isopropylcarbonyloxy, butylcarbonyloxy, tert.butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, octylcarbonyloxy, nonylcarbonyloxy, decylcarbonyloxy, undecylcarbonyloxy, dodecylcarbonyloxy or hexadecylcarbonyloxy group, a phenyl-C~~-alkyloxycarbonyl group such as the benzyloxycarbonyl, phenylethoxycarbonyl or phenylpropoxycarbonyl group, a 3-amino-propionyl group wherein the amino group may be mono- or disubstituted by C»-alkyl or C3_~-cycloaikyl groups and the substituents may be identical or different, a C~_3-alkylsu!phony!-C2_4-alkyloxycarbonyl, C,_3-alkyloxy-C2~,-alkyloxy-C2_4-alkyloxycarbonyl, RP-CO-O-(RqCR~)-O-CO, C~_s-alkyl-CO-NH-(RSCRt)-O-CO or C~_6-alkyl-CO-O-(RSCR, )-(RSCR~)-O-CO group, wherein Rp to R~ are as hereinbefore defined, RS and Rt, which may be identical or different, denote hydrogen atoms or C~_3-alkyl groups.
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Moreover, the saturated alkyl and alkyloxy moieties which contain more than 2 carbon atoms mentioned in the foregoing definitions and those that follow, unless otherwise stated, also include the branched isomers thereof such as, for example, the isopropyl, tert.butyl, isobutyl group, etc.
Preferred compounds of the above general formula I are those wherein R' denotes a methyl group substituted by a group Ra, where Ra denotes a 3,4-dihydro-quinolinyl group, a 3,4-dihydro-isoquinolinyl group, a 1,4-dihydro-quinazolinyl or 4-oxo-1,4-dihydro-quinazolinyl group, a 3,4-dihydro-quinazolinyl or 4-oxo-3,4-dihydro-quinazolinyl group, a 1H-benzo[d][1,2]oxazinyl or 1-oxo-1H-benzo[dj[1,2]oxazinyl group, a 4H-benzo[e][1,3]oxazinyl or 4-oxo-4H-benzo[e][1,3]oxazinyl group, a 4H-benzo[dJ[1,3]oxazinyl or 4-oxo-4H-benzo[dJ[1,3]oxazinyl group, a 2H-benzo[1,4]oxazinyl or 2-oxo-2H-benzo[1,4]oxazinyl group, a 4H-benzo[e][1,3]thiazinyl or 4-oxo-4H-benzo[e][1,3]thiazinyl group, a 4H-benzo[d]j1,3]thiazinyl or 2H-benzo [1,4]thiazinyl group, a 2-oxo-2H-benzo[e](1,3]oxazinyl or 2,2-dioxo-1H-benzo[c][1,2]thiazinyl group, a 2,3-dihydro-1 H-benzo[e][1,4]diazepinyl or 2-oxo-2,3-dihydro-1 H-benzo[e][1,4]diazepinyl group, Boehringer Ingelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text a 4,5-dihydro-3H benzo[b][1,4]diazepinyl or 4-oxo-4,5-dihydro-3H-benzo[bJ[1,4]diazepinyl group, a 5-oxo-4,5-dihydro-3H-benzo[e][1,4]diazepinyl group, a 2,3-dihydro-benzo[t][1,4]oxazepinyl or 2,3-dihydro-benzo[b][1,4Joxazepinyl group, a 2,3-dihydro-benzo[t][1,4]thiazepinyl or 2,3-dihydro-benzo[b][1,4]thiazepinyl group, a 5-oxo-4,5-dihydro-benzo[tj[1,3,4]oxadiazepinyl group, a 11H-dibenzo[b,e]azepinyi or 11-oxo-11H-dibenzo[b,e]azepinyl group, a 11 H-benzo[e]pyrido[3,2-b]azepinyl or a 5H-1,9,10-triaza-dibenzo[a,d]-cycloheptenyl group, a 5H-dibenzo[b,e][1,4]diazepinyl or dibenzo[b,t][1,4]oxazepinyl group, a dibenzo[b,f][1,4]thiazepinyl, 5-oxo-dibenzo[b,fJ[1,4Jthiazepinyl or 5,5-dioxo-dibenzo[b,t][1,4Jthiazepinyl group, a 5H-dibenzo[a,dJcycloheptenyl or 5H-dibenzo[b,t]azepinyl group, a phenanthridinyl, benzo[c][1,5]naphthyridinyl, benzo[h][1,6]naphthyridinyl, benzo[c][1,8]naphthyridinyl, benzo[t][1,7]naphthyridinyl or 1,5,9-triaza-phenanthrenyl group, a 1,2,3,4-tetrahydro-phenanthridinyl, 1,2,3,4,4a,10b-hexahydro-phenan-thridinyl, 2,3-dihydro-1H-4-aza-cyclopenta[a]naphthyl or 8,9,10,11-tetrahydro-7H-6-aza-cyclohepta[a]naphthyl group, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text a 2,3-dihydro-1H-4-oxa-10-aza-phenanthrenyl or 1-oxo-2,3-dihydro-1H-4-oxa 10-aza-phenanthrenyl group, a phenanthrenyl, benzo[h]quinolinyl, benzo[tjquinolinyl or benzo[t]quinoxalinyl 5 group, a 5H-benzo[a]pyrrolo[1,2-a][1,4]diazepinyl, thieno[3,2-b][1,4]benzoxazepinyl, 5H-dibenzo[d,t][1,3]diazepinyl or 5-oxa-7-aza-dibenzo[a,c]cycloheptenyl group, 10 a naphtho[1,2-d]oxazolyl, naphtho[2,1-djoxazolyl , naphtho[1,2-d]thiazolyl, naphtho[2,1-d]thiazolyl, naphtho[1,2-d]imidazolyl, naphtho[1,2-b]furany~ or naphtho[2,1-b]furanyl group, or a furo[3,2-c]isoquinolinyl, pyrazolo[1,5-c]quinazolinyl or 1H-perimidinyl 15 group, while the benzo groups of the above mentioned radicals Ra are substituted by the groups R'° to R'3 and the alkylene units of the above mentioned groups Ra may be substituted by one or two fluorine atoms or one or two C,_3-alkyl or 20 C~_3-alkyloxy-carbonyl groups and the imino groups of the above mentioned radicals Ra may be substituted by a C~_3-alkyl group and R'° denotes a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, a C,_3-alkyl or cyclopropyl group, a hydroxy, C,_3-alkyloxy or cyclopropyloxy group, a nitro, amino, C~_3-alkylamino or di-(C~_3-alkyl)amino group, a C~_3-alkyl-carbonylamino or C~_3-alkyl-sulphonylamino group, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text a cyano, carboxy, C~_3-alkyloxy-carbonyl, aminocarbonyl, C~_3-alkyl-aminocarbonyl or di-(C~_3-alkyl)-aminocarbonyl group, a mercapto, C~_3-alkylsulphanyl, C~_3-alkysulphinyl, C~_3-alkylsulphonyl or aminosulphonyl group or a difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy group and R", R'2 and R'3, which may be identical or different, in each case represent a hydrogen atom, a fluorine, chlorine or bromine atom, a methyl, trifluoromethyl or methoxy group, R2 denotes a hydrogen atom or a C~_3-alkyl, cyclopropyl, trifluoromethyl, cyanomethyl or 2-cyano-ethyl group, Y denotes a nitrogen atom or a group of formula C-R5, while R5 denotes a hydrogen atom or a C~_3-alkyl group, R3 denotes a 2-buten-1-yl or 3-methyl-2-buten-1-yl group, a 1-buten-1-yl group, a 2-butyn-1-yl group or a 1-cyclopenten-1-ylmethyl group and R4 denotes a (3-amino-piperidin-1-yl) group, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text while, unless otherwise stated, the above mentioned alkyl groups may be straight-chain or branched, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
Particularly preferred are those compounds of the above general formula I
wherein R' denotes a methyl group substituted by a group Ra, where Ra denotes a 3,4-dihydro-quinolin-2-yl group, a 3,4-dihydro-isoquinolin-1-yl group, a 1,4-dihydro-quinazolin-2-yl or 4-oxo-1,4-dihydro-quinazolin-2-yl group, a 3,4-dihydro-quinazolin-2-yl or 4-oxo-3,4-dihydro-quinazolin-2-yl group, a 1H-benzo[dJ[1,2]oxazin-4-yl or 1-oxo-1H-benzo[dj[1,2]oxazin-4-yl group, a 4H-benzo[e][1,3]oxazin-2-yl or 4-oxo-4H-benzo[e][1,3]oxazin-2-yl group, a 4H-benzo[dJ[1,3]oxazin-2-yl or 4-oxo-4H-benzo[d][1,3]oxazin-2-yl group, a 2H-benzo[1,4]oxazin-3-yl or 2-oxo-2H-benzo[1,4]oxazin-3-yl group, a 4H-benzo[e][1,3]thiazin-2-yl or 4-oxo-4H-benzo[e][1,3]thiazin-2-yl group, a 4H-benzo[d][1,3]thiazin-2-yl or 2H-benzo[1,4]thiazin-3-yl group, a 2-oxo-2H-benzo[e][1,3]oxazin-4-yl or 2,2-dioxo-1H-benzo[c][1,2)thiazin-4-yl group, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text a 2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl or2-oxo-2,3-dihydro-1H-benzo[e](1,4]diazepin-5-yl group, a 4,5-dihydro-3H benzo(b][1,4]diazepin-2-yl or 4-oxo-4,5-dihydro-3H-benzo[b][1,4]diazepin-2-yl group, a 5-oxo-4,5-dihydro-3H-benzo[e)[1,4]diazepin-2-yl group, a 2,3-dihydro-benzo[t][1,4]oxazepin-5-yl or 2,3-dihydro-benzo[b][1,4]oxazepin-4-yl group, a 2,3-dihydro-benzo[tJ[1,4]thiazepin-5-yl or 2,3-dihydro-benzo[b][1,4]thiazepin-4-yl group, a 5-oxo-4,5-dihydro-benzo[t][1,3,4]oxadiazepin-2-yl group, a 11H-dibenzo[b,e]azepin-6-yl or 11-oxo-11H-dibenzo[b,e]azepin-6-yl group, a 11 H-benzo[e]pyrido(3,2-b]azepin-6-yl or a 5H-1,9,10-triaza-dibenzo[a,d]-cyclohepten-11-y) group, a 5H-dibenzo[b,e][1,4]diazepin-11-yl or dibenzo[b,tJ(1,4]oxazepin-11-yl group, a dibenzo[b,fJ[1,4]thiazepin-11-yl, 5-oxo-dibenzo[b,tJ[1,4]thiazepin-11-yl or 5,5-dioxo-dibenzo[b,tJ[1,4]thiazepin-11-yl group, a 5H-dibenzo[a,d]cyclohepten-10-yl or 5H-dibenzo[b,t]azepin-10-yl group, a phenanthridin-6-yl, benzo[c][1,5]naphthyridin-6-yl, benzo[h][1,6]naphthyridin-5-yl, benzo[c][1,8]naphthyridin-6-yl, benzo[t][1,7]naphthyridin-5-yl or 1,5,9-triaza-phenanthren-10-yl group, Boehringer Ingelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text a 1,2,3,4-tetrahydro-phenanthridin-6-yl, 1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl, 2,3-dihydro-1H-4-aza-cyclopenta[a]naphth-5-yl or 8,9,10,11-tetrahydro-7H-6-aza-cyclohepta[a]naphth-5-yl group, a 2,3-dihydro-1 H-4-oxa-10-aza-phenanthren-9-yl or 1-oxo-2,3-dihydro-1 H-4-oxa-10-aza-phenanthren-9-yl group, a phenanthren-9-yl, benzo[h]quinolin-6-yl, benzo[t]quinolin-6-yl or benzo[fJquinoxalin-6-yl group, a 5H-benzo[e]pyrroto[1,2-a][1,4]diazepin-11-yl, thieno[3,2-b](1,4]benzoxaze-pin-9-yl, 5H-dibenzo[d,t](1,3]diazepin-6-yl or 5-oxa-7-aza-di-benzo[a,c]cyclohepten-6-yl group, a naphtho[1,2-d]oxazol-2-yl, naphtho[2,1-d]oxazol-2-yl, naphtho[1,2-d]thiazol-2-yl, naphtho[2,1-d]thiazol-2-yl, naphtho[1,2-d]imidazol-2-yl, naphtho(1,2-b]furan-2-yl or naphtho[2,1-b]furan-2-yl group, or a furo[3,2-c]isoquinolin-5-yl, pyrazolo[1,5-c]quinazolin-5-yl or 1 H-perimidin-2-yl group, while the benzo groups of the above mentioned radicals Ra are substituted by the groups R'° to R'3 and the alkylene units of the above mentioned groups Ra may be substituted by one or two fluorine atoms or one or two methyl groups and the imino groups of the above mentioned radicals Ra may be substituted by a methyl group and R'° denotes a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, a methyl or ethyl group, a hydroxy, methoxy or ethoxy group or Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text a difluoromethyl, trifluoromethyl, difluoromethoxy, or trifluoromethoxy group and 5 R", R'2 and R'3, which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom or a methyl, trifluoromethyl or methoxy group, R2 denotes a hydrogen atom or a methyl, cyanomethyl, trifluoromethyl, ethyl, 2-cyano-ethyl, propyl, eyclopropyl or isopropyl group, Y denotes a nitrogen atom or a group of formula C-R5, while R5 denotes a hydrogen atom or a methyl, ethyl, propyl or isopropyl group, R3 denotes a 2-buten-1-yl or 3-methyl-2-buten-1-yf group, a 1-buten-1-yl group, a 2-butyn-1-yl group or a 1-cyclopenten-1-ylmethyl group and R4 denotes a (3-amino-piperidin-1-yl) group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Most particularly preferred are those compounds of the above general formula I
wherein R' denotes a 4-oxo-3,4-dihydro-quinazolin-2-ylmethyl group, a dibenzo[b,fj[1,4joxazepin-11-ylmethyl group, a phenanthridin-6-ylmethyi group, a phenanthren-9-ylmethyl group or a naphtho[1,2-dJoxazol-2-ylmethyl or naphtho[2,1-dJoxazol-2-ylmethyl group, R2 denotes a hydrogen atom or a methyl group, Y denotes a nitrogen atom, R3 denotes a 2-butyn-1-yl group and R4 denotes a (3-amino-piperidin-1-yl) group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text The following compounds of general formula I deserve special mention:
(1) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,tj[1,4]oxazepin-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one I~ o N
i N i N, >
C N Nw I N ~~
NHZ
(2) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-djpyridazin-4-one o N
N
N
I ~N N~ I N
/ NHZ
(3) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthren-9-yl)methyl]-3,5-dihydro-imidazo[4, 5-d]pyridazin-4-one N N
I / N w I ~~N~
\N
/ NHZ
(4) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-7-methyl-3, 5-di hydro-imidazo[4, 5-d]pyridazi n-4-one O
I ' I N~ N
N N~N
(5) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,t][1,4]oxazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text O
N N
O 1N N w I ~~N~
~N
NHz \ /
(6) 2-((S)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo(b,t][1,4)oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one N N
O ~N N ~ I ~~ N
N
/ \ ,NH2 (7) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one O
N N
O IN N w I ~~ N
N
/ \ NH2 (8) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[2,1-dJoxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one O
\ O~N N
\ N Nw I ~~N\ /
~N
I I ~ R4 N
the tautomers, the enantiomers, the diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV), the preparation thereof, the use thereof for the prevention or treatment of diseases or conditions associated with an increased DPP-IV activity or capable of being prevented or alleviated by reducing the DPP-IV
activity, particularly type I or type II diabetes mellitus, the pharmaceutical compositions containing a compound of general formula (I) or a physiologically acceptable salt thereof as well as processes for the preparation thereof.
The present invention thus relates to the above compounds of general formula I
which have valuable pharmacological properties, the pharmaceutical compositions containing the pharmacologically effective compounds, the use thereof and processes for the preparation thereof.
In the above general formula I
R' denotes a C~_3-alkyl group substituted by a group Ra, where Boehringer Ingelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text Ra denotes a 3,4-dihydro-quinolinyl, 3,4-dihydro-isoquinolinyl, 1,4-dihydro-quinazolinyl, 3,4-dihydro-quinazolinyl, 1H-benzo[dJ[1,2]oxazinyl, 4H-benzo[e][1,3]oxazinyl, 4H-benzo[off[1,3]oxazinyl or 2H-benzo[1,4]oxazinyl group, wherein in each case in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocyclyl moiety a methylene group may be replaced by a carbonyl group, a 4H-benzo[e][1,3]thiazinyl, 4H-benzo[d][1,3]thiazinyl or 2H-benzo [1,4]thia-zinyl group wherein in each case in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocyclyl moiety a methylene group may be replaced by a carbonyl group and the sulphur atom may be replaced by a sulphinyl or sulphonyl group, a 2-oxo-2H-benzo[e][1,3]oxazinyl or 2,2-dioxo-1H-benzo[c][1,2]thiazinyl group wherein in each case in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom, a 2,3-dihydro-1H-benzo[e][1,4]diazepinyl, 4,5-dihydro-3H-benzo[bJ[1,4]diaze-piny! or 5-oxo-4,5-dihydro-3H-benzo[e][1,4]diazepinyl group wherein in each case in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocyclyl moiety a methylene group may be replaced by a carbonyl group, a 2,3-dihydro-benzo[~[1,4]oxazepinyl or 2,3-dihydro-benzo[b][1,4]oxazepinyl group wherein in each case Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocyclyl moiety a methylene group may be replaced by a carbonyl group, a 2,3-dihydro-benzo[b][1,4]thiazepinyl or 2,3-dihydro-benzo[tj[1,4]thiazepinyl group wherein in each case in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocyclyl moiety a methylene group may be replaced by a carbonyl group and the sulphur atom may be replaced by a sulphinyl or sulphonyl group, a 5-oxo-4,5-dihydro-benzo[t][1,3,4]oxadiazepinyl group wherein in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom, a 11H-dibenzo[b,e]azepinyl or 5H-dibenzo[a,d]cycloheptenyl group wherein in each case in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and the methylene group in the heterocyclyl moiety may be replaced by an oxygen or sulphur atom, a carbonyl, sulphinyl or sulphonyl group or by an imino group substituted by RX, where RX denotes a hydrogen atom or a C~~-alkyl, C2_4-alkenyl, C2_a-alkynyl, C~s-cycloalkyl, C~s-cycloalkyl-C~_3-alkyl, aryl, aryl-C~_3-alkyl, hydroxy-C2~-alkyl, C~_3-alkyloxy-C2_4-alkyl, C~s-cycfoalkyloxy-C2_4-alkyl, amino-C2~-alkyl, C~_3-alkylamino-C2~-alkyl, di-(C,_3-alkyl)-amino-C2~-alkyl, C~_3-alkyl-carbonyl, C,_3-alkyloxy-carbonyl, C~_3-alkyloxy-carbonyl-C~_3-alkyl, aryl-carbonyl, C,_3-alkyl-sulphonyl or aryl-sulphonyl group, a phenanthridinyl group wherein Boehringer Ingelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom, and a 1,2,3,4-tetrahydro-phenanthridinyl, 1,2,3,4,4a,10b-hexahydro-phenan-thridinyl, 2,3-dihydro-1 H-4-aza-cyclopenta[a]naphthyl or a 8,9,10,11-tetrahydro-7H-6-aza-cyclohepta[a]naphthyl group wherein in each case in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and one or two methylene groups may each be replaced by an oxygen atom or a carbonyl group, while, if two methylene groups are each replaced by an oxygen atom, the oxygen atoms must be separated from one another by at least two methylene units, a phenanthrenyl group wherein in each case one to three of the methyne groups in position 1 to 4 and 5 to 8 may each be replaced by a nitrogen atom, a 1,2,3,4-tetrahydro-phenanthrenyl or a 1,2,3,4,5,6,7,8-octahydro-phenanthrenyl group wherein in each case one or two of the methylene groups in position 1 to 4 and 5 to 8 may each be replaced by an oxygen atom or a carbonyl group, while, if two methylene groups are each replaced by an oxygen atom, the oxygen atoms must be separated from one another by at least two methylene units, a 5H-benza[a]pyrrolo[1,2-a][1,4]diazepinyl, thieno[3,2-b][1,4]benzoxazepinyl, 5H-dibenzo[d,t][1,3]diazepinyl or a 5-oxa-7-aza-dibenzo[a,c]cycloheptenyl group wherein in each case Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom, a naphtho[1,2-djoxazolyl, naphtho[2,1-dJoxazolyl , naphtho[1,2-dJthiazolyl, 5 naphtho[2,1-dJthiazolyl, naphtho[1,2-dJimidazolyl, naphtho[1,2-b]furanyl or naphtho[2,1-b]furanyl group wherein in each case in the naphthyl moiety one to three methyne groups may each be replaced by a nitrogen atom, or a furo[3,2-c]isoquinolinyl, pyrazolo[1,5-c]quinazolinyl or 1H-perimidinyl group, while the methylene and methyne groups of the above mentioned radicals Ra may be substituted by the groups R'° to R'3 and additionally by a Ci_3-alkyl group and the imino groups of the above mentioned radicals Ra may be substituted by the groups RX as hereinbefore defined and R'° denotes a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, a C,~-alkyl, hydroxy, or C~_4-alkyloxy group, a nitro, amino, C,_3-alkylamino, di-(C,_3-alkyl)amino, cyano-C,_3-alkylamino, N-(cyano-C~_3-alkyl)-N-(C~_3-alkyl)-amino, C~_3-alkyloxy-carbonyl-C,_3-alkylamino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, or 4-(C~_3-alkyl)-piperazin-1-yl group, a C~_3-alkyl-carbonylamino, arylcarbonylamino, aryl-C~_3-alkyl-carbonylamino, C,_3-alkyloxy-carbonylamino, aminocarbonylamino, C~_3-alkylaminocarbonylamino, di-(C,_3-alkyl)aminocarbonylamino, pyrrolidin-1-yl-carbonylamino, piperidin-1-yl-carbonylamino, morpholin-4-yl-carbonylamino, piperazin-1-yl-carbonylamino or 4-(C1_3-alkyl)-piperazin-Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 1-yl-carbonyfamino, C~_3-alkyl-sulphonylamino, bis-(C~_3-alkylsulphonyl)-amino, aminosulphonylamino, C~_3-alkylamino-sulphonylamino, di-(C~_3-alkyl)amino-sulphonylamino, pyrrolidin-1-yl-sulphonylamino, piperidin-1-yl-sulphonylamino, morpholin-4-yl-sulphonylamino, piperazin-1-yl-sulphonylamino or 4-(C~_3-alkyl)-piperazin-1-yl-sulphonylamino, (C~_3-alkylamino)thiocarbonylamino, (C~_3-alkyloxy-carbonyl-amino)carbonylamino, arylsulphonylamino or aryl-C~_3-alkyl-sulphonyl-amino group, an N-(C~_3-alkyl)-C~_3-alkyl-carbonylamino, N-(C~_3-alkyl)-arylcarbonyl-amino, N-(C~_3-alkyl)-aryl-C~_3-alkyl-carbonylamino, N-(C~_3-alkyl)-C~_3-alkyloxy-carbonylamino, N-(aminocarbonyl)-C~_3-alkylamino, N-(C~_3-alkyl-aminocarbonyl)-C~_3-alkylamino , N-[di-(C~_3-aikyl)aminocarbonyl]-C~_3-alkylamino, N-(C~_3-alkyl)-C~_3-alkyl-sulphonylamino, N-(C~_3-alkyl)-arylsulphonylamino, or N-(C~_3-alkyl)-aryl-C~_3-alkyl-sulphonylamino group, a 2-oxo-imidazolidin-1-yf, 2,4-dioxo-imidazolidin-1-yl, 2,5-dioxo-imidazolidin-1-yl or 2-oxo-hexahydropyrimidin-1-yl group wherein the nitrogen atom in the 3 position may be substituted in each case by a methyl or ethyl group, a cyano, carboxy, C~_3-alkyloxy-carbonyl, aminocarbonyl, C~_3-alkyl-aminocarbonyl, di-(C~_3-alkyl)-aminocarbonyl, pyrrolidin-1-yl-carbonyl, piperidin-1-yl-carbonyl, morpholin-4-yl-carbonyl, piperazin-1-yl-carbonyl or 4-(C~_3-alkyl)-piperazin-1-yl-carbonyl group, a C~_3-alkyl-carbonyl or an arylcarbonyl group, a carboxy-Cy_3-alkyl, C~_3-alkyloxy-carbonyl-C,_3-alkyl, cyano-C,-3-alkyl, aminocarbonyl-C~_3-alkyl, C~_3-alkyl-aminocarbonyl-C,_3-alkyl, di-(C~_3-alkyl)-aminocarbonyl-C~_3-alkyl, pyrrolidin-1-yl-carbonyl-C~_3-alkyl, piperidin-1-yl-carbonyl-C~_3-alkyl, morpholin-4-yl-carbonyl-C~_3-alkyl, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text piperazin-1-yl-carbonyl-C~_3-alkyl or 4-(C~_3-alkyl)-piperazin-1-yl-carbonyl-C~_3-alkyl group, a carboxy-C~_3-alkyloxy, C~_3-alkyloxy-carbonyl-C~_3-alkyloxy, cyano-C~_3-alkyloxy, aminocarbonyl-C~_3-alkyloxy, C~_3-alkyl-aminocarbonyl-C~_3-alkyloxy, di-(C~-3-alkyl)-aminocarbonyl-C~_3-alkyloxy, pyrrolidin-1-yl-carbonyl-C~_3-alkyloxy, piperidin-1-yl-carbonyl-C~_3-alkyloxy, morpholin-4-yl-carbonyl-C~_3-alkyloxy, piperazin-1-yl-carbonyl-C~_3-alkyloxy or 4-(C~_3-alkyl)-piperazin-1-yl-carbonyl-C~_3-alkyloxy group, a hydroxy-C~_3-alkyl, C~_3-alkyloxy-C,_3-alkyl, amino-G~_3-alkyl, C~_3-alkylamino-C~_3-alkyl, di-(C~_3-alkyl)-amino-C~_3-alkyl, pyrrolidin-1-yl-C1_3-alkyl, piperidin-1-yl-C~-3-alkyl, morpholin-4-yl-C~_3-alkyl, piperazin-1-yl-C~_3-alkyl or 4-(C~_3-alkyl)-piperazin-1-yl-C~_3-alkyl group, a hydroxy-C~_3-alkyloxy, C~_3-alkyloxy-C~_3-alkyloxy, C~_3-alkylsulphanyl-C~_3-alkyloxy, C~_3-alkylsulphinyl-C~_3-alkyloxy, C~_3-alkylsufphonyl-C~_3-alkyloxy, amino-C~_3-alkyloxy, C~_3-alkylamino-C~_3-alkyloxy, di-(C~_3-alkyl)-amino-C~_3-alkyloxy, pyrrolidin-1-yl-C~_3-alkyloxy, piperidin-1-yl-C~_3-alkyloxy, morpholin-4-yl-C~_3-alkyloxy, piperazin-1-yl-C~_3-alkyloxy or 4-(C~_3-alkyl)-piperazin-1-yl-C~_3-alkyloxy group, a mercapto, C~_3-alkylsulphanyl, C~_3-alkysulphinyl, C~_3-alkylsulphonyl, C~_3-alkylsulphonyloxy, arylsulphonyloxy, trifluoromethylsulphanyl, trifluoromethylsulphinyl or trifluoromethylsulphonyl group, a sulpho, aminosulphonyl, C~_3-alkyl-aminosulphonyl, di-(C~_3-alkyl)-aminosulphonyl, pyrrolidin-1-yl-sulphonyl, piperidin-1-yl-sulphonyl, morpholin-4-yl-sulphonyl, piperazin-1-yl-sulphonyl or 4-(C1_3-alkyl)-piperazin-1-yl-sulphonyl group, a methyl or methoxy group substituted by 1 to 3 fluorine atoms, an ethyl or ethoxy group substituted by 1 to 5 fluorine atoms, Boehringer Ingelheim International GmbH Case 1/1502 55216 ingelheim foreign filing text a C2~-alkenyl or Cz_4-alkynyl group, a C3~-alkenyloxy or C3_4-alkynyloxy group, a C3~-cycloalkyl or C~.6-cycloalkyloxy group, a C3~-cycloalkyl-C~_3-alkyl or C3_s-cycloalkyl-C~_3-alkyloxy group or an aryl, aryloxy, aryl-C~.3-alkyl or aryl-C~_3-alkyloxy group, R" and R'2, which may be identical or different, in each case represent a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, a C~_3-alkyl, trifluoromethyl, hydroxy, C~_3-alkyloxy or cyano group, or R" together with R'2, if these are bound to adjacent carbon atoms, also denotes a methylenedioxy, difluoromethylenedioxy, ethylenedioxy or a straight-chain C3_5-alkylene group and R'3 denotes a hydrogen atom, a fluorine, chlorine or bromine atom, a trifluoromethyl, C~_3-alkyl or C~_3-alkyloxy group, R2 denotes a hydrogen, fluorine or chlorine atom, a C~~-alkyl group, a C2_4-alkenyl group, a C3~,-alkynyl group, a C3_6-cycloalkyl group, a C3~-cycloalkyl-C~_3-alkyl group, 8oehringer lngelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydro-furanylmethyl or tetrahydropyranylmethyl group, an aryl group, an aryl-C~_4-alkyl group, an aryl-CZ_3-alkenyl group, an arylcarbonyl group, an arylcarbonyl-C~_2-alkyl group, a heteroaryl group, a heteroaryl-C~_3-alkyl group, a furanylcarbonyl, thienylcarbonyl, thiazolyicarbonyl or pyridylcarbonyl group, a furanylcarbonylmethyl, thienylcarbonylmethyl, thiazolylcarbonylmethyl or pyridylcarbonylmethyl group, a C~_4-alkyl-carbonyl group, a C~_4-alkyl-carbonyl-C~_2-alkyl group, a C3~-cycloalkyl-carbonyl group, a C3_fi-cycloalkyl-carbonyl-C~_2-alkyl group, an aryl-A or aryl-A-C~_3-alkyl group, where A denotes an oxygen or sulphur atom, an imino, C~_3-alkylimino, sulphinyl or sulphonyl group, a group Rb, where Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Rb denotes a cyano, carboxy, C~_3-alkyloxy-carbonyl, aminocarbonyl, C~_3-alkylamino-carbonyl, di-(C~_3-alkyl)-amino-carbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4-5 methylpiperazin-1-ylcarbonyl, 4-ethylpiperazin-1-ylcarbonyl, hydroxy, mercapto, C~_3-alkyloxy, C~_3-alkylsulphenyl, C~_3-alkylsulphinyl, C~_3-alkyl-sulphonyl, amino, C~_3-alkylamino, di-(C~_3-alkyl)-amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl or 4-ethyl-piperazin-1-yl group, or a C~_4-alkyl group substituted by a group Rb, where Rb is as hereinbefore defined, Y denotes a nitrogen atom or a group of formula C-R5, while RS is defined like R2 and in each case one of the two groups R2 and RS
must be a hydrogen atom or a C~_3-alkyl group, R3 denotes a C3_$-alkyl group, a C~_3-alkyl group substituted by a group R~, where R~ denotes a C~~-cycloalkyl group optionally substituted by one or two C~_3-alkyl groups, a C5_~-cycloalkenyl group optionally substituted by one or two C~_3-alkyl groups, an aryl group or a furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidyl or pyrazinyl group, while the above mentioned heterocyclic groups may each be substituted by one or two C~-3-alkyl groups or by a fluorine, chlorine, bromine or iodine atom or by a trifluoromethyl, cyano or C~_3-alkyloxy group, Boehringer Ingelheim International GmbH Case 111502 55216 Ingelheim foreign filing text a C3_$-alkenyl group, a C3_s-alkenyl group substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl group, a C3_$-alkynyl group, an aryl group or an aryl-C2_4-alkenyl group, and R4 denotes an azetidin-1-yl or pyrrolidin-1-yl group which is substituted in the 3 position by an amino, C~_3-alkylamino or a di-(C,_3-alkyl)amino group and may additionally be substituted by one or two C~_3-alkyl groups, a piperidin-1-yl or hexahydroazepin-1-yl group which is substituted in the 3 position or in the 4 position by an amino, C~_3-alkylamino or a di-(C~_3-alkyl)amino group and may additionally be substituted by one or two C~_3-alkyl groups, a 3-amino-piperidin-1-yl group wherein the piperidin-1-yl moiety is additionally substituted by an aminocarbonyl, C~_2-alkyl-aminocarbonyl, di-(C~_2-alkyl)aminocarbonyl, pyrrolidin-1-yl-carbonyl, (2-cyano-pyrrolidin-1-yl-)carbonyl, thiazolidin-3-yl-carbonyl, (4-cyano-thiazolidin-3-yl)carbonyl, piperidin-1-ylcarbonyl or morpholin-4-ylcarbonyl group, a 3-amino-piperidin-1-yl group wherein the piperidin-1-yl moiety in the 4 position or in the 5 position is additionally substituted by a hydroxy or methoxy group, a 3-amino-piperidin-1-yl group wherein the methylene group in the 2 position or in the 6 position is replaced by a carbonyl group, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text a piperidin-1-yl or hexahydroazepin-1-yl group substituted in the 3 position by an amino, C~_3-alkylamino or di-(C~_3-alkyl)-amino- group, wherein in each case two hydrogen atoms on the carbon skeleton of the piperidin-1-yl or hexahydroazepin-1-yl-group are replaced by a straight-chain alkylene bridge, this bridge containing 2 to 5 carbon atoms if the two hydrogen atoms are located on the same carbon atom, or to 4 carbon atoms, if the hydrogen atoms are located on adjacent carbon atoms, or 1 to 4 carbon atoms, if the hydrogen atoms are located on carbon atoms which are separated by one atom, or 1 to 3 carbon atoms if the two hydrogen atoms are located on carbon atoms separated by two atoms, an azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl or hexahydroazepin-1-yl group which is substituted by an amino-C~_3-alkyl, C~-3-alkylamino-C~_3-alkyl or a di-(C~_3-alkyl)-amino-C,_3-alkyl group, a piperazin-1-yl or [1,4]diazepan-1-yl group optionally substituted at the carbon skeleton by one or two C~_3-alkyl groups, a 3-imino-piperazin-1-yl, 3-imino-[1,4]diazepan-1-yl or 5-imino-[1,4]diazepan-1-yl group optionally substituted at the carbon skeleton by one or two C~_3-alkyl groups, a [1,4)diazepan-1-yl group optionally substituted by one or two C~_3-alkyl groups, which is substituted in the 6 position by an amino group, a C3_~-cycloalkyl group which is substituted by an amino, C~_3-alkylamino or di-(C~_3-alkyl)-amino group, a C3_~-cycloalkyl group which is substituted by an amino-C~_3-alkyl, C~_3-alkylamino-C,_3-alkyl or a di-(C~_3-alkyl)amino-C~_3-alkyl group, a C3_~-cycloalkyl-C~_2-alkyl group wherein the cycloalkyl moiety is substituted by an amino, C,_3-alkylamino or di-(C~_3-alkyl)-amino group, a C3_~-cycloalkyl-C~_2-alkyl group wherein the cycloalkyl moiety is substituted by an amino-C~_3-alkyl, C~_3-alkylamino-C~_3-alkyl or a di-(C~_3-alkyl)amino-C,_3-alkyl group, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text a C3_~-cycloalkylamino group wherein the cycloalkyl moiety is substituted by an amino, C~_3-alkylamino or di-(C,_3-alkyl)-amino group, while the two nitrogen atoms at the cycloalkyl moiety are separated from one another by at least two carbon atoms, an N-(C3_~-cycloalkyl)-N-(C~-3-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino, C~_3-alkylamino or di-(C~_3-alkyl)-amino group, while the two nitrogen atoms at the cycloalkyl moiety are separated from one another by at least two carbon atoms, a C3_~-cycloalkylamino group wherein the cycloalkyl moiety is substituted by an amino-C~-3-alkyl, C~_3-alkylamino-C~_3-alkyl or a di-(C~_3-alkyl)amino-C~_3-alkyl group, an N-(C3_~-cycloalkyl)-N-(C~_3-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino-C~_3-alkyl, C,_3-alkylamino-C~_3-alkyl or a di-(C~_3-alkyl)amino-C~_3-alkyl group, a C3_~-cycloalkyl-C~_2-alkyl-amino group wherein the cycfoalkyl moiety is substituted by an amino, C~_3-alkylamino or di-(C~_3-alkyl)-amino group, an N-(C3_~-cycloalkyl-C~_2-alkyl)-N-(C~_2-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino, C~_3-alkylamino or di-(C~_3-alkyl)-amino group, a C3_~-cycloalkyl-C,_2-alkyl-amino group wherein the cycloalkyl moiety is substituted by an amino-C~_3-alkyl, C~_3-alkylamino-C~_3-alkyl or a di-(C~_3-alkyl)amino-C~_3-alkyl group, an N-(C3_~-cycloalkyl-C~-2-alkyl)-N-(C~_2-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino-C~_3-alkyl, C~_3-alkylamino-C~_3-alkyl or a di-(C~_3 alkyl)amino-C~_3-alkyl group, a R'9-C2_4-alkylamino group wherein R'9 is separated from the nitrogen atom of the C2_4-alkylamino moiety by at least two carbon atoms and Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text R'9 denotes an amino, C~_3-alkylamino or di-(C~_3-alkyl)-amino group, an R'9-C2_4-alkylamino group wherein the nitrogen atom of the C2_4-alkylamino moiety is substituted by a C~_3-alkyl group and R'9 is separated from the nitrogen atom of the C2_4-alkylamino moiety by at least two carbon atoms, while R'9 is as hereinbefore defined, an amino group substituted by the group R2° wherein R2° denotes an azetidin-3-yl, azetidin-2-ylmethyl, azetidin-3-ylmethyl, pyrrolidin-3-yl, pyrrolidin-2-ylmethyl, pyrrolidin-3-ylmethyl, piperidin-3-yl, piperidin-4-yl, piperidin-2-ylmethyl, piperidin-3-ylmethyl or piperidin-4-yfmethyl group, while the groups mentioned for R2° may each be substituted by one or two C~_3-alkyl groups, an amino group substituted by the group R2° and a C~_3-alkyl group wherein R2° is as hereinbefore defined, white the groups mentioned for R2° may each be substituted by one or two C~_3-alkyl groups, an R'9-C3_4-alkyl group wherein the C3_4-alkyl moiety is straight-chained and may additionally be substituted by one or two C~_3-alkyl groups, while R'9 is as hereinbefore defined, a 3-amino-2-oxo-piperidin-5-yl or 3-amino-2-oxo-1-methyl-piperidin-5-yl group, a pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, hexahydroazepin-3-yl or hexahydroazepin-4-yl group which is substituted in the 1 position by an amino, C~_3-alkylamino or di-(C~_3-alkyl)amino group, or an azetidin-2-yl-C~_2-alkyl, azetidin-3-yl-C~_2-alkyl, pyrrolidin-2-yl-C~_2-alkyl, pyrrolidin-3-yl, pyrrolidin-3-yl-C~_2-alkyl, piperidin-2-yl-C~_2-alkyl, piperidin-3-yl, piperidin-3-yl-C~_2-alkyl, piperidin-4-yl or piperidin-4-yl-C~_2-alkyl group, while the above mentioned groups may each be substituted by one or two C~_3-alkyl groups, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filin4 text while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups which may be mono- or disubstituted by Rh, while the substituents may be identical or different and R,, denotes a fluorine, chlorine, bromine or iodine atom, a trifluoromethyl, cyano, nitro, amino, aminocarbonyl, 5 aminosulphonyl, methylsulphonyl, acetylamino, methylsulphonylamino, C~_3-alkyl, cyclopropyf, ethenyl, ethynyl, hydroxy, C~_3-alkyloxy, difluoromethoxy or trifluoromethoxy group, by the heteroaryl groups mentioned in the definition of the above groups are meant a 10 pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl or isoquinolinyl group, or a pyrrolyl, furanyl, thienyl or pyridyl group, wherein one or two methyne groups are replaced by nitrogen atoms, or an indolyl, benzofuranyl, benzothiophenyl, quinolinyl or isoquinolinyl group, wherein one to three methyne groups are replaced by nitrogen atoms, and the above mentioned heteroaryl groups may be mono- or disubstituted by Rh, while the substituents may be identical or different and R,, is as hereinbefore defined, while, unless otherwise stated, the above mentioned alkyl, alkenyl and alkynyl groups may be straight-chain or branched, and the hydrogen atoms of the methyl or ethyl groups contained in the definitions may be wholly or partly replaced by fluorine atoms, the tautomers, enantiomers, diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof.
Compounds of the above general formula I which contain one or more groups that can be cleaved in vivo are so-called prodrugs.
Boehringer Ingelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text The carboxy groups mentioned in the definition of the above mentioned groups may be replaced by a group which can be converted into a carboxy group in vivo or by a group which is negatively charged under physiological conditions, and furthermore the amino and imino groups mentioned in the definition of the above mentioned groups may be substituted by a group which can be cleaved in vivo.
Such groups are described for example in WO 98!46576 and by N.M. Nielsen ef al. in International Journal of Pharmaceutics 39, 75-85 (1987).
By a group which can be converted in vivo into a carboxy group is meant, for example, a hydroxymethyl group, a carboxy group esterified with an alcohol wherein the alcohol moiety is preferably a C~_6-alkanol, a phenyl-C~_3-alkanol, a C3_9-cycloalkanol, while a C5_s-cycloaikanol may additionally be substituted by one or two C~_3-alkyl groups, a CS_s-cycloalkanol wherein a methylene group in the 3 or 4 position is replaced by an oxygen atom or by an imino group optionally substituted by a C,_3-alkyl, phenyl-C~_3-alkyl, phenyl-C~_3-alkyloxycarbonyl or C2~-alkanoyl group and the cycloalkanol moiety may additionally be substituted by one or two C~_3-alkyl groups, a C4_~-cycloalkenol, a C3_5-alkenol, a phenyl-C3_5-alkenol, a C3_5-alkynol or phenyl-C3_5-alkynol with the proviso that no bonds to the oxygen atom start from a carbon atom which carries a double or triple bond, a C3_$-cycloalkyl-C~_3-alkanol, a bicycloalkanol with a total of 8 to 10 carbon atoms which may additionally be substituted in the bicycloalkyl moiety by one or two C~_3-alkyl groups, a 1,3-dihydro-3-oxo-1-isobenzofuranol or an alcohol of formula Rp-CO-O-(RqCR~)-OH, wherein Rp denotes a C~_s-alkyl, C~~-cycloalkyl, C,_s-alkyloxy, C5_~-cycloalkyloxy, phenyl or phenyl-C,_3-alkyl group, Rq denotes a hydrogen atom, a C~_3-alkyl, C5_~-cycloalkyl or phenyl group and R~ denotes a hydrogen atom or a C~_3-alkyl group, Boehringer Ingelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text by a group which is negatively charged under physiological conditions is meant, for example, a tetrazol-5-yl, phenylcarbonylaminocarbonyl, trifluoromethylcarbonylaminocarbonyl, C~_6-alkylsulphonylamino, phenylsulphonylamino, benzylsulphonylamino, trifluoromethylsulphonylamino, C~_6-alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, benzylsulphonylaminocarbonyl or periluoro-C~_6-alkylsulphonylaminocarbonyl group and by a group which can be cleaved in vivo from an imino or amino group is meant, for example, a hydroxy group, an acyl group such as a phenylcarbonyl group optionally mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C,_3-alkyl or C~_3-alkyloxy groups, while the substituents may be identical or different, a pyridinoyl group or a C~_~s-alkanoyl group such as the formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, a 3,3,3-trichloropropionyl or allyloxycarbonyl group, a C~_~s-alkyloxycarbonyl or C~_~s-alkylcarbonyloxy group, wherein hydrogen atoms may be wholly or partially replaced by fluorine or chlorine atoms such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert.butoxycarbonyl, pentoxycarbonyl, hexoxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, hexadecyloxycarbonyl, methylcarbonyloxy, ethylcarbonyloxy, 2,2,2-trichloroethylcarbonyloxy, propylcarbonyloxy, isopropylcarbonyloxy, butylcarbonyloxy, tert.butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, octylcarbonyloxy, nonylcarbonyloxy, decylcarbonyloxy, undecylcarbonyloxy, dodecylcarbonyloxy or hexadecylcarbonyloxy group, a phenyl-C~~-alkyloxycarbonyl group such as the benzyloxycarbonyl, phenylethoxycarbonyl or phenylpropoxycarbonyl group, a 3-amino-propionyl group wherein the amino group may be mono- or disubstituted by C»-alkyl or C3_~-cycloaikyl groups and the substituents may be identical or different, a C~_3-alkylsu!phony!-C2_4-alkyloxycarbonyl, C,_3-alkyloxy-C2~,-alkyloxy-C2_4-alkyloxycarbonyl, RP-CO-O-(RqCR~)-O-CO, C~_s-alkyl-CO-NH-(RSCRt)-O-CO or C~_6-alkyl-CO-O-(RSCR, )-(RSCR~)-O-CO group, wherein Rp to R~ are as hereinbefore defined, RS and Rt, which may be identical or different, denote hydrogen atoms or C~_3-alkyl groups.
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Moreover, the saturated alkyl and alkyloxy moieties which contain more than 2 carbon atoms mentioned in the foregoing definitions and those that follow, unless otherwise stated, also include the branched isomers thereof such as, for example, the isopropyl, tert.butyl, isobutyl group, etc.
Preferred compounds of the above general formula I are those wherein R' denotes a methyl group substituted by a group Ra, where Ra denotes a 3,4-dihydro-quinolinyl group, a 3,4-dihydro-isoquinolinyl group, a 1,4-dihydro-quinazolinyl or 4-oxo-1,4-dihydro-quinazolinyl group, a 3,4-dihydro-quinazolinyl or 4-oxo-3,4-dihydro-quinazolinyl group, a 1H-benzo[d][1,2]oxazinyl or 1-oxo-1H-benzo[dj[1,2]oxazinyl group, a 4H-benzo[e][1,3]oxazinyl or 4-oxo-4H-benzo[e][1,3]oxazinyl group, a 4H-benzo[dJ[1,3]oxazinyl or 4-oxo-4H-benzo[dJ[1,3]oxazinyl group, a 2H-benzo[1,4]oxazinyl or 2-oxo-2H-benzo[1,4]oxazinyl group, a 4H-benzo[e][1,3]thiazinyl or 4-oxo-4H-benzo[e][1,3]thiazinyl group, a 4H-benzo[d]j1,3]thiazinyl or 2H-benzo [1,4]thiazinyl group, a 2-oxo-2H-benzo[e](1,3]oxazinyl or 2,2-dioxo-1H-benzo[c][1,2]thiazinyl group, a 2,3-dihydro-1 H-benzo[e][1,4]diazepinyl or 2-oxo-2,3-dihydro-1 H-benzo[e][1,4]diazepinyl group, Boehringer Ingelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text a 4,5-dihydro-3H benzo[b][1,4]diazepinyl or 4-oxo-4,5-dihydro-3H-benzo[bJ[1,4]diazepinyl group, a 5-oxo-4,5-dihydro-3H-benzo[e][1,4]diazepinyl group, a 2,3-dihydro-benzo[t][1,4]oxazepinyl or 2,3-dihydro-benzo[b][1,4Joxazepinyl group, a 2,3-dihydro-benzo[t][1,4]thiazepinyl or 2,3-dihydro-benzo[b][1,4]thiazepinyl group, a 5-oxo-4,5-dihydro-benzo[tj[1,3,4]oxadiazepinyl group, a 11H-dibenzo[b,e]azepinyi or 11-oxo-11H-dibenzo[b,e]azepinyl group, a 11 H-benzo[e]pyrido[3,2-b]azepinyl or a 5H-1,9,10-triaza-dibenzo[a,d]-cycloheptenyl group, a 5H-dibenzo[b,e][1,4]diazepinyl or dibenzo[b,t][1,4]oxazepinyl group, a dibenzo[b,f][1,4]thiazepinyl, 5-oxo-dibenzo[b,fJ[1,4Jthiazepinyl or 5,5-dioxo-dibenzo[b,t][1,4Jthiazepinyl group, a 5H-dibenzo[a,dJcycloheptenyl or 5H-dibenzo[b,t]azepinyl group, a phenanthridinyl, benzo[c][1,5]naphthyridinyl, benzo[h][1,6]naphthyridinyl, benzo[c][1,8]naphthyridinyl, benzo[t][1,7]naphthyridinyl or 1,5,9-triaza-phenanthrenyl group, a 1,2,3,4-tetrahydro-phenanthridinyl, 1,2,3,4,4a,10b-hexahydro-phenan-thridinyl, 2,3-dihydro-1H-4-aza-cyclopenta[a]naphthyl or 8,9,10,11-tetrahydro-7H-6-aza-cyclohepta[a]naphthyl group, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text a 2,3-dihydro-1H-4-oxa-10-aza-phenanthrenyl or 1-oxo-2,3-dihydro-1H-4-oxa 10-aza-phenanthrenyl group, a phenanthrenyl, benzo[h]quinolinyl, benzo[tjquinolinyl or benzo[t]quinoxalinyl 5 group, a 5H-benzo[a]pyrrolo[1,2-a][1,4]diazepinyl, thieno[3,2-b][1,4]benzoxazepinyl, 5H-dibenzo[d,t][1,3]diazepinyl or 5-oxa-7-aza-dibenzo[a,c]cycloheptenyl group, 10 a naphtho[1,2-d]oxazolyl, naphtho[2,1-djoxazolyl , naphtho[1,2-d]thiazolyl, naphtho[2,1-d]thiazolyl, naphtho[1,2-d]imidazolyl, naphtho[1,2-b]furany~ or naphtho[2,1-b]furanyl group, or a furo[3,2-c]isoquinolinyl, pyrazolo[1,5-c]quinazolinyl or 1H-perimidinyl 15 group, while the benzo groups of the above mentioned radicals Ra are substituted by the groups R'° to R'3 and the alkylene units of the above mentioned groups Ra may be substituted by one or two fluorine atoms or one or two C,_3-alkyl or 20 C~_3-alkyloxy-carbonyl groups and the imino groups of the above mentioned radicals Ra may be substituted by a C~_3-alkyl group and R'° denotes a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, a C,_3-alkyl or cyclopropyl group, a hydroxy, C,_3-alkyloxy or cyclopropyloxy group, a nitro, amino, C~_3-alkylamino or di-(C~_3-alkyl)amino group, a C~_3-alkyl-carbonylamino or C~_3-alkyl-sulphonylamino group, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text a cyano, carboxy, C~_3-alkyloxy-carbonyl, aminocarbonyl, C~_3-alkyl-aminocarbonyl or di-(C~_3-alkyl)-aminocarbonyl group, a mercapto, C~_3-alkylsulphanyl, C~_3-alkysulphinyl, C~_3-alkylsulphonyl or aminosulphonyl group or a difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy group and R", R'2 and R'3, which may be identical or different, in each case represent a hydrogen atom, a fluorine, chlorine or bromine atom, a methyl, trifluoromethyl or methoxy group, R2 denotes a hydrogen atom or a C~_3-alkyl, cyclopropyl, trifluoromethyl, cyanomethyl or 2-cyano-ethyl group, Y denotes a nitrogen atom or a group of formula C-R5, while R5 denotes a hydrogen atom or a C~_3-alkyl group, R3 denotes a 2-buten-1-yl or 3-methyl-2-buten-1-yl group, a 1-buten-1-yl group, a 2-butyn-1-yl group or a 1-cyclopenten-1-ylmethyl group and R4 denotes a (3-amino-piperidin-1-yl) group, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text while, unless otherwise stated, the above mentioned alkyl groups may be straight-chain or branched, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
Particularly preferred are those compounds of the above general formula I
wherein R' denotes a methyl group substituted by a group Ra, where Ra denotes a 3,4-dihydro-quinolin-2-yl group, a 3,4-dihydro-isoquinolin-1-yl group, a 1,4-dihydro-quinazolin-2-yl or 4-oxo-1,4-dihydro-quinazolin-2-yl group, a 3,4-dihydro-quinazolin-2-yl or 4-oxo-3,4-dihydro-quinazolin-2-yl group, a 1H-benzo[dJ[1,2]oxazin-4-yl or 1-oxo-1H-benzo[dj[1,2]oxazin-4-yl group, a 4H-benzo[e][1,3]oxazin-2-yl or 4-oxo-4H-benzo[e][1,3]oxazin-2-yl group, a 4H-benzo[dJ[1,3]oxazin-2-yl or 4-oxo-4H-benzo[d][1,3]oxazin-2-yl group, a 2H-benzo[1,4]oxazin-3-yl or 2-oxo-2H-benzo[1,4]oxazin-3-yl group, a 4H-benzo[e][1,3]thiazin-2-yl or 4-oxo-4H-benzo[e][1,3]thiazin-2-yl group, a 4H-benzo[d][1,3]thiazin-2-yl or 2H-benzo[1,4]thiazin-3-yl group, a 2-oxo-2H-benzo[e][1,3]oxazin-4-yl or 2,2-dioxo-1H-benzo[c][1,2)thiazin-4-yl group, Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text a 2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl or2-oxo-2,3-dihydro-1H-benzo[e](1,4]diazepin-5-yl group, a 4,5-dihydro-3H benzo(b][1,4]diazepin-2-yl or 4-oxo-4,5-dihydro-3H-benzo[b][1,4]diazepin-2-yl group, a 5-oxo-4,5-dihydro-3H-benzo[e)[1,4]diazepin-2-yl group, a 2,3-dihydro-benzo[t][1,4]oxazepin-5-yl or 2,3-dihydro-benzo[b][1,4]oxazepin-4-yl group, a 2,3-dihydro-benzo[tJ[1,4]thiazepin-5-yl or 2,3-dihydro-benzo[b][1,4]thiazepin-4-yl group, a 5-oxo-4,5-dihydro-benzo[t][1,3,4]oxadiazepin-2-yl group, a 11H-dibenzo[b,e]azepin-6-yl or 11-oxo-11H-dibenzo[b,e]azepin-6-yl group, a 11 H-benzo[e]pyrido(3,2-b]azepin-6-yl or a 5H-1,9,10-triaza-dibenzo[a,d]-cyclohepten-11-y) group, a 5H-dibenzo[b,e][1,4]diazepin-11-yl or dibenzo[b,tJ(1,4]oxazepin-11-yl group, a dibenzo[b,fJ[1,4]thiazepin-11-yl, 5-oxo-dibenzo[b,tJ[1,4]thiazepin-11-yl or 5,5-dioxo-dibenzo[b,tJ[1,4]thiazepin-11-yl group, a 5H-dibenzo[a,d]cyclohepten-10-yl or 5H-dibenzo[b,t]azepin-10-yl group, a phenanthridin-6-yl, benzo[c][1,5]naphthyridin-6-yl, benzo[h][1,6]naphthyridin-5-yl, benzo[c][1,8]naphthyridin-6-yl, benzo[t][1,7]naphthyridin-5-yl or 1,5,9-triaza-phenanthren-10-yl group, Boehringer Ingelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text a 1,2,3,4-tetrahydro-phenanthridin-6-yl, 1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl, 2,3-dihydro-1H-4-aza-cyclopenta[a]naphth-5-yl or 8,9,10,11-tetrahydro-7H-6-aza-cyclohepta[a]naphth-5-yl group, a 2,3-dihydro-1 H-4-oxa-10-aza-phenanthren-9-yl or 1-oxo-2,3-dihydro-1 H-4-oxa-10-aza-phenanthren-9-yl group, a phenanthren-9-yl, benzo[h]quinolin-6-yl, benzo[t]quinolin-6-yl or benzo[fJquinoxalin-6-yl group, a 5H-benzo[e]pyrroto[1,2-a][1,4]diazepin-11-yl, thieno[3,2-b](1,4]benzoxaze-pin-9-yl, 5H-dibenzo[d,t](1,3]diazepin-6-yl or 5-oxa-7-aza-di-benzo[a,c]cyclohepten-6-yl group, a naphtho[1,2-d]oxazol-2-yl, naphtho[2,1-d]oxazol-2-yl, naphtho[1,2-d]thiazol-2-yl, naphtho[2,1-d]thiazol-2-yl, naphtho[1,2-d]imidazol-2-yl, naphtho(1,2-b]furan-2-yl or naphtho[2,1-b]furan-2-yl group, or a furo[3,2-c]isoquinolin-5-yl, pyrazolo[1,5-c]quinazolin-5-yl or 1 H-perimidin-2-yl group, while the benzo groups of the above mentioned radicals Ra are substituted by the groups R'° to R'3 and the alkylene units of the above mentioned groups Ra may be substituted by one or two fluorine atoms or one or two methyl groups and the imino groups of the above mentioned radicals Ra may be substituted by a methyl group and R'° denotes a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, a methyl or ethyl group, a hydroxy, methoxy or ethoxy group or Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text a difluoromethyl, trifluoromethyl, difluoromethoxy, or trifluoromethoxy group and 5 R", R'2 and R'3, which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom or a methyl, trifluoromethyl or methoxy group, R2 denotes a hydrogen atom or a methyl, cyanomethyl, trifluoromethyl, ethyl, 2-cyano-ethyl, propyl, eyclopropyl or isopropyl group, Y denotes a nitrogen atom or a group of formula C-R5, while R5 denotes a hydrogen atom or a methyl, ethyl, propyl or isopropyl group, R3 denotes a 2-buten-1-yl or 3-methyl-2-buten-1-yf group, a 1-buten-1-yl group, a 2-butyn-1-yl group or a 1-cyclopenten-1-ylmethyl group and R4 denotes a (3-amino-piperidin-1-yl) group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Most particularly preferred are those compounds of the above general formula I
wherein R' denotes a 4-oxo-3,4-dihydro-quinazolin-2-ylmethyl group, a dibenzo[b,fj[1,4joxazepin-11-ylmethyl group, a phenanthridin-6-ylmethyi group, a phenanthren-9-ylmethyl group or a naphtho[1,2-dJoxazol-2-ylmethyl or naphtho[2,1-dJoxazol-2-ylmethyl group, R2 denotes a hydrogen atom or a methyl group, Y denotes a nitrogen atom, R3 denotes a 2-butyn-1-yl group and R4 denotes a (3-amino-piperidin-1-yl) group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text The following compounds of general formula I deserve special mention:
(1) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,tj[1,4]oxazepin-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one I~ o N
i N i N, >
C N Nw I N ~~
NHZ
(2) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-djpyridazin-4-one o N
N
N
I ~N N~ I N
/ NHZ
(3) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthren-9-yl)methyl]-3,5-dihydro-imidazo[4, 5-d]pyridazin-4-one N N
I / N w I ~~N~
\N
/ NHZ
(4) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-7-methyl-3, 5-di hydro-imidazo[4, 5-d]pyridazi n-4-one O
I ' I N~ N
N N~N
(5) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,t][1,4]oxazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text O
N N
O 1N N w I ~~N~
~N
NHz \ /
(6) 2-((S)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo(b,t][1,4)oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one N N
O ~N N ~ I ~~ N
N
/ \ ,NH2 (7) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one O
N N
O IN N w I ~~ N
N
/ \ NH2 (8) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[2,1-dJoxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one O
\ O~N N
\ N Nw I ~~N\ /
~N
(9) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[1,2-d]oxazol-2-yl )methyl]-3, 5-di hydro-i m idazo[4, 5-dJpyridazin-4-one Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text N~N N
O
I ~ ~ O N w I ~~ N
N
NHz (10) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-djpyridazin-4-one O
N~N N
NH N ~ I i~N
~--~N
O NHZ
, the enantiomers, the mixtures thereof and the salts thereof.
According to the invention the compounds of general formula I are obtained by methods known per se, for example by the following methods:
a) deprotecting a compound of general formula ~3 R1~ N /1 _N
I I ~~---R4~, Y~ N
(II), wherein R', R2, Y and R3 are as hereinbefore defined and R4" denotes one of the groups mentioned for R4 hereinbefore which contain an imino, amino or alkylamino group, while the imino, amino or alkylamino group is substituted by a protective group.
The liberating of an amino group from a protected precursor is a standard reaction in synthetic organic chemistry. There are many examples of suitable protective groups.
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text A summary of the chemistry of protective groups can be found in Theodora W.
Greene and Peter G. M. Wuts, Protective Groups in Organic Synthesis, Second Edition, 1991, published by John Wiley and Sons, and in Philip J. Kocienski, Protecting Groups, published by Georg Thieme, 1994.
The following are examples of protective groups:
the tert.-butyloxycarbonyl group which can be cleaved by treating with an acid such as for example trifluoroacetic acid or hydrochloric acid or by treating with 10 bromotrimethylsilane or iodotrimethylsilane, optionally using a solvent such as methylene chloride, ethyl acetate, dioxane, methanol, isopropanol or diethylether at temperatures between 0°C and 80°C, the 2,2,2-trichloroethoxycarbonyl group which can be cleaved by treating with metals 15 such as for example zinc or cadmium in a solvent such as acetic acid or a mixture of tetrahydrofuran and a weak aqueous acid at temperatures between 0°C and the boiling temperature of the solvent used and the carbobenzyloxycarbonyl group which can be cleaved for example by 20 hydrogenolysis in the presence of a noble metal catalyst such as for example palladium-charcoal and a solvent such as for example alcohols, ethyl acetate, dioxane, tetrahydrofuran or mixtures of these solvents at temperatures between 0°C
and the boiling point of the solvent, by treating with boron tribromide in methylene chloride at temperatures between -20°C and ambient temperature, or by treating 25 with aluminium chloride/anisol at temperatures between 0°C and ambient temperature.
Moreover, the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers, as mentioned hereinbefore. Thus, for example, 30 cis/trans mixtures may be resolved into their cis and trans isomers, and compounds with at least one stereocentre may be separated into their enantiomers.
Thus, for example, the cis/trans mixtures obtained may be resolved by chromatography into the cis and trans isomers thereof, the compounds of general Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text formula I obtained which occur as racemates may be separated by methods known per se (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971 ) into their optical antipodes and compounds of general formula I
with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g. by chromatography andlor fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.
The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-O-p-toluoyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+)- or (-)-menthol and an optically active acyl group in amides, for example, may be a (+)- or (-)-menthyloxycarbonyl.
Furthermore, the compounds of formula I obtained may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulphonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or malefic acid.
Moreover, if the new compounds of formula I thus obtained contain a carboxy group, they may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, particularly for pharmaceutical use into the physiologically acceptable salts thereof. Suitable bases for this purpose include for example sodium Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text hydroxide, potassium hydroxide, arginine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
The compounds of general formula II used as starting materials are either known from the literature or may be obtained by methods known from the literature (cf.
Examples I to XVI).
As already mentioned hereinbefore, the compounds of general formula I
according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibiting effect on the enzyme DPP-IV.
The biological properties of the new compounds were investigated as follows:
The ability of the substances and their corresponding salts to inhibit the DPP-IV
activity can be demonstrated in a test set-up in which an extract of human colon carcinoma cell line Caco-2 is used as the DPP IV source. The differentiation of the cells in order to induce the DPP-IV expression was carried out as described by Reiher et al. in an article entitled "Increased expression of intestinal cell line Caco-2" , which appeared in Proc. Natl. Acad. Sci. Vol. 90, pages 5757-5761 (1993). The cell extract was obtained from cells solubilised in a buffer (10mM Tris HCI, 0.15 M
NaCI, 0.04 t.i.u. aprotinin, 0.5% Nonidet-P40, pH 8.0) by centrifuging at 35,000 g for 30 minutes at 4°C (to remove cell debris).
The DPP-IV assay was carried out as follows:
50 NI substrate solution (AFC; AFC is amido-4-trifluoromethylcoumarin), final concentration 100 NM, were placed in black microtitre plates. 20 NI of assay buffer (final concentrations 50 mM Tris HCI pH 7.8, 50 mM NaCI, 1 % DMSO) was pipetted in. The reaction was started by adding 30 NI of solubilised Caco-2 protein (final concentration 0.14 Ng of protein per well). The test substances to be investigated were typically added prediluted in 20 NI, and the volume of assay buffer was then reduced accordingly. The reaction was carried out at ambient temperature, incubating for 60 minutes. Then the fluorescence was measured in a Victor 1420 Multilabel Counter, the excitation wavelength being 405 nm and the emission Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text wavelength being 535 nm. Blank readings (corresponding to 0 % activity) were obtained in mixtures without any Caco-2 protein (volume replaced by assay buffer), control values (corresponding to 100 % activity) were obtained in mixtures with no substance added. The potency of the test substances in question, expressed as ICSo values, was calculated from dosage/activity curves consisting of 11 measuring points in each case. The following results were obtained:
Compound DPP IV inhibition (Example No.) ICSO [nM]
1(1) 17 1 (2) 58 1(3) 8 1(4) 9 1(7) 3 1(8) 7 1(9) 3 The compounds prepared according to the invention are well tolerated, as for example when 10 mg/kg of the compound of Example 1 were administered to rats by oral route no changes in the animals' behaviour could be detected.
In view of their ability to inhibit DPP-IV activity, the compounds of general formula I
according to the invention and the corresponding pharmaceutically acceptable salts thereof are suitable for treating all those conditions or illnesses which can be influenced by the inhibition of the DPP-IV activity. It is therefore to be expected that the compounds according to the invention will be suitable for the prevention or treatment of diseases or conditions such as type I and type II diabetes mellitus, diabetic complications, metabolic acidosis or ketosis, insulin resistance, dyslipidaemias of various origins, arthritis, atherosclerosis and related diseases, obesity, allograft transplantation and calcitonin-induced osteoporosis. fn addition these substances are capable of preventing B-cell degeneration such as e.g.
apoptosis or necrosis of pancreatic B-cells. The substances are also suitable for Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text improving or restoring the function of pancreatic cells and also increasing the number and size of pancreatic B-cells. Additionally, and on the basis of the role of the Glucagon-Like Peptides, such as e.g. GLP-1 and GLP-2 and their link with DPP-IV
inhibition, it is likely that the compounds according to the invention are suitable for achieving, inter alia, a sedative or anxiety-relieving effect and also of favourably affecting catabolic states after operations or hormonal stress responses or of reducing mortality or morbidity after myocardial infarct. They are also suitable for treating all conditions which are connected with the above mentioned effects and which are mediated by GLP-1 or GLP-2. The compounds according to the invention may also be used as diuretics or antihypertensives and are suitable for preventing and treating acute renal failure. They are also suitable for the prevention and treatment of chronic inflammatory intestinal diseases. It is also expected that DPP-IV
inhibitors and hence also the compounds according to the invention may be used to treat infertility or to improve fertility in humans or mammals, particularly when the infertility is connected with insulin resistance or polycystic ovary syndrome.
The substances are also suitable for treating deficiencies of growth hormone which are associated with reduced stature.
The compounds according to the invention may also be used in conjunction with other active substances. Therapeutic agents which are suitable for such combinations include, for example, antidiabetics, such as metformin, sulphonylureas (e.g. glibenclamide, tolbutamide, glimepiride), nateglinide, repaglinide, thiazolidine-dione (e.g. rosiglitazone, pioglitazone), PPAR-gamma agonists (e.g. GI
262570), alpha-glucosidase inhibitors (e.g. acarbose, voglibose), alpha2 antagonists, insulin and insulin analogues, GLP-1 and GLP-1 analogues (e.g. exendin-4) or amylin.
Also, inhibitors of protein tyrosine phosphatase 1, substances which influence deregulated glucose production in the liver, such as e.g. inhibitors of glucose-6-phosphatase, or fructose-1,6-bisphosphatase, glycogen phosphorylase, glucagon receptor antagonists and inhibitors of phosphoenol pyruvate carboxykinase, glycogen synthase kinase or pyruvate dehydrokinase, lipid lowering agents, such as HMG-CoA-reductase inhibitors (e.g. simvastatin, atorvastatin), fibrates (e.g.
bezafibrate, fenofibrate), nicotinic acid and its derivatives, cholesterol absorption inhibitors such as for example ezetimibe, bile acid-binding substances such as for example cholestyramine, HDL-raising compounds such as for example inhibitors of CETP
or Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text regulators of ABC1 or active substances for the treatment of obesity, such as e.g.
sibutramine or tetrahydrolipostatin, or f33-agonists such as SB-418790 or AD-9677.
It is also possible to combine the compounds with drugs for treating high blood 5 pressure such as e.g. All antagonists or ACE inhibitors, diuretics, (3-blockers, etc., or combinations thereof.
The dosage required to achieve such an effect is expediently, by intravenous route, 1 to 100 mg, preferably 1 to 30 mg, and by oral route 1 to 1000 mg, preferably 1 to 100 10 mg, in each case 1 to 4 times a day. For this purpose, the compounds of formula I
prepared according to the invention, optionally combined with other active substances, may be incorporated together with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, 15 water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof into conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.
The Examples that follow are intended to illustrate the invention:
Boehringer Ingelheim International GmbH Case 111502 55216 fngelheim foreign filing text Preparation of the starting compounds:
Example I
2-[3-(tert.-butyloxycarbonylam ino)-piperidi n-1-yl]-3-(2-butyn-1-yl )-5-[(dibenzo[b,t][1,4]-oxazeain-11-vl)methyll-3,5-dihvdro-imidazof4,5-dlayridazin-4-one 317 mg 11-chloromethyl-dibenzo[b,f][1,4]oxazepin are added to 400 mg 2-[3-(tert.-butyloxycarbonylam ino)-pi peridin-1-yl]-3-(2-butyn-1-yl )-3, 5-d ihyd ro-i midazo[4, 5-dJpyridazin-4-one and 276 mg potassium carbonate in 4 ml N,N-dimethylformamide.
The reaction mixture is stirred for two hours at 80°C. For working up it is combined with water and the precipitate formed is suction filtered. The crude product is purified by chromatography over a silica gel column with methylene chloride/methanol (100:0 to 70:30) as eluant.
Yield: 120 mg (20 % of theory) Mass spectrum (ESI+): m/z = 594 [M+H]+
The following compounds are obtained analogously to Example I:
(1 ) 2-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(phenan-thrid in-6-yl )methyl]-3, 5-dihyd ro-i midazo[4, 5-dj pyridazin-4-one (2) 2-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(phenanthren-9-yl )methyl]-3, 5-d i hyd ro-im idazo[4,5-djpyridazin-4-one (3) 2-[(R)-3-(tert.-butyloxycarbonylamino) -piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(phenan-thridin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one Rf value: 0.41 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 592 [M+H]+
(4) 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(dibenzo[b,t][1,4]oxazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-djpyridazin-4-one Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 2:8) Mass spectrum (ESI+): m/z = 608 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text (5) 2-bromo-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-djpyridazin-4-one Mass spectrum (ESI+): m/z = 474, 476 [M+H]+
(6) 2-bromo-3-(2-butyn-1-yl)-5-[(naphtho[2,1-d]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one Rf value: 0.80 (silica gel, methylene chloride/ethanol = 9:1 ) (7) 2-bromo-3-(2-butyn-1-yl)-5-[(naphtho[1,2-d]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one Rf value: 0.50 (silica gel, methylene chloride/methanol = 19:1 ) (8) 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-cyano-methyl-3,5-dihydro-imidazo[4,5-djpyridazin-4-one Rf value: 0.40 (silica gel, petroleum ether/ethyl acetate = 1:4) Mass spectrum (ESI+): m/z = 426 [M+H]+
Example II
2-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-3-(2-butyn-1-yl )-3, 5-dihydro-imidazoj4 5-dlpyridazin-4-one 2.50 g 3-(tert.-butyloxycarbonylamino)-piperidine are added to 2.65 g 2-bromo-3-(2-butyn-1-yl)-3,5-dihydro-imidazo[4,5-c~pyridazin-4-one and 2.12 g sodium carbonate in 5 ml dimethylsulphoxide. The reaction mixture is stirred overnight at 85°C.
After cooling to ambient temperature it is combined with water and extracted with ethyl acetate. The combined organic phases are dried over magnesium carbonate and evaporated down. The crude product is further reacted without any further purification.
Mass spectrum (ESI+): m/z = 387 [M+H]+
The following compounds are obtained analogously to Example II:
(1 ) 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-7-methyl-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one Rf value: 0.15 (silica gel, cyclohexane/ethyl acetate = 3:7) Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Mass spectrum (ESI+): m/z = 401 [M+H]+
(2) 2-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(dibenzo[b,t][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one Mass spectrum (ESI+): m/z = 594 [M+H]+
(3) 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(dibenzo[b,t][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-djpyridazin-4-one Mass spectrum (ESI~): m/z = 594 [M+HJ+
(4) 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(naphtho[2,1-d]oxazol-2-yl)methyl]-3, 5-dihyd ro-imidazo[4, 5-dJpyridazin-4-one Rf value: 0.70 (silica gel, methylene chloride/ethanol = 9:1 ) (5) 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-ylJ-3-(2-butyn-1-yl)-5-[(naphtho[1, 2-d]oxazol-2-yl )methyl]-3, 5-d ihyd ro-imidazo[4, 5-djpyridazi n-4-one Rf value: 0.65 (silica gel, methylene chloride/methanol = 9:1 ) Mass spectrum (ESI+): m/z = 568 [M+H]+
(6) 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one Mass spectrum (ESI+): m/z = 387 [M+H]+
Rf value: 0.50 (silica gel, methylene chloride/ethanol = 9:1 ) Examale III
2-bromo-3-(2-butyn-1-yl)-3,5-dihydro-imidazof4.5-dlpyridazin-4-one 0.63 ml hydrazine hydrate are added dropwise to 3.68 g methyl 2-bromo-3-(2-butyn-1-yl)-5-formyl-3H-imidazole-4-carboxylate in 50 ml of ethanol. The reaction mixture is stirred for one hour at ambient temperature, then 3 ml acetic acid are added and the reaction mixture is refluxed for a further hour. The precipitate formed is suction filtered, washed with ethanol and diethyl ether and dried.
Yield: 2.65 g (77 % of theory) Mass spectrum (ESI+): m/z = 267, 269 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example IV
methyl 2-bromo-3-l2-butyn-1-vl~ 5-formyl-3H-imidazole-4-carboxylate 45 ml diisobutylaluminium hydride solution (1M in toluene) are added dropwise to 12.45 g dimethyl 2-bromo-3-(2-butyn-1-yl)-1H-imidazole-4,5-dicarboxylate in 150 ml of tetrahydrofuran under an argon atmosphere at -65°C. The reaction mixture is stirred for two hours at -65°C, then another 9 ml diisobutylaluminium hydride solution are added. After another hour the reaction mixture is quenched at -65°C
with a mixture of 1 M hydrochloric acid and tetrahydrofuran (1:1 ) and stirred for ten minutes.
Then the cooling bath is removed, the reaction mixture is diluted with water and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with cyclohexane/ethyl acetate (2:1 to 1:1 ).
Yield: 9.58 g (85 % of theory) Mass spectrum (ESI+): m/z = 285, 287 [M+H]+
The following compounds are obtained analogously to Example IV:
(1 ) methyl 2-bromo-3-(3-methyl-2-buten-1-yl)-5-formyl-3H-imidazole-4-carboxylate Mass spectrum (ESI+): m/z = 301, 303 [M+H]+
Example V
dimethvl 2-bromo-3-(2-butvn-1-yl)-1 H-imidazole-4.5-dicarboxylate 4.53 ml of 1-bromo-2-butyne are added to 13.20 g dimethyl 2-bromo-1H-imidazole-4,5-dicarboxylate and 8.57 g potassium carbonate in 70 ml N,N-dimethylformamide and the reaction mixture is stirred overnight at ambient temperature.
For working up it is combined with water and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down.
Yield: 14.58 g (92 % of theory) Mass spectrum (ESI+): m/z = 315, 317 [M+H]+
The following compounds are obtained analogously to Example V:
(1) dimethyl 2-bromo-3-(3-methyl-2-buten-1-yl)-1H-imidazole-4,5-dicarboxylate Mass spectrum (ESI+): m/z = 331, 333 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example VI
Dimethyl 2-bromo-1 H-imidazole-4,5-dicarboxvlate 6.11 ml bromine are added to 19.80 g dimethyl 1 H imidazole-4,5-dicarboxylate and 5 14.92 g potassium carbonate in 600 ml methylene chloride. The reaction mixture is stirred for one hour at ambient temperature, then a mixture of saturated sodium sulphite solution and saturated sodium chloride solution (1:1) is added. The organic phase is largely separated off and the aqueous phase is extracted with ethyl acetate several times. The combined organic phases are dried over magnesium sulphate 10 and evaporated down, leaving about 7.40 g crude product. The aqueous phase is combined with ethyl acetate and extracted overnight in an extraction apparatus. The ethyl acetate extract is evaporated down and the flask residue is combined with the crude product already obtained.
Yield: 13.10 g (46 % of theory) 15 Mass spectrum (ESI+): m/z = 263, 265 [M+H]+
Example VII
2-Bromo-3-(2-but~m1-yl -7-methyl-3.5-dihydro-imidazo[4.5-dlpyridazin-4-one 0.50 ml of 1-bromo-2-butyne are added to 1.30 g 2-bromo-7-methyl-3,5-dihydro-20 imidazo[4,5-d]pyridazin-4-one and 0.99 ml Hunig base in 30 ml of N,N-dimethylformamide. The reaction mixture is stirred for three hours at ambient temperature. Then the solvent is distilled off in vacuo using the rotary evaporator.
The flask residue is stirred with 40 ml of water and 0.5 ml concentrated aqueous ammonia solution, suction filtered and washed with ethanol as well as diethyl ether.
25 Yield: 1.30 g (82 % of theory) Rf value: 0.60 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 281, 283 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example VIII
2-bromo-7-methyl-3,5-dihydro-imidazoj4.5-d]pyridazin-4-one 5.20 ml of a 1.8 M solution of bromine in acetonitrile are slowly added dropwise to 1.40 g of 7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and 1.30 g potassium carbonate in 40 ml acetonitrile. Then the reaction mixture is heated to 70°C, whereupon the mixture is rapidly decolourised. More bromine solution and potassium carbonate are added batchwise until the reaction has ended, according to HPLC-MS.
For working up the reaction mixture is evaporated down, stirred with 100 ml of water and suction filtered. The filtrate is acidified with 1 M hydrochloric acid and extracted with ethyl acetate. The combined extracts are dried over sodium sulphate and evaporated down.
Yield: 1.30 g (61 % of theory) Rf value: 0.37 (silica gel, methylene chloride/methanol = 9:1 ) Mass spectrum (ESI+): m/z = 229, 231 [M+H]+
Example IX
7-methyl-3.5-dihydro-imidazof4.5-dlpyridazin-4-one A solution of 4.00 g sodium nitrite in 15 ml of water is added dropwise at 50°C to 2.20 g of 4-amino-7-methyl-3H-imidazo[4,5-d]pyridazine in a mixture of 30 ml acetic acid, 5 ml of water and 0.5 ml concentrated sulphuric acid. The reaction mixture is stirred for a further two hours at 50°C and then heated to 90°C
for one hour. After cooling to ambient temperature the reaction mixture is diluted with 30 ml of water.
The precipitate formed is suction filtered, washed with water, ethanol and diethyl ether and dried.
Yield: 1.00 g (45 % of theory) Mass spectrum (ESI+): m/z = 151 [M+H]+
Example X
4-amino-7-methyl-3H-imidazo~4.5-dJpyridazine A mixture of 2.00 g 5-acetyl-3H-imidazole-4-carbonitrile and 4.00 ml hydrazine hydrate in 50 ml of ethanol is heated to 100 °C, until the reaction is complete according to HPLC-MS. After cooling to ambient temperature the reaction mixture is evaporated down, stirred with 20 ml of cold ethanol and suction filtered. The filter cake is washed with diethyl ether and dried.
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Yield: 2.10 g (95 % of theory) Mass spectrum (ESI+): m/z = 150 [M+H]+
Example XI
5-acetyl-3H-imidazole-4-carbonitrile 57 ml of a 3 M solution of methylmagnesium bromide in diethyl ether are added to 7.00 g of 4,5-dicyano-imidazole in 80 ml of tetrahydrofuran under an argon atmosphere, while the temperature is maintained between 5°C and 15°C.
After two hours the reaction is complete according to thin layer chromatography and the reaction mixture is diluted with 400 ml of ethyl acetate. Then 400 ml saturated ammonium chloride solution are slowly added. After ten minutes the mixture is acidified with semiconcentrated sulphuric acid and stirred for another twenty minutes before the organic phase is separated off. The aqueous phase is extracted with ethyl acetate and the combined organic phases are dried over sodium sulphate and evaporated down. The flask residue is stirred with ethyl acetate, suction filtered and washed with ethyl acetate and diethyl ether.
Yield: 3.30 g (43 % of theory) Mass spectrum (ESI+): m/z = 136 [M+H]+
Example XII
2-chloromethyl-naphthol2 1-dloxazole Prepared by reacting 2.93 g of 2-amino-1-naphthol with 3.54 g of 2-chloro-1,1,1-triethoxy-ethane in 25 ml of ethanol at 60°C.
Yield: 1.90 g (58 % of theory) Rf value: 0.55 (silica gel, petroleum ether/ethyl acetate = 9:1 ) Mass spectrum (ESI+): m/z = 218, 220 [M+H]+
The following compounds are obtained analogously to Example XII:
(1 ) 2-chloromethyl-naphtho[1,2-dJoxazole Rf value: 0.90 (silica gel, methylene chloride/methanol = 19:1 ) Mass spectrum (ESI+): m/z = 218, 220 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example XIII
2-bromo-3-( 3-methyl-2-buten-1-yl)-3, 5-dihydro-imidazof 4.5-clpyridin-4-one 1.55 g Burgess reagent (methoxycarbonylsulphamoyl-triethylammonium-N-betaine) are added to 1.60 g of 2-bromo-7-hydroxy-3-(3-methyl-2-buten-1-yl)-3,5,6,7-tetrahydro-imidazo[4,5-c]pyridin-4-one in 20 ml methylene chloride and 4 ml of tetrahydrofuran. The reaction mixture is stirred for eight hours at 60°C, then another 0.3 equivalents Burgess reagent is added. After a further two hours the cooled reaction mixture is combined with aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down. The flask residue is chromatographed through a silica gel column with methylene chloride/methanol (1:0 to 10:1) as eluant.
Yield: 1.06 g (60 % of theory) Mass spectrum (ESI+): m/z = 282, 284 [M+H]+
Example XIV
2-bromo-7-hydrox ~-L313-methyl-2-buten-1-yl~ 3,5.6,7-tetrahydro-imidaz~4,5-,p~rridin-4-one 90 ml of water and 5.40 g iron powder are added to 4.15 g methyl 2-bromo-5-(1-hydroxy-2-nitro-ethyl)-3-(3-methyl-2-buten-1-yl)-3H-imidazole-4-carboxylate in 270 ml of ethanol. The mixture is refluxed, combined with 36 ml glacial acetic acid and stirred for one and a half hours at reflux temperature. The cooled reaction solution is filtered through Celite. The filtrate is evaporated down, combined with ethanol and made basic with solid potassium carbonate. The mixture is stirred for three hours at 60°C. Then the ethanol is distilled off, the flask residue is combined with water and extracted with ethyl acetate. The combined extracts are dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with methylene chloridelmethanol (1:1 to 7:1) as eluant.
Yield: 1.62 g (47 % of theory) Mass spectrum (ESI+): m/z = 300, 302 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example XV
Methyl 2-bromo-5-( 1-hyd roxy-2-nitro-ethyl)-3-(3-methyl-2-buten-1-yl)-3H-imidazole-4-carboxvlate 35 ml nitromethane are added to 1.14 g caesium carbonate in 15 ml of methanol at ambient temperature. Then the mixture is combined with a solution of 3.50 g methyl 2-bromo-3-(3-methyl-2-buten-1-yl)-5-formyl-3H-imidazole-4-carboxylate in 20 ml of methanol and 5 ml methylene chloride and stirred for 15 minutes at ambient temperature. Then 0.5 ml acetic acid are added and the solution is evaporated down in vacuo. The flask residue is combined with aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down.
Yield: 4.15 g (99 % of theory) Mass spectrum (ESI+): m/z = 362, 364 [M+H]+
Example XVI
2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl )-5-[(4-oxo-3, 4-dihvdro-auinazolin-2-yl)methyll-3 5-dihvdro-imidazof4 5-dlpyridazin-4-one 40 mg sodium methoxide (95 %) are added to a solution of 605 mg 2-[(R)-3-(tert.-butyloxycarbonylamino)-pi peridi n-1-yl]-3-(2-butyn-1-yl )-5-cyanomethyl-3, 5-d ihyd ro-imidazo[4,5-dJpyridazin-4-one in 9 ml of methanol. The mixture is stirred for one hour at ambient temperature and then neutralised with 41 pL glacial acetic acid.
Then a solution of 195 mg anthranilic acid in 2 ml of methanol is added and the reaction mixture is heated to 70°C. After about two hours a white, voluminous precipitate is formed and the reaction mixture is cooled to ambient temperature. The precipitate formed is suction filtered, washed with cold methanol and dried.
Yield: 234 mg (30 % of theory) Mass spectrum (ESI+): m/z = 545 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Preparation of the final compounds:
Example 1 ' N
i N' G N Nw I N ~~
NHZ
5 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,tj[1,4]oxazepin-11-yl)methyl]-3 5-dih dro-imidazo 4 5- ridazin-4-one 0.33 ml trifluoroacetic acid are added to 120 mg 2-[3-(tert.-butyloxycarbonylamino)-pi peridin-1-yl]-3-(2-butyn-1-yl )-5-[(di benzo[b, t] [1,4]oxazepin-11-yl )methyl]-3, 5-dihydro-imidazo[4,5-dJpyridazin-4-one in 3 ml methylene chloride while cooling with 10 an ice bath. The reaction mixture is stirred overnight at ambient temperature.
For working up it is poured onto cooled saturated potassium carbonate solution and extracted with methylene chloride. The organic phase is separated off and evaporated down. The crude product is purified by chromatography over a silica gel column with methylene chloride/methanol (100:0 to 70:30) as eluant.
15 Yield: 63 mg (63 % of theory) Mass spectrum (ESI+): m/z = 494 [M+H]+
The following compounds are obtained analogously to Example 1:
20 (1) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one O
w N N
I
~N Nw ~ N N
NHZ
Mass spectrum (ESI+): m/z = 478 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text (2) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthren-9-yl)methyl)-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one N
_N ,. I /~--N
N
/ NHz Mass spectrum (ESI+): m/z = 477 [M+H]+
(3) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-c~pyridazin-4-one x trifluoroacetic acid ~ il' N I N~-N
N N~N
I / NHZ x CF3COOH
Rf value: 0.45 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/
trifluoroacetic acid = 50:50:0.1 ) Mass spectrum (ESI+): m/z = 492 [M+H]+
(4) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,t][1,4]oxazepin-11-yl)methyl]-7-methyl-3, 5-dihydro-imidazo[4, 5-dJpyridazin-4-one N N
O 1N N w I ~~ N
~N
NHZ
Carried out with isopropanolic hydrochloric acid (5-6 M) in methylene chloride.
Mass spectrum (ESI+): m/z = 508 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim forei4n filing text (5) 2-((S)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,tj[1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one O
I
N N
0 ,N N ~ I ~~ N
N
/ \ ~NHz Mass spectrum (ESI+): m/z = 494 [M+H]+
(6) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one N N
0 1N N w I ~~ N
N
/ \ NH2 Mass spectrum (ESI+): m/z = 494 [M+H]+
(7) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[2,1-dJoxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one \ G~N I N~N
\ N N~ N
N Hz Rf value: 0.40 (silica gel, methylene chloride/ethanol/conc. aqueous ammonia =
90:10:2) Mass spectrum (ESI+): m/z = 468 [M+H]+
(8) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[1,2-d]oxazol-2-yl )methyl]-3, 5-di hydro-i midazo[4, 5-c~pyridazin-4-one N~ N
\ O N~ N
NHz Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Mass spectrum (ESI+): m/z = 468 [M+H]+
(9) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one o i N~N N
NH N ~ I ~~N~
'N
p NHz Mass spectrum (ESI+): m/z = 445 [M+H]+
The following compounds may also be obtained analogously to the foregoing Examples and other methods known from the literature:
No. Name Structural formula 2-(3-amino-piperidin-1-yl)-3-(2-buten-1-(1) yl)-5-[(3,4-dihydro-quinolin-2-yl)methyl]- I N N
6,7-dimethyl-3,5-dihydro-imidazo[4,5- ~ N ~ N
~~-N
c]pyridin-4-one ~ ~ ~ NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- N o (2) yl)-5-[(3,4-dihydro-isoquinolin-1- ~ \ ~N I N
N
yl)methyl]-7-cyclopropyl-3,5-dihydro- N ~ ~--(N
NHZ
imidazo[4,5-dJpyridazin-4-one 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- N o ( ) yl)-5-[(3,3-dimethyl-3,4-dihydro- ~ N
3 ~N
isoquinolin-1-yl)methyl]-3,5-dihydro- - N ~ I i~-N
~-.~N
im idazo[4, 5-dJpyridazin-4-one NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- N O
( ) yl)-5-[(4,4-dimethyl-3,4-dihydro- ~ N N
4 ~ i~ N
isoquinolin-1-yl)methyl]-3,5-dihydro- ~ ~ N ~ N
imidazo[4,5-dJpyridazin-4-one NHz Boehringer lngelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ o ( ) yl)-5-[(1-methyl-1,4-dihydro-quinazolin-2- / ~ N N
yl)methyl]-3,5-dihydro-imidazo[4,5- N N ~ ~ ~ N
~N
d]pyridazin-4-one NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ o ( ) yl)-5-[(1-methyl-4-oxo-1,4-dihydro- / ~ N N
quinazolin-2-yl)methyl]-3,5-dihydro- N N ~ ~ ~ N
~N
imidazo[4,5-dJpyridazin-4-one ~ NHz 2-(3-amino-piperidin-1-yl}-3-(2-buten-1- F I o yl)-5-[(5,6,7,8-tetrafluoro-1-methyl-1,4- F ~ N
N
(7) dihydro-quinazolin-2-yl)methyl]-3,5- F ~ ~ ~ ~ ~ ~~--N~
N
dihydro-imidazo[4,5-c]pyridin-4-one F NHZ
2-(3-amino-piperidin-1-yl)-3-(2-buten-1- \ N o (8) yl)-5-[(3,4-dihydro-quinazolin-2-yl)methyl]- / ~ NH N I N N
3,5-dihydro-imidazo[4,5-dJpyridazin-4-one N~N
2-(3-amino-piperidin-1-yl )-3-(2-butyn-1- o (9) yl)-5-[(3-methyl-3,4-dihydro-quinazolin-2- I ~ N~ N
N
yl)methyl]-3,5-dihydro-imidazo[4,5- ~N~ N ~ ~ ~~N
~N
d]pyridazin-4-one NHZ
2-(3-amino-piperidin-1-yl )-3-(2-butyn-1- o yl)-5-[(3-methyl-3,4-dihydro-quinazolin-2- ~ N~ N
N
(10) I meth I -3,5-dih dro-imidazo 4,5- ~ I ~ w ~ ~ N
Y ) Y ] Y [ w ~N
c]pyridin-4-one NH2 2-(3-ami no-piperidi n-1-yl )-3-( 1-buten-1-(11) yl)-5-[(1H-benzo[dJ[1,2]oxazin-4- o-N N o ' N
yl)methyl]-3,5-dlhydro-imidazo[4,5- / \ N \ ~ i~-N
d]pyridazin-4-one N ~---(NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- o_N o (12) yl)-5-[(1-oxo-1H-benzo[d][1,2]oxazin-4- o ~ N
yl)methyl]-3,5-dihydro-imidazo[4,5- / \ N ~ ~ i~--N
~--(N
dJpyridazin-4-one NH2 Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-( 3-ami no-piperidi n-1-yl )-3-(2-butyn-1- p yl)-5-[(4H-benzo[e][1,3]oxazin-2- ~~N N N
O
I ~ ~ O N w I ~~ N
N
NHz (10) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-djpyridazin-4-one O
N~N N
NH N ~ I i~N
~--~N
O NHZ
, the enantiomers, the mixtures thereof and the salts thereof.
According to the invention the compounds of general formula I are obtained by methods known per se, for example by the following methods:
a) deprotecting a compound of general formula ~3 R1~ N /1 _N
I I ~~---R4~, Y~ N
(II), wherein R', R2, Y and R3 are as hereinbefore defined and R4" denotes one of the groups mentioned for R4 hereinbefore which contain an imino, amino or alkylamino group, while the imino, amino or alkylamino group is substituted by a protective group.
The liberating of an amino group from a protected precursor is a standard reaction in synthetic organic chemistry. There are many examples of suitable protective groups.
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text A summary of the chemistry of protective groups can be found in Theodora W.
Greene and Peter G. M. Wuts, Protective Groups in Organic Synthesis, Second Edition, 1991, published by John Wiley and Sons, and in Philip J. Kocienski, Protecting Groups, published by Georg Thieme, 1994.
The following are examples of protective groups:
the tert.-butyloxycarbonyl group which can be cleaved by treating with an acid such as for example trifluoroacetic acid or hydrochloric acid or by treating with 10 bromotrimethylsilane or iodotrimethylsilane, optionally using a solvent such as methylene chloride, ethyl acetate, dioxane, methanol, isopropanol or diethylether at temperatures between 0°C and 80°C, the 2,2,2-trichloroethoxycarbonyl group which can be cleaved by treating with metals 15 such as for example zinc or cadmium in a solvent such as acetic acid or a mixture of tetrahydrofuran and a weak aqueous acid at temperatures between 0°C and the boiling temperature of the solvent used and the carbobenzyloxycarbonyl group which can be cleaved for example by 20 hydrogenolysis in the presence of a noble metal catalyst such as for example palladium-charcoal and a solvent such as for example alcohols, ethyl acetate, dioxane, tetrahydrofuran or mixtures of these solvents at temperatures between 0°C
and the boiling point of the solvent, by treating with boron tribromide in methylene chloride at temperatures between -20°C and ambient temperature, or by treating 25 with aluminium chloride/anisol at temperatures between 0°C and ambient temperature.
Moreover, the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers, as mentioned hereinbefore. Thus, for example, 30 cis/trans mixtures may be resolved into their cis and trans isomers, and compounds with at least one stereocentre may be separated into their enantiomers.
Thus, for example, the cis/trans mixtures obtained may be resolved by chromatography into the cis and trans isomers thereof, the compounds of general Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text formula I obtained which occur as racemates may be separated by methods known per se (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971 ) into their optical antipodes and compounds of general formula I
with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g. by chromatography andlor fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.
The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-O-p-toluoyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+)- or (-)-menthol and an optically active acyl group in amides, for example, may be a (+)- or (-)-menthyloxycarbonyl.
Furthermore, the compounds of formula I obtained may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulphonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or malefic acid.
Moreover, if the new compounds of formula I thus obtained contain a carboxy group, they may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, particularly for pharmaceutical use into the physiologically acceptable salts thereof. Suitable bases for this purpose include for example sodium Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text hydroxide, potassium hydroxide, arginine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
The compounds of general formula II used as starting materials are either known from the literature or may be obtained by methods known from the literature (cf.
Examples I to XVI).
As already mentioned hereinbefore, the compounds of general formula I
according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibiting effect on the enzyme DPP-IV.
The biological properties of the new compounds were investigated as follows:
The ability of the substances and their corresponding salts to inhibit the DPP-IV
activity can be demonstrated in a test set-up in which an extract of human colon carcinoma cell line Caco-2 is used as the DPP IV source. The differentiation of the cells in order to induce the DPP-IV expression was carried out as described by Reiher et al. in an article entitled "Increased expression of intestinal cell line Caco-2" , which appeared in Proc. Natl. Acad. Sci. Vol. 90, pages 5757-5761 (1993). The cell extract was obtained from cells solubilised in a buffer (10mM Tris HCI, 0.15 M
NaCI, 0.04 t.i.u. aprotinin, 0.5% Nonidet-P40, pH 8.0) by centrifuging at 35,000 g for 30 minutes at 4°C (to remove cell debris).
The DPP-IV assay was carried out as follows:
50 NI substrate solution (AFC; AFC is amido-4-trifluoromethylcoumarin), final concentration 100 NM, were placed in black microtitre plates. 20 NI of assay buffer (final concentrations 50 mM Tris HCI pH 7.8, 50 mM NaCI, 1 % DMSO) was pipetted in. The reaction was started by adding 30 NI of solubilised Caco-2 protein (final concentration 0.14 Ng of protein per well). The test substances to be investigated were typically added prediluted in 20 NI, and the volume of assay buffer was then reduced accordingly. The reaction was carried out at ambient temperature, incubating for 60 minutes. Then the fluorescence was measured in a Victor 1420 Multilabel Counter, the excitation wavelength being 405 nm and the emission Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text wavelength being 535 nm. Blank readings (corresponding to 0 % activity) were obtained in mixtures without any Caco-2 protein (volume replaced by assay buffer), control values (corresponding to 100 % activity) were obtained in mixtures with no substance added. The potency of the test substances in question, expressed as ICSo values, was calculated from dosage/activity curves consisting of 11 measuring points in each case. The following results were obtained:
Compound DPP IV inhibition (Example No.) ICSO [nM]
1(1) 17 1 (2) 58 1(3) 8 1(4) 9 1(7) 3 1(8) 7 1(9) 3 The compounds prepared according to the invention are well tolerated, as for example when 10 mg/kg of the compound of Example 1 were administered to rats by oral route no changes in the animals' behaviour could be detected.
In view of their ability to inhibit DPP-IV activity, the compounds of general formula I
according to the invention and the corresponding pharmaceutically acceptable salts thereof are suitable for treating all those conditions or illnesses which can be influenced by the inhibition of the DPP-IV activity. It is therefore to be expected that the compounds according to the invention will be suitable for the prevention or treatment of diseases or conditions such as type I and type II diabetes mellitus, diabetic complications, metabolic acidosis or ketosis, insulin resistance, dyslipidaemias of various origins, arthritis, atherosclerosis and related diseases, obesity, allograft transplantation and calcitonin-induced osteoporosis. fn addition these substances are capable of preventing B-cell degeneration such as e.g.
apoptosis or necrosis of pancreatic B-cells. The substances are also suitable for Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text improving or restoring the function of pancreatic cells and also increasing the number and size of pancreatic B-cells. Additionally, and on the basis of the role of the Glucagon-Like Peptides, such as e.g. GLP-1 and GLP-2 and their link with DPP-IV
inhibition, it is likely that the compounds according to the invention are suitable for achieving, inter alia, a sedative or anxiety-relieving effect and also of favourably affecting catabolic states after operations or hormonal stress responses or of reducing mortality or morbidity after myocardial infarct. They are also suitable for treating all conditions which are connected with the above mentioned effects and which are mediated by GLP-1 or GLP-2. The compounds according to the invention may also be used as diuretics or antihypertensives and are suitable for preventing and treating acute renal failure. They are also suitable for the prevention and treatment of chronic inflammatory intestinal diseases. It is also expected that DPP-IV
inhibitors and hence also the compounds according to the invention may be used to treat infertility or to improve fertility in humans or mammals, particularly when the infertility is connected with insulin resistance or polycystic ovary syndrome.
The substances are also suitable for treating deficiencies of growth hormone which are associated with reduced stature.
The compounds according to the invention may also be used in conjunction with other active substances. Therapeutic agents which are suitable for such combinations include, for example, antidiabetics, such as metformin, sulphonylureas (e.g. glibenclamide, tolbutamide, glimepiride), nateglinide, repaglinide, thiazolidine-dione (e.g. rosiglitazone, pioglitazone), PPAR-gamma agonists (e.g. GI
262570), alpha-glucosidase inhibitors (e.g. acarbose, voglibose), alpha2 antagonists, insulin and insulin analogues, GLP-1 and GLP-1 analogues (e.g. exendin-4) or amylin.
Also, inhibitors of protein tyrosine phosphatase 1, substances which influence deregulated glucose production in the liver, such as e.g. inhibitors of glucose-6-phosphatase, or fructose-1,6-bisphosphatase, glycogen phosphorylase, glucagon receptor antagonists and inhibitors of phosphoenol pyruvate carboxykinase, glycogen synthase kinase or pyruvate dehydrokinase, lipid lowering agents, such as HMG-CoA-reductase inhibitors (e.g. simvastatin, atorvastatin), fibrates (e.g.
bezafibrate, fenofibrate), nicotinic acid and its derivatives, cholesterol absorption inhibitors such as for example ezetimibe, bile acid-binding substances such as for example cholestyramine, HDL-raising compounds such as for example inhibitors of CETP
or Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text regulators of ABC1 or active substances for the treatment of obesity, such as e.g.
sibutramine or tetrahydrolipostatin, or f33-agonists such as SB-418790 or AD-9677.
It is also possible to combine the compounds with drugs for treating high blood 5 pressure such as e.g. All antagonists or ACE inhibitors, diuretics, (3-blockers, etc., or combinations thereof.
The dosage required to achieve such an effect is expediently, by intravenous route, 1 to 100 mg, preferably 1 to 30 mg, and by oral route 1 to 1000 mg, preferably 1 to 100 10 mg, in each case 1 to 4 times a day. For this purpose, the compounds of formula I
prepared according to the invention, optionally combined with other active substances, may be incorporated together with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, 15 water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof into conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.
The Examples that follow are intended to illustrate the invention:
Boehringer Ingelheim International GmbH Case 111502 55216 fngelheim foreign filing text Preparation of the starting compounds:
Example I
2-[3-(tert.-butyloxycarbonylam ino)-piperidi n-1-yl]-3-(2-butyn-1-yl )-5-[(dibenzo[b,t][1,4]-oxazeain-11-vl)methyll-3,5-dihvdro-imidazof4,5-dlayridazin-4-one 317 mg 11-chloromethyl-dibenzo[b,f][1,4]oxazepin are added to 400 mg 2-[3-(tert.-butyloxycarbonylam ino)-pi peridin-1-yl]-3-(2-butyn-1-yl )-3, 5-d ihyd ro-i midazo[4, 5-dJpyridazin-4-one and 276 mg potassium carbonate in 4 ml N,N-dimethylformamide.
The reaction mixture is stirred for two hours at 80°C. For working up it is combined with water and the precipitate formed is suction filtered. The crude product is purified by chromatography over a silica gel column with methylene chloride/methanol (100:0 to 70:30) as eluant.
Yield: 120 mg (20 % of theory) Mass spectrum (ESI+): m/z = 594 [M+H]+
The following compounds are obtained analogously to Example I:
(1 ) 2-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(phenan-thrid in-6-yl )methyl]-3, 5-dihyd ro-i midazo[4, 5-dj pyridazin-4-one (2) 2-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(phenanthren-9-yl )methyl]-3, 5-d i hyd ro-im idazo[4,5-djpyridazin-4-one (3) 2-[(R)-3-(tert.-butyloxycarbonylamino) -piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(phenan-thridin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one Rf value: 0.41 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 592 [M+H]+
(4) 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(dibenzo[b,t][1,4]oxazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-djpyridazin-4-one Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 2:8) Mass spectrum (ESI+): m/z = 608 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text (5) 2-bromo-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-djpyridazin-4-one Mass spectrum (ESI+): m/z = 474, 476 [M+H]+
(6) 2-bromo-3-(2-butyn-1-yl)-5-[(naphtho[2,1-d]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one Rf value: 0.80 (silica gel, methylene chloride/ethanol = 9:1 ) (7) 2-bromo-3-(2-butyn-1-yl)-5-[(naphtho[1,2-d]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one Rf value: 0.50 (silica gel, methylene chloride/methanol = 19:1 ) (8) 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-cyano-methyl-3,5-dihydro-imidazo[4,5-djpyridazin-4-one Rf value: 0.40 (silica gel, petroleum ether/ethyl acetate = 1:4) Mass spectrum (ESI+): m/z = 426 [M+H]+
Example II
2-[3-(tert.-butyloxycarbonylami no)-piperidin-1-yl]-3-(2-butyn-1-yl )-3, 5-dihydro-imidazoj4 5-dlpyridazin-4-one 2.50 g 3-(tert.-butyloxycarbonylamino)-piperidine are added to 2.65 g 2-bromo-3-(2-butyn-1-yl)-3,5-dihydro-imidazo[4,5-c~pyridazin-4-one and 2.12 g sodium carbonate in 5 ml dimethylsulphoxide. The reaction mixture is stirred overnight at 85°C.
After cooling to ambient temperature it is combined with water and extracted with ethyl acetate. The combined organic phases are dried over magnesium carbonate and evaporated down. The crude product is further reacted without any further purification.
Mass spectrum (ESI+): m/z = 387 [M+H]+
The following compounds are obtained analogously to Example II:
(1 ) 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-7-methyl-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one Rf value: 0.15 (silica gel, cyclohexane/ethyl acetate = 3:7) Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Mass spectrum (ESI+): m/z = 401 [M+H]+
(2) 2-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(dibenzo[b,t][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one Mass spectrum (ESI+): m/z = 594 [M+H]+
(3) 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(dibenzo[b,t][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-djpyridazin-4-one Mass spectrum (ESI~): m/z = 594 [M+HJ+
(4) 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(naphtho[2,1-d]oxazol-2-yl)methyl]-3, 5-dihyd ro-imidazo[4, 5-dJpyridazin-4-one Rf value: 0.70 (silica gel, methylene chloride/ethanol = 9:1 ) (5) 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-ylJ-3-(2-butyn-1-yl)-5-[(naphtho[1, 2-d]oxazol-2-yl )methyl]-3, 5-d ihyd ro-imidazo[4, 5-djpyridazi n-4-one Rf value: 0.65 (silica gel, methylene chloride/methanol = 9:1 ) Mass spectrum (ESI+): m/z = 568 [M+H]+
(6) 2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one Mass spectrum (ESI+): m/z = 387 [M+H]+
Rf value: 0.50 (silica gel, methylene chloride/ethanol = 9:1 ) Examale III
2-bromo-3-(2-butyn-1-yl)-3,5-dihydro-imidazof4.5-dlpyridazin-4-one 0.63 ml hydrazine hydrate are added dropwise to 3.68 g methyl 2-bromo-3-(2-butyn-1-yl)-5-formyl-3H-imidazole-4-carboxylate in 50 ml of ethanol. The reaction mixture is stirred for one hour at ambient temperature, then 3 ml acetic acid are added and the reaction mixture is refluxed for a further hour. The precipitate formed is suction filtered, washed with ethanol and diethyl ether and dried.
Yield: 2.65 g (77 % of theory) Mass spectrum (ESI+): m/z = 267, 269 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example IV
methyl 2-bromo-3-l2-butyn-1-vl~ 5-formyl-3H-imidazole-4-carboxylate 45 ml diisobutylaluminium hydride solution (1M in toluene) are added dropwise to 12.45 g dimethyl 2-bromo-3-(2-butyn-1-yl)-1H-imidazole-4,5-dicarboxylate in 150 ml of tetrahydrofuran under an argon atmosphere at -65°C. The reaction mixture is stirred for two hours at -65°C, then another 9 ml diisobutylaluminium hydride solution are added. After another hour the reaction mixture is quenched at -65°C
with a mixture of 1 M hydrochloric acid and tetrahydrofuran (1:1 ) and stirred for ten minutes.
Then the cooling bath is removed, the reaction mixture is diluted with water and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with cyclohexane/ethyl acetate (2:1 to 1:1 ).
Yield: 9.58 g (85 % of theory) Mass spectrum (ESI+): m/z = 285, 287 [M+H]+
The following compounds are obtained analogously to Example IV:
(1 ) methyl 2-bromo-3-(3-methyl-2-buten-1-yl)-5-formyl-3H-imidazole-4-carboxylate Mass spectrum (ESI+): m/z = 301, 303 [M+H]+
Example V
dimethvl 2-bromo-3-(2-butvn-1-yl)-1 H-imidazole-4.5-dicarboxylate 4.53 ml of 1-bromo-2-butyne are added to 13.20 g dimethyl 2-bromo-1H-imidazole-4,5-dicarboxylate and 8.57 g potassium carbonate in 70 ml N,N-dimethylformamide and the reaction mixture is stirred overnight at ambient temperature.
For working up it is combined with water and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down.
Yield: 14.58 g (92 % of theory) Mass spectrum (ESI+): m/z = 315, 317 [M+H]+
The following compounds are obtained analogously to Example V:
(1) dimethyl 2-bromo-3-(3-methyl-2-buten-1-yl)-1H-imidazole-4,5-dicarboxylate Mass spectrum (ESI+): m/z = 331, 333 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example VI
Dimethyl 2-bromo-1 H-imidazole-4,5-dicarboxvlate 6.11 ml bromine are added to 19.80 g dimethyl 1 H imidazole-4,5-dicarboxylate and 5 14.92 g potassium carbonate in 600 ml methylene chloride. The reaction mixture is stirred for one hour at ambient temperature, then a mixture of saturated sodium sulphite solution and saturated sodium chloride solution (1:1) is added. The organic phase is largely separated off and the aqueous phase is extracted with ethyl acetate several times. The combined organic phases are dried over magnesium sulphate 10 and evaporated down, leaving about 7.40 g crude product. The aqueous phase is combined with ethyl acetate and extracted overnight in an extraction apparatus. The ethyl acetate extract is evaporated down and the flask residue is combined with the crude product already obtained.
Yield: 13.10 g (46 % of theory) 15 Mass spectrum (ESI+): m/z = 263, 265 [M+H]+
Example VII
2-Bromo-3-(2-but~m1-yl -7-methyl-3.5-dihydro-imidazo[4.5-dlpyridazin-4-one 0.50 ml of 1-bromo-2-butyne are added to 1.30 g 2-bromo-7-methyl-3,5-dihydro-20 imidazo[4,5-d]pyridazin-4-one and 0.99 ml Hunig base in 30 ml of N,N-dimethylformamide. The reaction mixture is stirred for three hours at ambient temperature. Then the solvent is distilled off in vacuo using the rotary evaporator.
The flask residue is stirred with 40 ml of water and 0.5 ml concentrated aqueous ammonia solution, suction filtered and washed with ethanol as well as diethyl ether.
25 Yield: 1.30 g (82 % of theory) Rf value: 0.60 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI+): m/z = 281, 283 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example VIII
2-bromo-7-methyl-3,5-dihydro-imidazoj4.5-d]pyridazin-4-one 5.20 ml of a 1.8 M solution of bromine in acetonitrile are slowly added dropwise to 1.40 g of 7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and 1.30 g potassium carbonate in 40 ml acetonitrile. Then the reaction mixture is heated to 70°C, whereupon the mixture is rapidly decolourised. More bromine solution and potassium carbonate are added batchwise until the reaction has ended, according to HPLC-MS.
For working up the reaction mixture is evaporated down, stirred with 100 ml of water and suction filtered. The filtrate is acidified with 1 M hydrochloric acid and extracted with ethyl acetate. The combined extracts are dried over sodium sulphate and evaporated down.
Yield: 1.30 g (61 % of theory) Rf value: 0.37 (silica gel, methylene chloride/methanol = 9:1 ) Mass spectrum (ESI+): m/z = 229, 231 [M+H]+
Example IX
7-methyl-3.5-dihydro-imidazof4.5-dlpyridazin-4-one A solution of 4.00 g sodium nitrite in 15 ml of water is added dropwise at 50°C to 2.20 g of 4-amino-7-methyl-3H-imidazo[4,5-d]pyridazine in a mixture of 30 ml acetic acid, 5 ml of water and 0.5 ml concentrated sulphuric acid. The reaction mixture is stirred for a further two hours at 50°C and then heated to 90°C
for one hour. After cooling to ambient temperature the reaction mixture is diluted with 30 ml of water.
The precipitate formed is suction filtered, washed with water, ethanol and diethyl ether and dried.
Yield: 1.00 g (45 % of theory) Mass spectrum (ESI+): m/z = 151 [M+H]+
Example X
4-amino-7-methyl-3H-imidazo~4.5-dJpyridazine A mixture of 2.00 g 5-acetyl-3H-imidazole-4-carbonitrile and 4.00 ml hydrazine hydrate in 50 ml of ethanol is heated to 100 °C, until the reaction is complete according to HPLC-MS. After cooling to ambient temperature the reaction mixture is evaporated down, stirred with 20 ml of cold ethanol and suction filtered. The filter cake is washed with diethyl ether and dried.
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Yield: 2.10 g (95 % of theory) Mass spectrum (ESI+): m/z = 150 [M+H]+
Example XI
5-acetyl-3H-imidazole-4-carbonitrile 57 ml of a 3 M solution of methylmagnesium bromide in diethyl ether are added to 7.00 g of 4,5-dicyano-imidazole in 80 ml of tetrahydrofuran under an argon atmosphere, while the temperature is maintained between 5°C and 15°C.
After two hours the reaction is complete according to thin layer chromatography and the reaction mixture is diluted with 400 ml of ethyl acetate. Then 400 ml saturated ammonium chloride solution are slowly added. After ten minutes the mixture is acidified with semiconcentrated sulphuric acid and stirred for another twenty minutes before the organic phase is separated off. The aqueous phase is extracted with ethyl acetate and the combined organic phases are dried over sodium sulphate and evaporated down. The flask residue is stirred with ethyl acetate, suction filtered and washed with ethyl acetate and diethyl ether.
Yield: 3.30 g (43 % of theory) Mass spectrum (ESI+): m/z = 136 [M+H]+
Example XII
2-chloromethyl-naphthol2 1-dloxazole Prepared by reacting 2.93 g of 2-amino-1-naphthol with 3.54 g of 2-chloro-1,1,1-triethoxy-ethane in 25 ml of ethanol at 60°C.
Yield: 1.90 g (58 % of theory) Rf value: 0.55 (silica gel, petroleum ether/ethyl acetate = 9:1 ) Mass spectrum (ESI+): m/z = 218, 220 [M+H]+
The following compounds are obtained analogously to Example XII:
(1 ) 2-chloromethyl-naphtho[1,2-dJoxazole Rf value: 0.90 (silica gel, methylene chloride/methanol = 19:1 ) Mass spectrum (ESI+): m/z = 218, 220 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example XIII
2-bromo-3-( 3-methyl-2-buten-1-yl)-3, 5-dihydro-imidazof 4.5-clpyridin-4-one 1.55 g Burgess reagent (methoxycarbonylsulphamoyl-triethylammonium-N-betaine) are added to 1.60 g of 2-bromo-7-hydroxy-3-(3-methyl-2-buten-1-yl)-3,5,6,7-tetrahydro-imidazo[4,5-c]pyridin-4-one in 20 ml methylene chloride and 4 ml of tetrahydrofuran. The reaction mixture is stirred for eight hours at 60°C, then another 0.3 equivalents Burgess reagent is added. After a further two hours the cooled reaction mixture is combined with aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down. The flask residue is chromatographed through a silica gel column with methylene chloride/methanol (1:0 to 10:1) as eluant.
Yield: 1.06 g (60 % of theory) Mass spectrum (ESI+): m/z = 282, 284 [M+H]+
Example XIV
2-bromo-7-hydrox ~-L313-methyl-2-buten-1-yl~ 3,5.6,7-tetrahydro-imidaz~4,5-,p~rridin-4-one 90 ml of water and 5.40 g iron powder are added to 4.15 g methyl 2-bromo-5-(1-hydroxy-2-nitro-ethyl)-3-(3-methyl-2-buten-1-yl)-3H-imidazole-4-carboxylate in 270 ml of ethanol. The mixture is refluxed, combined with 36 ml glacial acetic acid and stirred for one and a half hours at reflux temperature. The cooled reaction solution is filtered through Celite. The filtrate is evaporated down, combined with ethanol and made basic with solid potassium carbonate. The mixture is stirred for three hours at 60°C. Then the ethanol is distilled off, the flask residue is combined with water and extracted with ethyl acetate. The combined extracts are dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with methylene chloridelmethanol (1:1 to 7:1) as eluant.
Yield: 1.62 g (47 % of theory) Mass spectrum (ESI+): m/z = 300, 302 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example XV
Methyl 2-bromo-5-( 1-hyd roxy-2-nitro-ethyl)-3-(3-methyl-2-buten-1-yl)-3H-imidazole-4-carboxvlate 35 ml nitromethane are added to 1.14 g caesium carbonate in 15 ml of methanol at ambient temperature. Then the mixture is combined with a solution of 3.50 g methyl 2-bromo-3-(3-methyl-2-buten-1-yl)-5-formyl-3H-imidazole-4-carboxylate in 20 ml of methanol and 5 ml methylene chloride and stirred for 15 minutes at ambient temperature. Then 0.5 ml acetic acid are added and the solution is evaporated down in vacuo. The flask residue is combined with aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down.
Yield: 4.15 g (99 % of theory) Mass spectrum (ESI+): m/z = 362, 364 [M+H]+
Example XVI
2-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl )-5-[(4-oxo-3, 4-dihvdro-auinazolin-2-yl)methyll-3 5-dihvdro-imidazof4 5-dlpyridazin-4-one 40 mg sodium methoxide (95 %) are added to a solution of 605 mg 2-[(R)-3-(tert.-butyloxycarbonylamino)-pi peridi n-1-yl]-3-(2-butyn-1-yl )-5-cyanomethyl-3, 5-d ihyd ro-imidazo[4,5-dJpyridazin-4-one in 9 ml of methanol. The mixture is stirred for one hour at ambient temperature and then neutralised with 41 pL glacial acetic acid.
Then a solution of 195 mg anthranilic acid in 2 ml of methanol is added and the reaction mixture is heated to 70°C. After about two hours a white, voluminous precipitate is formed and the reaction mixture is cooled to ambient temperature. The precipitate formed is suction filtered, washed with cold methanol and dried.
Yield: 234 mg (30 % of theory) Mass spectrum (ESI+): m/z = 545 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Preparation of the final compounds:
Example 1 ' N
i N' G N Nw I N ~~
NHZ
5 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,tj[1,4]oxazepin-11-yl)methyl]-3 5-dih dro-imidazo 4 5- ridazin-4-one 0.33 ml trifluoroacetic acid are added to 120 mg 2-[3-(tert.-butyloxycarbonylamino)-pi peridin-1-yl]-3-(2-butyn-1-yl )-5-[(di benzo[b, t] [1,4]oxazepin-11-yl )methyl]-3, 5-dihydro-imidazo[4,5-dJpyridazin-4-one in 3 ml methylene chloride while cooling with 10 an ice bath. The reaction mixture is stirred overnight at ambient temperature.
For working up it is poured onto cooled saturated potassium carbonate solution and extracted with methylene chloride. The organic phase is separated off and evaporated down. The crude product is purified by chromatography over a silica gel column with methylene chloride/methanol (100:0 to 70:30) as eluant.
15 Yield: 63 mg (63 % of theory) Mass spectrum (ESI+): m/z = 494 [M+H]+
The following compounds are obtained analogously to Example 1:
20 (1) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one O
w N N
I
~N Nw ~ N N
NHZ
Mass spectrum (ESI+): m/z = 478 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text (2) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthren-9-yl)methyl)-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one N
_N ,. I /~--N
N
/ NHz Mass spectrum (ESI+): m/z = 477 [M+H]+
(3) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-c~pyridazin-4-one x trifluoroacetic acid ~ il' N I N~-N
N N~N
I / NHZ x CF3COOH
Rf value: 0.45 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/
trifluoroacetic acid = 50:50:0.1 ) Mass spectrum (ESI+): m/z = 492 [M+H]+
(4) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,t][1,4]oxazepin-11-yl)methyl]-7-methyl-3, 5-dihydro-imidazo[4, 5-dJpyridazin-4-one N N
O 1N N w I ~~ N
~N
NHZ
Carried out with isopropanolic hydrochloric acid (5-6 M) in methylene chloride.
Mass spectrum (ESI+): m/z = 508 [M+H]+
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim forei4n filing text (5) 2-((S)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,tj[1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one O
I
N N
0 ,N N ~ I ~~ N
N
/ \ ~NHz Mass spectrum (ESI+): m/z = 494 [M+H]+
(6) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one N N
0 1N N w I ~~ N
N
/ \ NH2 Mass spectrum (ESI+): m/z = 494 [M+H]+
(7) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[2,1-dJoxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-dJpyridazin-4-one \ G~N I N~N
\ N N~ N
N Hz Rf value: 0.40 (silica gel, methylene chloride/ethanol/conc. aqueous ammonia =
90:10:2) Mass spectrum (ESI+): m/z = 468 [M+H]+
(8) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[1,2-d]oxazol-2-yl )methyl]-3, 5-di hydro-i midazo[4, 5-c~pyridazin-4-one N~ N
\ O N~ N
NHz Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Mass spectrum (ESI+): m/z = 468 [M+H]+
(9) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one o i N~N N
NH N ~ I ~~N~
'N
p NHz Mass spectrum (ESI+): m/z = 445 [M+H]+
The following compounds may also be obtained analogously to the foregoing Examples and other methods known from the literature:
No. Name Structural formula 2-(3-amino-piperidin-1-yl)-3-(2-buten-1-(1) yl)-5-[(3,4-dihydro-quinolin-2-yl)methyl]- I N N
6,7-dimethyl-3,5-dihydro-imidazo[4,5- ~ N ~ N
~~-N
c]pyridin-4-one ~ ~ ~ NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- N o (2) yl)-5-[(3,4-dihydro-isoquinolin-1- ~ \ ~N I N
N
yl)methyl]-7-cyclopropyl-3,5-dihydro- N ~ ~--(N
NHZ
imidazo[4,5-dJpyridazin-4-one 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- N o ( ) yl)-5-[(3,3-dimethyl-3,4-dihydro- ~ N
3 ~N
isoquinolin-1-yl)methyl]-3,5-dihydro- - N ~ I i~-N
~-.~N
im idazo[4, 5-dJpyridazin-4-one NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- N O
( ) yl)-5-[(4,4-dimethyl-3,4-dihydro- ~ N N
4 ~ i~ N
isoquinolin-1-yl)methyl]-3,5-dihydro- ~ ~ N ~ N
imidazo[4,5-dJpyridazin-4-one NHz Boehringer lngelheim International GmbH Case 1!1502 55216 Ingelheim foreign filing text 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ o ( ) yl)-5-[(1-methyl-1,4-dihydro-quinazolin-2- / ~ N N
yl)methyl]-3,5-dihydro-imidazo[4,5- N N ~ ~ ~ N
~N
d]pyridazin-4-one NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ o ( ) yl)-5-[(1-methyl-4-oxo-1,4-dihydro- / ~ N N
quinazolin-2-yl)methyl]-3,5-dihydro- N N ~ ~ ~ N
~N
imidazo[4,5-dJpyridazin-4-one ~ NHz 2-(3-amino-piperidin-1-yl}-3-(2-buten-1- F I o yl)-5-[(5,6,7,8-tetrafluoro-1-methyl-1,4- F ~ N
N
(7) dihydro-quinazolin-2-yl)methyl]-3,5- F ~ ~ ~ ~ ~ ~~--N~
N
dihydro-imidazo[4,5-c]pyridin-4-one F NHZ
2-(3-amino-piperidin-1-yl)-3-(2-buten-1- \ N o (8) yl)-5-[(3,4-dihydro-quinazolin-2-yl)methyl]- / ~ NH N I N N
3,5-dihydro-imidazo[4,5-dJpyridazin-4-one N~N
2-(3-amino-piperidin-1-yl )-3-(2-butyn-1- o (9) yl)-5-[(3-methyl-3,4-dihydro-quinazolin-2- I ~ N~ N
N
yl)methyl]-3,5-dihydro-imidazo[4,5- ~N~ N ~ ~ ~~N
~N
d]pyridazin-4-one NHZ
2-(3-amino-piperidin-1-yl )-3-(2-butyn-1- o yl)-5-[(3-methyl-3,4-dihydro-quinazolin-2- ~ N~ N
N
(10) I meth I -3,5-dih dro-imidazo 4,5- ~ I ~ w ~ ~ N
Y ) Y ] Y [ w ~N
c]pyridin-4-one NH2 2-(3-ami no-piperidi n-1-yl )-3-( 1-buten-1-(11) yl)-5-[(1H-benzo[dJ[1,2]oxazin-4- o-N N o ' N
yl)methyl]-3,5-dlhydro-imidazo[4,5- / \ N \ ~ i~-N
d]pyridazin-4-one N ~---(NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- o_N o (12) yl)-5-[(1-oxo-1H-benzo[d][1,2]oxazin-4- o ~ N
yl)methyl]-3,5-dihydro-imidazo[4,5- / \ N ~ ~ i~--N
~--(N
dJpyridazin-4-one NH2 Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-( 3-ami no-piperidi n-1-yl )-3-(2-butyn-1- p yl)-5-[(4H-benzo[e][1,3]oxazin-2- ~~N N N
(13) yl)methyl]-3,5-dihydro-imidazo[4,5- II '~ N N ~ I N~
d]pyridazin-4-one NH2 2-(3-amino-piperidin-1-yl )-3-(2-buten-1- o (14) yl)-5 ((4,4-dimethyl-4H- I w o~ ~ N\
N~ i~N
benzo[a][1,3]oxazin-2-yl)methyl]-3,5- ~ N N
N
dihydro-imidazo[4, 5-dJpyridazin-4-one N HZ
2-( 3-amino-piperidi n-1-yl )-3-(2-butyn-1- p (15) yl) 5 [(4-oxo-4H-benzo[e][1,3]oxazin-2- I ~ o~N I NON
I
yl)methyl]-3,5-dihydro-imidazo[4,5- ~ N N ~ N
d]pyridazin-4-one o NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- \ N o f (16) yl)-5 ((4H-benzo[d][1,3]oxazin-2- ~ ~ ~N ~ ~-N
yl)methyl]-3,5-dihydro-imidazo[4,5- ~ N
d]pyridazin-4-one NH2 2-(3-amino-piperidin-1-yl )-3-(2-butyn-1- o 17 yl)-5 ((4H-benzo[d][1,3]oxazin-2- ~~N N
( ) yl)methyl]-7-methyl-3,5-dihydro- ~w\ ~~o ~ I N>-N
imidazo[4,5-c]pyridin-4-one NHz 2-(3-ami no-piperidi n-1-yl )-3-(2-butyn-1- o (19) yl)-5-((4,4-dimethyl-4H- I \ N~N ~ N>-N
benzo[d][1,3]oxazin-2-yl)methyl]-3,5- ~ o N ~ N
dihydro-imidazo[4,5-dJpyridazin-4-one NHZ
2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1- o 20 yl) 5 [(4-oxo-4H-benzo[dj[1,3]oxazin-2- I ~ N~N N N
( ) yl)methyl]-3,5-dihydro-imidazo[4,5- ~ o N ~ I N
dJpyridazin-4-one o NHZ
2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1- o (21 ) yl)-5-[(2H-benzo[1,4]oxazin-3-yl)methyl]- ~ j N~N \ ~ N~.-N
N
3,5-dihydro-imidazo[4,5-dJpyridazin-4-one o NH
z Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- o 0 22 yl)-5-[(2-oxo-2H-benzo[1,4]oxazin-3- o~N ~ N
( ) yl)methyl]-3,5-dihydro-imidazo[4,5- / N N~N~ ~---d]pyridazin-4-one ~ I NH2 2-( 3-a m i no-pi perid i n-1-yl )-3-( 2-butyn-1- o yl)-5-[(2,2-dimethyl-2H-benzo[1,4]oxazin- o~N N
(23) N N ~ ~ i~N
3-yl)methyl]-3,5-dihydro-imidazo[4,5- ~ ' NN
dJpyridazin-4-one ~ NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ g~ o (24) yl)-5-[4H-benzo[e][1,3]thiazin-2-yl)methyl]- ~ ~ IN N \ ~ N)--N
~N
3,5-dihydro-imidazo[4,5-dJpyridazin-4-one NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- o 25 yl)-5-[4,4-dimethyl-4H- ~ SAN N
( ) benzo[a][1,3]thiazin-2-yl)methyl]-3,5- ~ i N N~ ~ N~N
dihydro-imidazo[4,5-dJpyridazin-4-one ~ ~--~NHZ
2-( 3-a m i no-piperid i n-1-yl )-3-(2-butyn-1- o (26) yl)-5-[4-oxo-4H-benzo[e][1,3]thiazin-2- I ~ S~N ~ NON
yl)methyl]-3,5-dihydro-imidazoj4,5- ~ N N ~ N
dJpyridazin-4-one O NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- o I -5 4H-benzo 1,3 thiazin-2-27 y ) -[( [~lj ] W N~N N
( ) yl)methyl]-3,5-dihydro-imidazo[4,5- ~ i S N ~ ~ N N
dJpyridazin-4-one NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- o N
(28) yl)-5-[(2H-benzo[1,4]thiazin-3-yl)methyl]- ~ ~ ~N \ ~ NON
N
3,5-dihydro-imidazo[4,5-dJpyridazin-4-one NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- o -N O
(29) yl)-5-[(2-oxo-2H-benzo[e][1,3]oxazin-4- o ~ N N
~ ~ i~ N
yl)methyl]-3,5-dihydro-imidazo[4,5- / \ N
N
d]pyridazin-4-one NHZ
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-(3-am i no-piperid i n-1-yl )-3-(2-butyn-1-yl)-5-[(1-methyl-2,2-dioxo-1H- NS \ o ' N
(30) benzo[c][1,2]thiazin-4-yl)methyl]-3,5- / \ N \ I N~-'N
dihydro-imidazo[4,5-d]pyridazin-4-one ~---~NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- I ~ o yl)-5-[(2,3-dihydro-1H- ~ N N
( ) benzo[e][1,4]diazepin-5-yl)methyl]-3,5- HN~N N~ ~ ~N
N
dihydro-imidazo[4,5-d]pyridazin-4-one NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- I ~ p 32 yl)-5-[(2-oxo-2,3-dihydro-1H-benzo[e][1,4] ~ 1 N N
( ) HN N N w l ~~N~
diazepin-5-yl)methyl]-3,5-dihydro- \N
imidazo[4,5-dJpyridazin-4-one o NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- I ~ o 33 yl)-5-[(1-methyl-2,3-dihydro-1H- i N N
( ) benzo[e][1,4]diazepin-5-yl)methyl]-3,5- -NON N ~. ~ N~'N
dihydro-imidazo[4,5-djpyridazin-4-one ~--~NHa 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- I ~ p 34 yl) 5 [(1-methyl-2-oxo-2,3-dihydro-1H- ~ , N N
( ) benzo[e][1,4]diazepin-5-yl)methyl]-3,5- -N N N ~ ~ N N.
dihydro-imidazo[4,5-djpyridazin-4-one O ~--(NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- p (35) yl) 5 [(4-oxo-4,5-dihydro-3H- ~ ~ N~ N I N N
benzo[b][1,4)diazepin-2-yl)methyl]-3,5- ~ N ~ N
NH
dihydro-imidazo[4,5-dJpyridazin-4-one H p z 2-(3-am i no-piperidi n-1-yl )-3-(2-butyn-1- p (36) yl)-5-[(5-methyl-4-oxo-4,5-dihydro-3H- \ / N~ N I N N
benzo[b][1,4]diazepin-2-yl)methyl]-3,5- N N ~ N
dihydro-imidazo[4,5-dJpyridazin-4-one ~ o NH2 Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 5a 2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1- o yl)-5-[5-oxo-4,5-dihydro-3H- ~ N~ N N
(37) benzo[e][1,4]diazepin-2-yl)methyl]-3,5- \ / ~N ~ I NON
dihydro-imidazo[4,5-d]pyridazin-4-one o 2-(3-am i no-piperidi n-1-yl )-3-(2-butyn-1- o 3$ yl)-5-[4-methyl-5-oxo-4,5-dihydro-3H- ~ N~ N N
I
( ) benzo[e][1,4]diazepin-2-yl)methyl]-3,5- \ / ~N ~ I NON
dihydro-imidazo[4,5-dJpyridazin-4-one p \ NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-~N O
(39) yl)-5-[(2,3-dihydro-benzo[t][1,4]oxazepin- o ~ N N
5-yl)methyl]-3,5-dihydro-imidazo[4,5- ' / N ~ ~ ~~N~
\N
d]pyridazin-4-one \ NH2 2-(3-ami no-piperid i n-1-yl )-3-(2-butyn-1-(40) yl)-5-[(3,3-dimethyl-2,3-dihydro- o N N o N
benzo[f][1,4]oxazepin-5-yl)methyl]-3,5- - N \ ~ ~~-N
\ / NN
dihydro-imidazo[4,5-c~pyridazin-4-one NHz 2-(3-ami no-piperid i n-1-yl )-3-(2-butyn-1-yl)-5-[(2,2-dimethyl-2,3-dihydro- ~N O
N
(41 ) benzo[t][1,4]oxazepin-5-yl)methyl]-7- o 'N ~ ,~N
r I
methyl-3,5-dihydro-imidazo[4,5- \ / N ~ N
dJpyridazin-4-one 2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1- o (42) YI)-5-[(2,3-dihydro-benzo[b][1,4]oxazepin- ~ N~ N N
4-yl)methyl]-7-methyl-3,5-dihydro- \ ~ N ~ ~ ~N
~N
imidazo[4,5-dJpyridazin-4-one o NHz 2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1-yl )-5-[(6, 6-di methyl-2, 3-di hyd ro- o 43 benzo b 1 4 oxaze in-4- I meth I -7- ' N~ N N
( ) [ ][ , ] p Y) Y] \ ~ N\ ~ ~~-N
- \ N
methyl-3,5-dihydro imidazo[4,5- O NH2 d]pyridazin-4-one Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-(3-am i no-piperidi n-1-yl )-3-(2-butyn-1- o 44 yl)-5 [(2,3-dihydro-benzo[b][1,4]thiazepin- ~ N~ N N
( ) 4-yl)methyl]-7-methyl-3,5-dihydro- ~ / N ~ ~ ~ N
~N
imidazo[4,5-dJpyridazin-4-one S NHZ
2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1-yl )-5-[(2, 2-d imethyl-2, 3-di hyd ro- o ' N N N
(45) benzo[b][1,4]thiazepin-4-yl)methyl]-7- ~ / ~ ~ ~ ,~-N
N~N
methyl-3, 5-di hyd ro-i m idazo[4, 5- S NHZ
dJpyridazin-4-one 2-(3-am i no-piperidin-1-yl )-3-(2-butyn-1-/ o (46) yl) 5 [(2,3-dihydro-benzo[t][1,4]thiazepin- ~ N N
5-yl)methyl]-7-methyl-3,5-dihydro- SAN N ~ ~ NON
imidazo[4,5-dJpyridazin-4-one ~---(NH2 2-( 3-amino-piperidi n-1-yl )-3-(2-butyn-1-yl )-5-[(5-oxo-4, 5-d i hyd ro- _ o O~ N
(47) benzo[tj[1,3,4]oxadiazepin-2-yl)methyl]-7- \ / II N ~ ~~-N
,N N w N
methyl-3, 5-dihyd ro-i midazo(4, 5 N
d]pyridazin-4-one 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- / ~ o 4$ yl)-5-[(11H-dibenzo[b,e]azepin-6- ~ I N N
I
( ) yl)methyl]-7-ethyl-3,5-dihydro- N N ~ ~ N N
imidazo[4,5-dJpyridazin-4-one \ / NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- / ~ o (49) yl)-5-[(11H-dibenzo[b,e]azepin-6- ~~N ~ N~-N
yl)methyl]-7-cyanomethyl-3,5-dihydro- N N ~ N
imidazo[4,5-djpyridazin-4-one \ / ~~ NH2 N
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- / \
_ o (50) yl) 5 [(11,11-difluoro-11H-dibenzo- FF ~ N N
[b,e]azepin-6-yl)methyl]-3,5-dihydro- , N ~ N
Y\~~~N
imidazo[4,5-c]pyridin-4-one \ / NHZ
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text \ O
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ N
-N
(51 ) yl) 5 [(11-oxo-11 H-dibenzo[b,e]azepin-6- o N N ~ I N~N
yl)methyl]-7-(2-cyanoethyl)-3,5-dihydro- \ / NH2 im idazo[4, 5-dJ pyridazi n-4-one II
N
2-(3-amino-piperidin-1-yl)-3-(1-buten-1- ~ \ o (52) yl)-5-[(11H-benzo[e]pyrido(3,2-b]azepin-6- ~ I N N
yl)methyl]-7-methyl-3,5-dihydro-imidazo- _~ N ~ N
~~-N
[4,5-d]pyridazin-4-one N NHZ
2-(3-amino-piperidin-1-yl-(2-butyn-1-yl)-5- / ~~N o (53) ((5H-1,9,10-triaza-dibenzo[a,dJcyclo- I I N N
i~ N
hepten-11-yl)methyl]-3,5-dihydro- ~ N ~ N
imidazo[4,5-c]pyridin-4-one \ , N NHZ
2-(3-amino-piperidin-1-yl)-3-(2-buten-1- ~ ~ p (54) yl)-5 ((5-methyl-5H-dibenzo[b,e][1,4]- ~ ~ N I N~N
diazepin-11-yl)methyl]-7-methyl-3,5- -N N N~N
dihydro-imidazo[4,5-djpyridazin-4-one \ ~ NHz 2-(3-amino-piperidin-1-yl)-3-(1-buten-1- / \ o (55) yl)-5-[(dibenzo[b,f][1,4]oxazepin-11- o - I N N
yl)methyl]-3,5-dihydro-imidazo[4,5- N ~ I ~~N~
N
c]pyridin-4-one ~ NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ ~ o N
(56) yl)-5-[(dibenzo[b,t][1,4]thiazepin-11- ~ ~ N I ,~--N
N N~N
yl )methyl]-7-methyl-3, 5-dihyd ro- _ imidazo[4,5-dJpyridazin-4-one \
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-(3-amino-piperidin-1-yl)-3-(1-buten-1- / \ o (57) yl) 5 [(dibenzo(b,t][1,4]thiazepin-11- S ~ I N N
yl)methyl]-3,5-dihydro-imidazo[4,5- N ~ I N~-N
c]pyridin-4-one \ / NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ ~ O
yl)-5-[(5-oxo-dibenzo[b,f][1,4]thiazepin-11- ~ N N
58 0 ~ ' ~ ~~-N
( ) yl)methyl]-7-methyl-3,5-dihydro- =S N N ~ N
NHZ
imidazo[4,5-dJpyridazin-4-one \ /
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ ~ o yl)-5-[(5,5-dioxo-dibenzo[b,tj[1,4]- ~ N N
(59) thiazepin-11-yl)methyl]-7-methyl-3,5- o .S ~N N ~ ~ ~~N~
O - ,N
N Hz dihydro-imidazo[4,5-dJpyridazin-4-one \ /
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ ~ O
(60) yl)-5-[(5H-dibenzo[a,dJcyclohepten-10- ' 1 N ~ N
N~ i N
yl)methyl]-7-methyl-3,5-dihydro- N
NHZ
imidazo[4,5-dJpyridazin-4-one \ /
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ ~ o 61 yl) 5 [(5-methyl-5H-dibenzo[b,t]azepin-10- ~ 1 N ~ N N
' ( ) yl)methyl]-7-trifluoromethyl-3,5-dihydro- ~N N ~ N
NHz imidazo[4,5-dJpyridazin-4-one \ / F F F
2-( 3-amino-piperidi n-1-yl )-3-(3-methyl-2-I
(62) buten-1-yl)-5-[(phenanthridin-6-yl)methyl]- I ~ ~N o /
7-methyl-3,5-dihydro-imidazo[4,5- N N
dJpyridazin-4-one Iv ~ ~ ~~N~
'N
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text .57 I~
2-(3-amino-piperidi n-1-yl )-3-(2-buten-1-(63) YI)-5-[(phenanthridin-6-yl)methyl]-7- I ~ ~ N o /
meth I-3 5-dih dro-i y , y midazo[4,5- N N
dJpyridazin-4-one N ~ I i~--N' ~N
I~
2-(3-am i no-piperidin-1-yl )-3-( 1-buten-1-I T
(64) YI)-5-[(phenanthridin-6-yl)methyl]-7- ~ 'N o methyl-3,5-dihydro-imidazo[4,5- N N
dJpyridazin-4-one N ~ I ~~N~
'---(N
NHz 2-(3-amino-piperidin-1-yl)-3-[(1- ~ I i (65) cyclopenten-1-yl)methyl]-5- I / ~nl o /
[(phenanthridin-6-yl)methyl]-7-meth I-3 5-Y ~ N N
dihydro-imidazo[4,5-d]pyridazin-4-one N ~ ~ ~~N~
'N
2-(3-amino-piperidin-1-yl)-3-(1-buten-1- o (66) yl)-5-[(phenanthridin-6-yl)methyl]-3,5- I ~ N~ N I N~--N
dihydro-imidazo[4,5-c]pyridin-4-one ~ v 'N
NHz 2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1-yl)-5-[(benzo[c][1,5]naphthyridin-6- I
(67) yl)methyl]-7-cyclopropyl-3,5-dihydro- I ~ N \ I ~~-N
N~ _N
imidazo[4,5-dJpyridazin-4-one ~ NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- I ~ o (6$) yl)-5-[(benzo[h][1,6]naphthyridin-5- N ~ N N
yl)methyl]-3,5-dihydro-imidazo[4,5- I ~ N N~N N
d]pyridazin-4-one I / ~--~NHZ
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1- p (69) yl)-5-[(benzo[c][1,8]naphthyridin-6- N I N' N I N~N
yl)methyl]-3,5-dihydro-imidazo[4,5- ~ i N ~ N
dJpyridazin-4-one ~ I NH2 2-( 3-amino-piperidi n-1-yl )-3-(2-butyn-1- p (70) yl)-5-[(5-benzo[t][1,7]naphthyridin-5- ~ ~ N' N I NON
yl)methyl]-3,5-dihydro-imidazo[4,5- ~ 'N ~N
c]pyridin-4-one I ~ NHZ
2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1- p ( ) yl)-5-[(1,5,9-triaza-phenanthren-10- ~ ~ N' N I NON
yl)methyl]-3,5-dihydro-imidazo[4,5- N~ 'N ~N
c]pyridin-4-one I ~ NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- p (72) yl)-5-[(1,2,3,4-tetrahydrophenanthridin-6- I N' N ( NON
yl)methyl]-3,5-dihydro-imidazo[4,5- w c]pyridin-4-one 2-(3-ami no-piperid i n-1-yl )-3-(2-butyn-1- p (73) yl)-5-[(1,2,3,4,4a,10b-hexahydro- N' N ( NON
phenanthridin-6-yl)methyl]-3,5-dihydro- ~ ~N
NHZ
imidazo[4,5-c]pyridin-4-one 2-( 3-ami no-piperidin-1-yl )-3-(2-butyn-1- p (74) yl) 5 ((2,3-dihydro-1H-4-aza- ~ N' N I NON
cyclopenta[a]naphth-5-yl)methyl]-3,5- I ~ ~ N
dihyd ro-i midazo(4, 5-c]pyrid i n-4-one 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- p (75) yl)-5-[(8,9,10,11-tetrahydro-7H-6-aza- I N' N I NON
cyclohepta[a]naphth-5-yl )methyl]-3, 5- w NHZ
dihydro-imidazo[4,5-c]pyridin-4-one Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-( 3-amino-pi peridi n-1-yl )-3-(2-butyn-1- o (76) yl)-5 [(2,3-dihydro-1H-4-oxa-10-aza- I N' N I NON
phenanthren-9-yl)methyl]-3,5-dihydro- o imidazo[4,5-c]pyridin-4-one I ~ NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- o 0 (77) yl)-5 [(1-oxo-2,3-dihydro-1H-4-oxa-10- I N' N I N
N
aza-phenanthren-9-yl)methyl]-3,5- o ~ ~N
dihydro-imidazo[4,5-c]pyridin-4-one I ~ NH2 N
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- I i o (78) yl)-5-[(10-cyanophenanthren-9-yl)methyl]- ~ ~ ~ N N
N~ N
3, 5-di hydro-i midazo[4, 5-c] pynd in-4-one NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ \ o ' (79) yl)-5-[(benzo[h]quinolin-6-yl)methyl]-3,5- ~ \ N ~ N~-N
_ N / \ \ N
dlhydro Imidazo[4,5-c]pyndin-4-one I ~ NH
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ \ o ' (80) yl)-5-[(benzo[tJquinolin-6-yl)methyl]-3,5- ~ \ N ~ NON
N' N
_ _ dihydro imidazo[4,5 dJpyridazin-4-one ~ ~~ NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ \ o ' (81 ) yl)-5-[(benzo[t]quinoxalin-6-yl)methyl]-3,5- ~ ~ N I NON
_ _ __ dihydro imidazo[4,5 dJpyridazin 4 one N ~ / N ' N NH
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- / ~ o (82) yl)-5-[(5H-benzo[e]pyrrolo[1,2- N I N I NON
a][1,4]diazepin-11-yl)methyl]-7-methyl- ~ N N ' NHZ
3,5-dihydro-imidazo[4,5-dJpyridazin-4-one ~ /
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- / \ o (83) YI)-5-[(thieno[3,2-b][1,4]benzoxazepin-9- o ~ N N
yl)methyl]-7-trifluoromethyl-3,5-dihydro- N N ' I NON
imidazo[4,5-d]p ridazin-4-one \ s F NHZ
Y F F
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- / \
(84) YI)-5-[(thieno[3,2-b][1,4]benzoxazepin-9- O - I N N
yl)methyl]-3,5-dihydro-imidazo[4,5- N ~ ~ ~~N~
N
c]pyridin-4-one \ S NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- _ H o (85) YI)-5-[(5H-dibenzo[d,t][1,3]diazepin-6- \ ~ N~N I N~-N
yl)methyl]-7-methyl-3,5-dihydro- ~ N N ' N ~-~-NHZ
imidazo[4,5-d]pyridazin-4-one ~
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- _ / p (86) YI)-5-[(5-methyl-5H- \ / N~NI_ ~~ N~-N
dibenzo[d,t][1,3]diazepin-6-yl)methyl]-3,5- _ N ~N
NHZ
dihydro-imidazo[4,5-c]pyridin-4-one ~
2-( 3-amino-piperidi n-1-yl )-3-(3-methylbut-2-en-1-yl)-5-[(5-oxa-7-aza- o /
(87) dibenzo[a,c]cyclohepten-6-yl)methyl]-7- \ / ~~N N ~
methyl-3,5-dihydro-imidazo[4,5-c]pyridin- ~ N N
w I ~~-N
4-one \ ~ NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~
(88) yl)-5-[(naphtho[1,2-d]thiazol-2-yl)methyl]- ~ ~ \N~N \ ~ NON
3 5-dih dro-imidaz 4 N
y o[ ,5-d]pyndazin-4-one NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~
N
(89) yl)-5-[(naphtho[2,1-d]thiazol-2-yl)methyl]-3,5-dih dro-imidazo 4 5- ridazin-4-on N
Y [ ~ dIPY a NHz Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing tent 2-(3-amino-piperid i n-1-yl )-3-(2-butyn-1- o (90) yl)-5-[(3H-naphtho[1,2-c~imidazol-2 ~ ~ N~N N
NH N ~ I ~~N~
-yl )methyl]-3, 5-d ihyd ro-im idazo[4, 5- NN
dJpyridazin-4-one NHz 2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1-(91) yl)-5-[(naphtho[1,2-b]furan-2-yl)methyl]- ~ ~ ~ ~ N ~ NON
\N w N
3, 5-di hyd ro-im idazo[4, 5-d]pyndazi n-4-one NHZ
2-( 3-amino-piperidi n-1-yl )-3-(2-butyn-1-(92) yl)-5-[(naphtho[2,1-b]furan-2-yl)methyl]- ~ ~ ~ N N
O \N w I ~~N~
3,5-dihydro-imidazo[4,5-d]pyridazin-4-one \N
NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- \ I o %
(93) yl)-5-[(2-methyl-furo[3,2-c]isoquinolin-5- ~N I NON
N
yl)methyl]-3,5-dihydro-imidazo[4,5- p N
c]pyridin-4-one NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- _N O
(94) yl)-5-[(pyrazolo[1,5-c]quinazolin-5- ~ N~N ~ N~N
yl)methyl]-3,5-dihydro-imidazo[4,5- ~ N NON
dJpyridazin-4-one I i NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- H
N
(95) yl)-5-[(1H-perimidin-2-yl)methyl]-3,5- ~ \\ ~N~ I N>--N
dihydro-imidazo[4,5-dJpyridazin-4-one ~ ~ NHz Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example 2 Coated tablets containing 75 mq of active substance 1 tablet core contains:
active substance 75.0 mg calcium phosphate 93.0 mg corn starch 35.5 mg polyvinylpyrrolidone 10.0 mg hydroxypropylmethylcellulose 15.0 mg magnesium stearate 1.5 mg 230.0 mg Preparation:
The active substance is mixed with calcium phosphate, corn starch, polyvin-ylpyrrolidone, hydroxypropylmethylcellulose and half the specified amount of magnesium stearate. Blanks 13 mm in diameter are produced in a tablet-making machine and these are then rubbed through a screen with a mesh size of 1.5 mm using a suitable machine and mixed with the rest of the magnesium stearate.
This granulate is compressed in a tablet-making machine to form tablets of the desired shape.
Weight of core: 230 mg die: 9 mm, convex The tablet cores thus produced are coated with a film consisting essentially of hydroxypropylmethylcellulose. The finished film-coated tablets are polished with beeswax.
Weight of coated tablet: 245 mg.
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example 3 Tablets containinct 100 mct of active substance Composition:
1 tablet contains:
active substance 100.0 mg lactose 80.0 mg corn starch 34.0 mg polyvinylpyrrolidone 4.0 mg magnesium stearate 2.0 mp 220.0 mg Method of Preparation:
The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50°C
it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets.
Weight of tablet: 220 mg Diameter: 10 mm, biplanar, facetted on both sides and notched on one side.
Example 4 Tablets containing 150 mq of active substance Composition:
1 tablet contains:
active substance 150.0 mg powdered lactose 89.0 mg corn starch 40.0 mg colloidal silica 10.0 mg polyvinylpyrrolidone 10.0 mg magnesium stearate 1.0 ma 300.0 mg Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Preparation:
The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45°C, are passed through the same screen again and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture.
Weight of tablet: 300 mg die: 10 mm, flat Example 5 Hard gelatine capsules containing 150 ma of active substance 1 capsule contains:
active substance 150.0 mg corn starch (dried) approx. 80.0 mg lactose (powdered) approx. 87.0 mg magnesium stearate 3.0 ma approx. 420.0 mg Preparation:
The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is packed into size 1 hard gelatine capsules.
Capsule filling: approx. 320 mg Capsule shell: size 1 hard gelatine capsule.
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example 6 Suppositories containing 150 mg of active substance 1 suppository contains:
5 active substance 150.0 mg polyethyleneglycol 1500 550.0 mg polyethyleneglycol 6000 460.0 mg polyoxyethylene sorbitan monostearate 840.0 mg 2,000.0 mg Preparation:
After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moulds.
Example 7 Suspension containing 50 mg of active substance 100 ml of suspension contain:
active substance 1.00 g carboxymethylcellulose-Na-salt 0.10 g methyl p-hydroxybenzoate 0.05 g propyl p-hydroxybenzoate 0.01 g glucose 10.00 g glycerol 5.00 g 70% sorbitol solution 20.00 g flavouring 0.30 g dist. water ad 100 ml Preparation:
The distilled water is heated to 70°C. The methyl and propyl p-hydroxybenzoates together with the glycerol and sodium salt of carboxymethylcellulose are dissolved therein with stirring. The solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring. After the Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text sugar, the sorbitol solution and the flavouring have been added and dissolved, the suspension is evacuated with stirring to eliminate air.
ml of suspension contain 50 mg of active substance.
5 Example 8 Ampoules containing 10 ma active substance Composition:
active substance 10.0 mg 0.01 N hydrochloric acid q.s.
double-distilled water ad 2.0 ml Preparation:
The active substance is dissolved in the necessary amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 2 ml ampoules.
Example 9 Ampoules containing 50 mgr of active substance Composition:
active substance 50.0 mg 0.01 N hydrochloric acid q.s.
double-distilled water ad 10.0 ml Preparation:
The active substance is dissolved in the necessary amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 10 ml ampoules.
d]pyridazin-4-one NH2 2-(3-amino-piperidin-1-yl )-3-(2-buten-1- o (14) yl)-5 ((4,4-dimethyl-4H- I w o~ ~ N\
N~ i~N
benzo[a][1,3]oxazin-2-yl)methyl]-3,5- ~ N N
N
dihydro-imidazo[4, 5-dJpyridazin-4-one N HZ
2-( 3-amino-piperidi n-1-yl )-3-(2-butyn-1- p (15) yl) 5 [(4-oxo-4H-benzo[e][1,3]oxazin-2- I ~ o~N I NON
I
yl)methyl]-3,5-dihydro-imidazo[4,5- ~ N N ~ N
d]pyridazin-4-one o NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- \ N o f (16) yl)-5 ((4H-benzo[d][1,3]oxazin-2- ~ ~ ~N ~ ~-N
yl)methyl]-3,5-dihydro-imidazo[4,5- ~ N
d]pyridazin-4-one NH2 2-(3-amino-piperidin-1-yl )-3-(2-butyn-1- o 17 yl)-5 ((4H-benzo[d][1,3]oxazin-2- ~~N N
( ) yl)methyl]-7-methyl-3,5-dihydro- ~w\ ~~o ~ I N>-N
imidazo[4,5-c]pyridin-4-one NHz 2-(3-ami no-piperidi n-1-yl )-3-(2-butyn-1- o (19) yl)-5-((4,4-dimethyl-4H- I \ N~N ~ N>-N
benzo[d][1,3]oxazin-2-yl)methyl]-3,5- ~ o N ~ N
dihydro-imidazo[4,5-dJpyridazin-4-one NHZ
2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1- o 20 yl) 5 [(4-oxo-4H-benzo[dj[1,3]oxazin-2- I ~ N~N N N
( ) yl)methyl]-3,5-dihydro-imidazo[4,5- ~ o N ~ I N
dJpyridazin-4-one o NHZ
2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1- o (21 ) yl)-5-[(2H-benzo[1,4]oxazin-3-yl)methyl]- ~ j N~N \ ~ N~.-N
N
3,5-dihydro-imidazo[4,5-dJpyridazin-4-one o NH
z Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- o 0 22 yl)-5-[(2-oxo-2H-benzo[1,4]oxazin-3- o~N ~ N
( ) yl)methyl]-3,5-dihydro-imidazo[4,5- / N N~N~ ~---d]pyridazin-4-one ~ I NH2 2-( 3-a m i no-pi perid i n-1-yl )-3-( 2-butyn-1- o yl)-5-[(2,2-dimethyl-2H-benzo[1,4]oxazin- o~N N
(23) N N ~ ~ i~N
3-yl)methyl]-3,5-dihydro-imidazo[4,5- ~ ' NN
dJpyridazin-4-one ~ NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ g~ o (24) yl)-5-[4H-benzo[e][1,3]thiazin-2-yl)methyl]- ~ ~ IN N \ ~ N)--N
~N
3,5-dihydro-imidazo[4,5-dJpyridazin-4-one NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- o 25 yl)-5-[4,4-dimethyl-4H- ~ SAN N
( ) benzo[a][1,3]thiazin-2-yl)methyl]-3,5- ~ i N N~ ~ N~N
dihydro-imidazo[4,5-dJpyridazin-4-one ~ ~--~NHZ
2-( 3-a m i no-piperid i n-1-yl )-3-(2-butyn-1- o (26) yl)-5-[4-oxo-4H-benzo[e][1,3]thiazin-2- I ~ S~N ~ NON
yl)methyl]-3,5-dihydro-imidazoj4,5- ~ N N ~ N
dJpyridazin-4-one O NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- o I -5 4H-benzo 1,3 thiazin-2-27 y ) -[( [~lj ] W N~N N
( ) yl)methyl]-3,5-dihydro-imidazo[4,5- ~ i S N ~ ~ N N
dJpyridazin-4-one NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- o N
(28) yl)-5-[(2H-benzo[1,4]thiazin-3-yl)methyl]- ~ ~ ~N \ ~ NON
N
3,5-dihydro-imidazo[4,5-dJpyridazin-4-one NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- o -N O
(29) yl)-5-[(2-oxo-2H-benzo[e][1,3]oxazin-4- o ~ N N
~ ~ i~ N
yl)methyl]-3,5-dihydro-imidazo[4,5- / \ N
N
d]pyridazin-4-one NHZ
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-(3-am i no-piperid i n-1-yl )-3-(2-butyn-1-yl)-5-[(1-methyl-2,2-dioxo-1H- NS \ o ' N
(30) benzo[c][1,2]thiazin-4-yl)methyl]-3,5- / \ N \ I N~-'N
dihydro-imidazo[4,5-d]pyridazin-4-one ~---~NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- I ~ o yl)-5-[(2,3-dihydro-1H- ~ N N
( ) benzo[e][1,4]diazepin-5-yl)methyl]-3,5- HN~N N~ ~ ~N
N
dihydro-imidazo[4,5-d]pyridazin-4-one NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- I ~ p 32 yl)-5-[(2-oxo-2,3-dihydro-1H-benzo[e][1,4] ~ 1 N N
( ) HN N N w l ~~N~
diazepin-5-yl)methyl]-3,5-dihydro- \N
imidazo[4,5-dJpyridazin-4-one o NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- I ~ o 33 yl)-5-[(1-methyl-2,3-dihydro-1H- i N N
( ) benzo[e][1,4]diazepin-5-yl)methyl]-3,5- -NON N ~. ~ N~'N
dihydro-imidazo[4,5-djpyridazin-4-one ~--~NHa 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- I ~ p 34 yl) 5 [(1-methyl-2-oxo-2,3-dihydro-1H- ~ , N N
( ) benzo[e][1,4]diazepin-5-yl)methyl]-3,5- -N N N ~ ~ N N.
dihydro-imidazo[4,5-djpyridazin-4-one O ~--(NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- p (35) yl) 5 [(4-oxo-4,5-dihydro-3H- ~ ~ N~ N I N N
benzo[b][1,4)diazepin-2-yl)methyl]-3,5- ~ N ~ N
NH
dihydro-imidazo[4,5-dJpyridazin-4-one H p z 2-(3-am i no-piperidi n-1-yl )-3-(2-butyn-1- p (36) yl)-5-[(5-methyl-4-oxo-4,5-dihydro-3H- \ / N~ N I N N
benzo[b][1,4]diazepin-2-yl)methyl]-3,5- N N ~ N
dihydro-imidazo[4,5-dJpyridazin-4-one ~ o NH2 Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 5a 2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1- o yl)-5-[5-oxo-4,5-dihydro-3H- ~ N~ N N
(37) benzo[e][1,4]diazepin-2-yl)methyl]-3,5- \ / ~N ~ I NON
dihydro-imidazo[4,5-d]pyridazin-4-one o 2-(3-am i no-piperidi n-1-yl )-3-(2-butyn-1- o 3$ yl)-5-[4-methyl-5-oxo-4,5-dihydro-3H- ~ N~ N N
I
( ) benzo[e][1,4]diazepin-2-yl)methyl]-3,5- \ / ~N ~ I NON
dihydro-imidazo[4,5-dJpyridazin-4-one p \ NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-~N O
(39) yl)-5-[(2,3-dihydro-benzo[t][1,4]oxazepin- o ~ N N
5-yl)methyl]-3,5-dihydro-imidazo[4,5- ' / N ~ ~ ~~N~
\N
d]pyridazin-4-one \ NH2 2-(3-ami no-piperid i n-1-yl )-3-(2-butyn-1-(40) yl)-5-[(3,3-dimethyl-2,3-dihydro- o N N o N
benzo[f][1,4]oxazepin-5-yl)methyl]-3,5- - N \ ~ ~~-N
\ / NN
dihydro-imidazo[4,5-c~pyridazin-4-one NHz 2-(3-ami no-piperid i n-1-yl )-3-(2-butyn-1-yl)-5-[(2,2-dimethyl-2,3-dihydro- ~N O
N
(41 ) benzo[t][1,4]oxazepin-5-yl)methyl]-7- o 'N ~ ,~N
r I
methyl-3,5-dihydro-imidazo[4,5- \ / N ~ N
dJpyridazin-4-one 2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1- o (42) YI)-5-[(2,3-dihydro-benzo[b][1,4]oxazepin- ~ N~ N N
4-yl)methyl]-7-methyl-3,5-dihydro- \ ~ N ~ ~ ~N
~N
imidazo[4,5-dJpyridazin-4-one o NHz 2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1-yl )-5-[(6, 6-di methyl-2, 3-di hyd ro- o 43 benzo b 1 4 oxaze in-4- I meth I -7- ' N~ N N
( ) [ ][ , ] p Y) Y] \ ~ N\ ~ ~~-N
- \ N
methyl-3,5-dihydro imidazo[4,5- O NH2 d]pyridazin-4-one Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-(3-am i no-piperidi n-1-yl )-3-(2-butyn-1- o 44 yl)-5 [(2,3-dihydro-benzo[b][1,4]thiazepin- ~ N~ N N
( ) 4-yl)methyl]-7-methyl-3,5-dihydro- ~ / N ~ ~ ~ N
~N
imidazo[4,5-dJpyridazin-4-one S NHZ
2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1-yl )-5-[(2, 2-d imethyl-2, 3-di hyd ro- o ' N N N
(45) benzo[b][1,4]thiazepin-4-yl)methyl]-7- ~ / ~ ~ ~ ,~-N
N~N
methyl-3, 5-di hyd ro-i m idazo[4, 5- S NHZ
dJpyridazin-4-one 2-(3-am i no-piperidin-1-yl )-3-(2-butyn-1-/ o (46) yl) 5 [(2,3-dihydro-benzo[t][1,4]thiazepin- ~ N N
5-yl)methyl]-7-methyl-3,5-dihydro- SAN N ~ ~ NON
imidazo[4,5-dJpyridazin-4-one ~---(NH2 2-( 3-amino-piperidi n-1-yl )-3-(2-butyn-1-yl )-5-[(5-oxo-4, 5-d i hyd ro- _ o O~ N
(47) benzo[tj[1,3,4]oxadiazepin-2-yl)methyl]-7- \ / II N ~ ~~-N
,N N w N
methyl-3, 5-dihyd ro-i midazo(4, 5 N
d]pyridazin-4-one 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- / ~ o 4$ yl)-5-[(11H-dibenzo[b,e]azepin-6- ~ I N N
I
( ) yl)methyl]-7-ethyl-3,5-dihydro- N N ~ ~ N N
imidazo[4,5-dJpyridazin-4-one \ / NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- / ~ o (49) yl)-5-[(11H-dibenzo[b,e]azepin-6- ~~N ~ N~-N
yl)methyl]-7-cyanomethyl-3,5-dihydro- N N ~ N
imidazo[4,5-djpyridazin-4-one \ / ~~ NH2 N
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- / \
_ o (50) yl) 5 [(11,11-difluoro-11H-dibenzo- FF ~ N N
[b,e]azepin-6-yl)methyl]-3,5-dihydro- , N ~ N
Y\~~~N
imidazo[4,5-c]pyridin-4-one \ / NHZ
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text \ O
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ N
-N
(51 ) yl) 5 [(11-oxo-11 H-dibenzo[b,e]azepin-6- o N N ~ I N~N
yl)methyl]-7-(2-cyanoethyl)-3,5-dihydro- \ / NH2 im idazo[4, 5-dJ pyridazi n-4-one II
N
2-(3-amino-piperidin-1-yl)-3-(1-buten-1- ~ \ o (52) yl)-5-[(11H-benzo[e]pyrido(3,2-b]azepin-6- ~ I N N
yl)methyl]-7-methyl-3,5-dihydro-imidazo- _~ N ~ N
~~-N
[4,5-d]pyridazin-4-one N NHZ
2-(3-amino-piperidin-1-yl-(2-butyn-1-yl)-5- / ~~N o (53) ((5H-1,9,10-triaza-dibenzo[a,dJcyclo- I I N N
i~ N
hepten-11-yl)methyl]-3,5-dihydro- ~ N ~ N
imidazo[4,5-c]pyridin-4-one \ , N NHZ
2-(3-amino-piperidin-1-yl)-3-(2-buten-1- ~ ~ p (54) yl)-5 ((5-methyl-5H-dibenzo[b,e][1,4]- ~ ~ N I N~N
diazepin-11-yl)methyl]-7-methyl-3,5- -N N N~N
dihydro-imidazo[4,5-djpyridazin-4-one \ ~ NHz 2-(3-amino-piperidin-1-yl)-3-(1-buten-1- / \ o (55) yl)-5-[(dibenzo[b,f][1,4]oxazepin-11- o - I N N
yl)methyl]-3,5-dihydro-imidazo[4,5- N ~ I ~~N~
N
c]pyridin-4-one ~ NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ ~ o N
(56) yl)-5-[(dibenzo[b,t][1,4]thiazepin-11- ~ ~ N I ,~--N
N N~N
yl )methyl]-7-methyl-3, 5-dihyd ro- _ imidazo[4,5-dJpyridazin-4-one \
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-(3-amino-piperidin-1-yl)-3-(1-buten-1- / \ o (57) yl) 5 [(dibenzo(b,t][1,4]thiazepin-11- S ~ I N N
yl)methyl]-3,5-dihydro-imidazo[4,5- N ~ I N~-N
c]pyridin-4-one \ / NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ ~ O
yl)-5-[(5-oxo-dibenzo[b,f][1,4]thiazepin-11- ~ N N
58 0 ~ ' ~ ~~-N
( ) yl)methyl]-7-methyl-3,5-dihydro- =S N N ~ N
NHZ
imidazo[4,5-dJpyridazin-4-one \ /
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ ~ o yl)-5-[(5,5-dioxo-dibenzo[b,tj[1,4]- ~ N N
(59) thiazepin-11-yl)methyl]-7-methyl-3,5- o .S ~N N ~ ~ ~~N~
O - ,N
N Hz dihydro-imidazo[4,5-dJpyridazin-4-one \ /
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ ~ O
(60) yl)-5-[(5H-dibenzo[a,dJcyclohepten-10- ' 1 N ~ N
N~ i N
yl)methyl]-7-methyl-3,5-dihydro- N
NHZ
imidazo[4,5-dJpyridazin-4-one \ /
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ ~ o 61 yl) 5 [(5-methyl-5H-dibenzo[b,t]azepin-10- ~ 1 N ~ N N
' ( ) yl)methyl]-7-trifluoromethyl-3,5-dihydro- ~N N ~ N
NHz imidazo[4,5-dJpyridazin-4-one \ / F F F
2-( 3-amino-piperidi n-1-yl )-3-(3-methyl-2-I
(62) buten-1-yl)-5-[(phenanthridin-6-yl)methyl]- I ~ ~N o /
7-methyl-3,5-dihydro-imidazo[4,5- N N
dJpyridazin-4-one Iv ~ ~ ~~N~
'N
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text .57 I~
2-(3-amino-piperidi n-1-yl )-3-(2-buten-1-(63) YI)-5-[(phenanthridin-6-yl)methyl]-7- I ~ ~ N o /
meth I-3 5-dih dro-i y , y midazo[4,5- N N
dJpyridazin-4-one N ~ I i~--N' ~N
I~
2-(3-am i no-piperidin-1-yl )-3-( 1-buten-1-I T
(64) YI)-5-[(phenanthridin-6-yl)methyl]-7- ~ 'N o methyl-3,5-dihydro-imidazo[4,5- N N
dJpyridazin-4-one N ~ I ~~N~
'---(N
NHz 2-(3-amino-piperidin-1-yl)-3-[(1- ~ I i (65) cyclopenten-1-yl)methyl]-5- I / ~nl o /
[(phenanthridin-6-yl)methyl]-7-meth I-3 5-Y ~ N N
dihydro-imidazo[4,5-d]pyridazin-4-one N ~ ~ ~~N~
'N
2-(3-amino-piperidin-1-yl)-3-(1-buten-1- o (66) yl)-5-[(phenanthridin-6-yl)methyl]-3,5- I ~ N~ N I N~--N
dihydro-imidazo[4,5-c]pyridin-4-one ~ v 'N
NHz 2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1-yl)-5-[(benzo[c][1,5]naphthyridin-6- I
(67) yl)methyl]-7-cyclopropyl-3,5-dihydro- I ~ N \ I ~~-N
N~ _N
imidazo[4,5-dJpyridazin-4-one ~ NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- I ~ o (6$) yl)-5-[(benzo[h][1,6]naphthyridin-5- N ~ N N
yl)methyl]-3,5-dihydro-imidazo[4,5- I ~ N N~N N
d]pyridazin-4-one I / ~--~NHZ
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1- p (69) yl)-5-[(benzo[c][1,8]naphthyridin-6- N I N' N I N~N
yl)methyl]-3,5-dihydro-imidazo[4,5- ~ i N ~ N
dJpyridazin-4-one ~ I NH2 2-( 3-amino-piperidi n-1-yl )-3-(2-butyn-1- p (70) yl)-5-[(5-benzo[t][1,7]naphthyridin-5- ~ ~ N' N I NON
yl)methyl]-3,5-dihydro-imidazo[4,5- ~ 'N ~N
c]pyridin-4-one I ~ NHZ
2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1- p ( ) yl)-5-[(1,5,9-triaza-phenanthren-10- ~ ~ N' N I NON
yl)methyl]-3,5-dihydro-imidazo[4,5- N~ 'N ~N
c]pyridin-4-one I ~ NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- p (72) yl)-5-[(1,2,3,4-tetrahydrophenanthridin-6- I N' N ( NON
yl)methyl]-3,5-dihydro-imidazo[4,5- w c]pyridin-4-one 2-(3-ami no-piperid i n-1-yl )-3-(2-butyn-1- p (73) yl)-5-[(1,2,3,4,4a,10b-hexahydro- N' N ( NON
phenanthridin-6-yl)methyl]-3,5-dihydro- ~ ~N
NHZ
imidazo[4,5-c]pyridin-4-one 2-( 3-ami no-piperidin-1-yl )-3-(2-butyn-1- p (74) yl) 5 ((2,3-dihydro-1H-4-aza- ~ N' N I NON
cyclopenta[a]naphth-5-yl)methyl]-3,5- I ~ ~ N
dihyd ro-i midazo(4, 5-c]pyrid i n-4-one 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- p (75) yl)-5-[(8,9,10,11-tetrahydro-7H-6-aza- I N' N I NON
cyclohepta[a]naphth-5-yl )methyl]-3, 5- w NHZ
dihydro-imidazo[4,5-c]pyridin-4-one Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-( 3-amino-pi peridi n-1-yl )-3-(2-butyn-1- o (76) yl)-5 [(2,3-dihydro-1H-4-oxa-10-aza- I N' N I NON
phenanthren-9-yl)methyl]-3,5-dihydro- o imidazo[4,5-c]pyridin-4-one I ~ NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- o 0 (77) yl)-5 [(1-oxo-2,3-dihydro-1H-4-oxa-10- I N' N I N
N
aza-phenanthren-9-yl)methyl]-3,5- o ~ ~N
dihydro-imidazo[4,5-c]pyridin-4-one I ~ NH2 N
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- I i o (78) yl)-5-[(10-cyanophenanthren-9-yl)methyl]- ~ ~ ~ N N
N~ N
3, 5-di hydro-i midazo[4, 5-c] pynd in-4-one NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ \ o ' (79) yl)-5-[(benzo[h]quinolin-6-yl)methyl]-3,5- ~ \ N ~ N~-N
_ N / \ \ N
dlhydro Imidazo[4,5-c]pyndin-4-one I ~ NH
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ \ o ' (80) yl)-5-[(benzo[tJquinolin-6-yl)methyl]-3,5- ~ \ N ~ NON
N' N
_ _ dihydro imidazo[4,5 dJpyridazin-4-one ~ ~~ NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~ \ o ' (81 ) yl)-5-[(benzo[t]quinoxalin-6-yl)methyl]-3,5- ~ ~ N I NON
_ _ __ dihydro imidazo[4,5 dJpyridazin 4 one N ~ / N ' N NH
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- / ~ o (82) yl)-5-[(5H-benzo[e]pyrrolo[1,2- N I N I NON
a][1,4]diazepin-11-yl)methyl]-7-methyl- ~ N N ' NHZ
3,5-dihydro-imidazo[4,5-dJpyridazin-4-one ~ /
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- / \ o (83) YI)-5-[(thieno[3,2-b][1,4]benzoxazepin-9- o ~ N N
yl)methyl]-7-trifluoromethyl-3,5-dihydro- N N ' I NON
imidazo[4,5-d]p ridazin-4-one \ s F NHZ
Y F F
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- / \
(84) YI)-5-[(thieno[3,2-b][1,4]benzoxazepin-9- O - I N N
yl)methyl]-3,5-dihydro-imidazo[4,5- N ~ ~ ~~N~
N
c]pyridin-4-one \ S NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- _ H o (85) YI)-5-[(5H-dibenzo[d,t][1,3]diazepin-6- \ ~ N~N I N~-N
yl)methyl]-7-methyl-3,5-dihydro- ~ N N ' N ~-~-NHZ
imidazo[4,5-d]pyridazin-4-one ~
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- _ / p (86) YI)-5-[(5-methyl-5H- \ / N~NI_ ~~ N~-N
dibenzo[d,t][1,3]diazepin-6-yl)methyl]-3,5- _ N ~N
NHZ
dihydro-imidazo[4,5-c]pyridin-4-one ~
2-( 3-amino-piperidi n-1-yl )-3-(3-methylbut-2-en-1-yl)-5-[(5-oxa-7-aza- o /
(87) dibenzo[a,c]cyclohepten-6-yl)methyl]-7- \ / ~~N N ~
methyl-3,5-dihydro-imidazo[4,5-c]pyridin- ~ N N
w I ~~-N
4-one \ ~ NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~
(88) yl)-5-[(naphtho[1,2-d]thiazol-2-yl)methyl]- ~ ~ \N~N \ ~ NON
3 5-dih dro-imidaz 4 N
y o[ ,5-d]pyndazin-4-one NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- ~
N
(89) yl)-5-[(naphtho[2,1-d]thiazol-2-yl)methyl]-3,5-dih dro-imidazo 4 5- ridazin-4-on N
Y [ ~ dIPY a NHz Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing tent 2-(3-amino-piperid i n-1-yl )-3-(2-butyn-1- o (90) yl)-5-[(3H-naphtho[1,2-c~imidazol-2 ~ ~ N~N N
NH N ~ I ~~N~
-yl )methyl]-3, 5-d ihyd ro-im idazo[4, 5- NN
dJpyridazin-4-one NHz 2-(3-amino-piperidi n-1-yl )-3-(2-butyn-1-(91) yl)-5-[(naphtho[1,2-b]furan-2-yl)methyl]- ~ ~ ~ ~ N ~ NON
\N w N
3, 5-di hyd ro-im idazo[4, 5-d]pyndazi n-4-one NHZ
2-( 3-amino-piperidi n-1-yl )-3-(2-butyn-1-(92) yl)-5-[(naphtho[2,1-b]furan-2-yl)methyl]- ~ ~ ~ N N
O \N w I ~~N~
3,5-dihydro-imidazo[4,5-d]pyridazin-4-one \N
NHZ
2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- \ I o %
(93) yl)-5-[(2-methyl-furo[3,2-c]isoquinolin-5- ~N I NON
N
yl)methyl]-3,5-dihydro-imidazo[4,5- p N
c]pyridin-4-one NH2 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- _N O
(94) yl)-5-[(pyrazolo[1,5-c]quinazolin-5- ~ N~N ~ N~N
yl)methyl]-3,5-dihydro-imidazo[4,5- ~ N NON
dJpyridazin-4-one I i NHz 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1- H
N
(95) yl)-5-[(1H-perimidin-2-yl)methyl]-3,5- ~ \\ ~N~ I N>--N
dihydro-imidazo[4,5-dJpyridazin-4-one ~ ~ NHz Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example 2 Coated tablets containing 75 mq of active substance 1 tablet core contains:
active substance 75.0 mg calcium phosphate 93.0 mg corn starch 35.5 mg polyvinylpyrrolidone 10.0 mg hydroxypropylmethylcellulose 15.0 mg magnesium stearate 1.5 mg 230.0 mg Preparation:
The active substance is mixed with calcium phosphate, corn starch, polyvin-ylpyrrolidone, hydroxypropylmethylcellulose and half the specified amount of magnesium stearate. Blanks 13 mm in diameter are produced in a tablet-making machine and these are then rubbed through a screen with a mesh size of 1.5 mm using a suitable machine and mixed with the rest of the magnesium stearate.
This granulate is compressed in a tablet-making machine to form tablets of the desired shape.
Weight of core: 230 mg die: 9 mm, convex The tablet cores thus produced are coated with a film consisting essentially of hydroxypropylmethylcellulose. The finished film-coated tablets are polished with beeswax.
Weight of coated tablet: 245 mg.
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example 3 Tablets containinct 100 mct of active substance Composition:
1 tablet contains:
active substance 100.0 mg lactose 80.0 mg corn starch 34.0 mg polyvinylpyrrolidone 4.0 mg magnesium stearate 2.0 mp 220.0 mg Method of Preparation:
The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50°C
it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets.
Weight of tablet: 220 mg Diameter: 10 mm, biplanar, facetted on both sides and notched on one side.
Example 4 Tablets containing 150 mq of active substance Composition:
1 tablet contains:
active substance 150.0 mg powdered lactose 89.0 mg corn starch 40.0 mg colloidal silica 10.0 mg polyvinylpyrrolidone 10.0 mg magnesium stearate 1.0 ma 300.0 mg Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Preparation:
The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45°C, are passed through the same screen again and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture.
Weight of tablet: 300 mg die: 10 mm, flat Example 5 Hard gelatine capsules containing 150 ma of active substance 1 capsule contains:
active substance 150.0 mg corn starch (dried) approx. 80.0 mg lactose (powdered) approx. 87.0 mg magnesium stearate 3.0 ma approx. 420.0 mg Preparation:
The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is packed into size 1 hard gelatine capsules.
Capsule filling: approx. 320 mg Capsule shell: size 1 hard gelatine capsule.
Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text Example 6 Suppositories containing 150 mg of active substance 1 suppository contains:
5 active substance 150.0 mg polyethyleneglycol 1500 550.0 mg polyethyleneglycol 6000 460.0 mg polyoxyethylene sorbitan monostearate 840.0 mg 2,000.0 mg Preparation:
After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moulds.
Example 7 Suspension containing 50 mg of active substance 100 ml of suspension contain:
active substance 1.00 g carboxymethylcellulose-Na-salt 0.10 g methyl p-hydroxybenzoate 0.05 g propyl p-hydroxybenzoate 0.01 g glucose 10.00 g glycerol 5.00 g 70% sorbitol solution 20.00 g flavouring 0.30 g dist. water ad 100 ml Preparation:
The distilled water is heated to 70°C. The methyl and propyl p-hydroxybenzoates together with the glycerol and sodium salt of carboxymethylcellulose are dissolved therein with stirring. The solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring. After the Boehringer Ingelheim International GmbH Case 1/1502 55216 Ingelheim foreign filing text sugar, the sorbitol solution and the flavouring have been added and dissolved, the suspension is evacuated with stirring to eliminate air.
ml of suspension contain 50 mg of active substance.
5 Example 8 Ampoules containing 10 ma active substance Composition:
active substance 10.0 mg 0.01 N hydrochloric acid q.s.
double-distilled water ad 2.0 ml Preparation:
The active substance is dissolved in the necessary amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 2 ml ampoules.
Example 9 Ampoules containing 50 mgr of active substance Composition:
active substance 50.0 mg 0.01 N hydrochloric acid q.s.
double-distilled water ad 10.0 ml Preparation:
The active substance is dissolved in the necessary amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 10 ml ampoules.
Claims (10)
1-yl-carbonylamino, piperidin-1-yl-carbonylamino, morpholin-4-yl-carbonylamino, piperazin-1-yl-carbonylamino or 4-(C1-3-alkyl)-piperazin-1-yl-carbonylamino, C1-3-alkyl-sulphonylamino, bis-(C1-3-alkylsulphonyl)-amino, aminosulphonylamino, C1-3-alkylamino-sulphonylamino, di-(C1-3-alkyl)amino-sulphonylamino, pyrrolidin-1-yl-sulphonylamino, piperidin-1-yl-sulphonylamino, morpholin-4-yl-sulphonylamino, piperazin-1-yl-sulphonylamino or 4-(C1-3-alkyl)-piperazin-1-yl-sulphonylamino, (C1-3-alkylamino)thiocarbonylamino, (C1-3-alkyloxy-carbonyl-amino)carbonylamino, arylsulphonylamino or aryl-C1-3-alkyl-sulphonyl-amino group, an N-(C1-3-alkyl)-C1-3-alkyl-carbonylamino, N-(C1-3-alkyl)-arylcarbonyl-amino, N-(C1-3-alkyl)-aryl-C1-3-alkyl-carbonylamino, N-(C1-3-alkyl)-C1-3-alkyloxy-carbonylamino, N-(aminocarbonyl)-C1-3-alkylamino, N-(C1-3-alkyl-aminocarbonyl)-C1-3-alkylamino, N-[di-(C1-3-alkyl)aminocarbonyl]-C1-3-alkylamino, N-(C1-3-alkyl)-C1-3-alkyl-sulphonylamino, N-(C1-3-alkyl)-arylsulphonylamino, or N-(C1-3-alkyl)-aryl-C1-3-alkyl-sulphonylamino group, a 2-oxo-imidazolidin-1-yl, 2,4-dioxo-imidazolidin-1-yl, 2,5-dioxo-imidazolidin-1-yl or 2-oxo-hexahydropyrimidin-1-yl group wherein the nitrogen atom in the 3 position may be substituted in each case by a methyl or ethyl group, a cyano, carboxy, C1-3-alkyloxy-carbonyl, aminocarbonyl, C1-3-alkyl-aminocarbonyl, di-(C1-3-alkyl)-aminocarbonyl, pyrrolidin-1-yl-carbonyl, piperidin-1-yl-carbonyl, morpholin-4-yl-carbonyl, piperazin-1-yl-carbonyl or 4-(C1-3-alkyl)-piperazin-1-yl-carbonyl group, a C1-3-alkyl-carbonyl or an arylcarbonyl group, a carboxy-C1-3-alkyl, C1-3-alkyloxy-carbonyl-C1-3-alkyl, cyano-C1-3-alkyl, aminocarbonyl-C1-3-alkyl, C1-3-alkyl-aminocarbonyl-C1-3-alkyl, di-(C1-3-alkyl)-aminocarbonyl-C1-3-alkyl, pyrrolidin-1-yl-carbonyl-C1-3-alkyl, piperidin-1-yl-carbonyl-C1-3-alkyl, morpholin-4-yl-carbonyl-C1-3-alkyl, piperazin-1-yl-carbonyl-C1-3-alkyl or 4-(C1-3-alkyl)-piperazin-1-yl-carbonyl-C1-3-alkyl group, a carboxy-C1-3-alkyloxy, C1-3-alkyloxy-carbonyl-C1-3-alkyloxy, cyano-C1-3-alkyloxy, aminocarbonyl-C1-3-alkyloxy, C1-3-alkyl-aminocarbonyl-C1-3-alkyloxy, di-(C1-3-alkyl)-aminocarbonyl-C1-3-alkyloxy, pyrrolidin-1-yl-carbonyl-C1-3-alkyloxy, piperidin-1-yl-carbonyl-C1-3-alkyloxy, morpholin-4-yl-carbonyl-C1-3-alkyloxy, piperazin-1-yl-carbonyl-C1-3-alkyloxy or 4-(C1-3-alkyl)-piperazin-1-yl-carbonyl-C1-3-alkyloxy group, a hydroxy-C1-3-alkyl, C1-3-alkyloxy-C1-3-alkyl, amino-C1-3-alkyl, C1-3-alkylamino-C1-3-alkyl, di-(C1-3-alkyl)-amino-C1-3-alkyl, pyrrolidin-1-yl-C1-3-alkyl, piperidin-1-yl-C1-3-alkyl, morpholin-4-yl-C1-3-alkyl, piperazin-1-yl-C1-3-alkyl or 4-(C1-3-alkyl)-piperazin-1-yl-C1-3-alkyl group, a hydroxy-C1-3-alkyloxy, C1-3-alkyloxy-C1-3-alkyloxy, C1-3-alkylsulphanyl-C1-3-alkyloxy, C1-3-alkylsulphinyl-C1-3-alkyloxy, C1-3-alkylsulphonyl-C1-3-alkyloxy, amino-C1-3-alkyloxy, C1-3-alkylamino-C1-3-alkyloxy, di-(C1-3-alkyl)-amino-C1-3-alkyloxy, pyrrolidin-1-yl-C1-3-alkyloxy, piperidin-1-yl-C1-3-alkyloxy, morpholin-4-yl-C1-3-alkyloxy, piperazin-1-yl-C1-3-alkyloxy or 4-(C1-3-alkyl)-piperazin-1-yl-C1-3-alkyloxy group, a mercapto, C1-3-alkylsulphanyl, C1-3-alkysulphinyl, C1-3-alkylsulphonyl, C1-3-alkylsulphonyloxy, arylsulphonyloxy, trifluoromethylsulphanyl, trifluoromethylsulphinyl or trifluoromethylsulphonyl group, a sulpho, aminosulphonyl, C1-3-alkyl-aminosulphonyl, di-(C1-3-alkyl)-aminosulphonyl, pyrrolidin-1-yl-sulphonyl, piperidin-1-yl-sulphonyl, morpholin-4-yl-sulphonyl, piperazin-1-yl-sulphonyl or 4-(C1-3-alkyl)-piperazin-1-yl-sulphonyl group, a methyl or methoxy group substituted by 1 to 3 fluorine atoms, an ethyl or ethoxy group substituted by 1 to 5 fluorine atoms, a C2-4-alkenyl or C2-4-alkynyl group, a C3-4-alkenyloxy or C3-4-alkynyloxy group, a C3-6-cycloalkyl or C3-6-cycloalkyloxy group, a C3-6-cycloalkyl-C1-3-alkyl or C3-6-cycloalkyl-C1-3-alkyloxy group or an aryl, aryloxy, aryl-C1-3-alkyl or aryl-C1-3-alkyloxy group, R11 and R12, which may be identical or different, in each case represent a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, a C1-3-alkyl, trifluoromethyl, hydroxy, C1-3-alkyloxy or cyano group, or R11 together with R12, if these are bound to adjacent carbon atoms, also denotes a methylenedioxy, difluoromethylenedioxy, ethylenedioxy or a straight-chain C3-5-alkylene group and R13 denotes a hydrogen atom, a fluorine, chlorine or bromine atom, a trifluoromethyl, C1-3-alkyl or C1-3-alkyloxy group, R2 denotes a hydrogen, fluorine or chlorine atom, a C1-6-alkyl group, a C2-4-alkenyl group, a C3-4-alkynyl group, a C3-6-cycloalkyl group, a C3-6-cycloalkyl-C1-3-alkyl group, a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydro-furanylmethyl or tetrahydropyranylmethyl group, an aryl group, an aryl-C1-4-alkyl group, an aryl-C2-3-alkenyl group, an arylcarbonyl group, an arylcarbonyl-C1-2-alkyl group, a heteroaryl group, a heteroaryl-C1-3-alkyl group, a furanylcarbonyl, thienylcarbonyl, thiazolylcarbonyl or pyridylcarbonyl group, a furanylcarbonylmethyl, thienylcarbonylmethyl, thiazolylcarbonylmethyl or pyridylcarbonylmethyl group, a C1-4-alkyl-carbonyl group, a C1-4-alkyl-carbonyl-C1-2-alkyl group, a C3-6-cycloalkyl-carbonyl group, a C3-6-cycloalkyl-carbonyl-C1-2-alkyl group, an aryl-A or aryl-A-C1-3-alkyl group, where A denotes an oxygen or sulphur atom, an imino, C1-3-alkylimino, sulphinyl or sulphonyl group, a group R b, where R b denotes a cyano, carboxy, C1-3-alkyloxy-carbonyl, aminocarbonyl, C1-3-alkylamino-carbonyl, di-(C1-3-alkyl)-amino-carbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, 4-ethylpiperazin-1-ylcarbonyl, hydroxy, mercapto, C1-3-alkyloxy, C1-3-alkylsulphenyl, C1-3-alkylsulphinyl, C1-3-alkyl-sulphonyl, amino, C1-3-alkylamino, di-(C1-3-alkyl)-amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl or 4-ethyl-piperazin-1-yl group, or a C1-4-alkyl group substituted by a group R b, where R b is as hereinbefore defined, Y denotes a nitrogen atom or a group of formula C-R5, while R5 is defined like R2 and in each case one of the two groups R2 and R5 must be a hydrogen atom or a C1-3-alkyl group, R3 denotes a C3-8-alkyl group, a C1-3-alkyl group substituted by a group R c, where R c denotes a C3-7-cycloalkyl group optionally substituted by one or two C1-3-alkyl groups, a C5-7-cycloalkenyl group optionally substituted by one or two C1-3-alkyl groups, an aryl group or a furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidyl or pyrazinyl group, while the above mentioned heterocyclic groups may each be substituted by one or two C1-3-alkyl groups or by a fluorine, chlorine, bromine or iodine atom or by a trifluoromethyl, cyano or C1-3-alkyloxy group, a C3-8-alkenyl group, a C3-6-alkenyl group substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl group, a C3-8-alkynyl group, an aryl group or an aryl-C2-4-alkenyl group, and R4 denotes an azetidin-1-yl or pyrrolidin-1-yl group which is substituted in the 3 position by an amino, C1-3-alkylamino or a di-(C1-3-alkyl)amino group and may additionally be substituted by one or two C1-3-alkyl groups, a piperidin-1-yl or hexahydroazepin-1-yl group which is substituted in the 3 position or in the 4 position by an amino, C1-3-alkylamino or a di-(C1-3-alkyl)amino group and may additionally be substituted by one or two C1-3-alkyl groups, a 3-amino-piperidin-1-yl group wherein the piperidin-1-yl-moiety is additionally substituted by an aminocarbonyl, C1-2-alkyl-aminocarbonyl, di-(C1-2-alkyl)aminocarbonyl, pyrrolidin-1-yl-carbonyl, (2-cyano-pyrrolidin-1-yl-)carbonyl, thiazolidin-3-yl-carbonyl, (4-cyano-thiazolidin-3-yl)carbonyl, piperidin-1-ylcarbonyl or morpholin-4-ylcarbonyl group, a 3-amino-piperidin-1-yl group wherein the piperidin-1-yl moiety in the 4 position or in the 5 position is additionally substituted by a hydroxy or methoxy group, a 3-amino-piperidin-1-yl group wherein the methylene group in the 2 position or in the 6 position is replaced by a carbonyl group, a piperidin-1-yl or hexahydroazepin-1-yl group substituted in the 3 position by an amino, C1-3-alkylamino or di-(C1-3-alkyl)-amino- group, wherein in each case two hydrogen atoms on the carbon skeleton of the piperidin-1-yl or hexahydroazepin-1-yl-group are replaced by a straight-chain alkylene bridge, this bridge containing
2 to 5 carbon atoms if the two hydrogen atoms are located on the same carbon atom, or to 4 carbon atoms, if the hydrogen atoms are located on adjacent carbon atoms, or 1 to 4 carbon atoms, if the hydrogen atoms are located on carbon atoms which are separated by one atom, or 1 to 3 carbon atoms if the two hydrogen atoms are located on carbon atoms separated by two atoms, an azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl or hexahydroazepin-1-yl group which is substituted by an amino-C1-3-alkyl, C1-3-alkylamino-C1-3-alkyl or a di-(C1-3-alkyl)-amino-C1-3-alkyl group, a piperazin-1-yl or [1,4]diazepan-1-yl group optionally substituted at the carbon skeleton by one or two C1-3-alkyl groups, a 3-imino-piperazin-1-yl, 3-imino-[1,4]diazepan-1-yl or 5-imino-[1,4]diazepan-1-yl group optionally substituted at the carbon skeleton by one or two C1-3-alkyl groups, a [1,4]diazepan-1-yl group optionally substituted by one or two C1-3-alkyl groups, which is substituted in the 6 position by an amino group, a C3-7-cycloalkyl group which is substituted by an amino, C1-3-alkylamino or di-(C1-3-alkyl)-amino group, a C3-7-cycloalkyl group which is substituted by an amino-C1-3-alkyl, C1-3-alkylamino-C1-3-alkyl or a di-(C1-3-alkyl)amino-C1-3-alkyl group, a C3-7-cycloalkyl-C1-2-alkyl group wherein the cycloalkyl moiety is substituted by an amino, C1-3-alkylamino or di-(C1-3-alkyl)-amino group, a C3-7-cycloalkyl-C1-2-alkyl group wherein the cycloalkyl moiety is substituted by an amino-C1-3-alkyl, C1-3-alkylamino-C1-3-alkyl or a di-(C1-3-alkyl)amino-C1-3-alkyl group, a C3-7-cycloalkylamino group wherein the cycloalkyl moiety is substituted by an amino, C1-3-alkylamino or di-(C1-3-alkyl)-amino group, while the two nitrogen atoms at the cycloalkyl moiety are separated from one another by at least two carbon atoms, an N-(C3-7-cycloalkyl)-N-(C1-3-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino, C1-3-alkylamino or di-(C1-3-alkyl)-amino group, while the two nitrogen atoms at the cycloalkyl moiety are separated from one another by at least two carbon atoms, a C3-7-cycloalkylamino group wherein the cycloalkyl moiety is substituted by an amino-C1-3-alkyl, C1-3-alkylamino-C1-3-alkyl or a di-(C1-3-alkyl)amino-C1-3-alkyl group, an N-(C3-7-cycloalkyl)-N-(C1-3-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino-C1-3-alkyl, C1-3-alkylamino-C1-3-alkyl or a di-(C1-3-alkyl)amino-C1-3-alkyl group, a C3-7-cycloalkyl-C1-2-alkyl-amino group wherein the cycloalkyl moiety is substituted by an amino, C1-3-alkylamino or di-(C1-3-alkyl)-amino group, an N-(C3-7-cycloalkyl-C1-2-alkyl)-N-(C1-2-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino, C1-3-alkylamino or di-(C1-3-alkyl)-amino group, a C3-7-cycloalkyl-C1-2-alkyl-amino group wherein the cycloalkyl moiety is substituted by an amino-C1-3-alkyl, C1-3-alkylamino-C1-3-alkyl or a di-(C1-3-alkyl)amino-C1-3-alkyl group, an N-(C3-7-cycloalkyl-C1-2-alkyl)-N-(C1-2-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino-C1-3-alkyl, C1-3-alkylamino-C1-3-alkyl or a di-(C1-3-alkyl)amino-C1-3-alkyl group, a R19-C2-4-alkylamino group wherein R19 is separated from the nitrogen atom of the C2-4-alkylamino moiety by at least two carbon atoms and R19 denotes an amino, C1-3-alkylamino or di-(C1-3-alkyl)-amino group, an R19-C2-4-alkylamino group wherein the nitrogen atom of the C2-4-alkylamino moiety is substituted by a C1-3-alkyl group and R19 is separated from the nitrogen atom of the C2-4-alkylamino moiety by at least two carbon atoms, while R19 is as hereinbefore defined, an amino group substituted by the group R20 wherein R20 denotes an azetidin-3-yl, azetidin-2-ylmethyl, azetidin-3-ylmethyl, pyrrolidin-3-yl, pyrrolidin-2-ylmethyl, pyrrolidin-3-ylmethyl, piperidin-3-yl, piperidin-4-yl, piperidin-2-ylmethyl, piperidin-3-ylmethyl or piperidin-4-ylmethyl group, while the groups mentioned for R20 may each be substituted by one or two C1-3-alkyl groups, an amino group substituted by the group R20 and a C1-3-alkyl group wherein R20 is as hereinbefore defined, while the groups mentioned for R20 may each be substituted by one or two C1-3-alkyl groups, an R19-C3-4-alkyl group wherein the C3-4-alkyl moiety is straight-chained and may additionally be substituted by one or two C1-3-alkyl groups, while R19 is as hereinbefore defined, a 3-amino-2-oxo-piperidin-5-yl or 3-amino-2-oxo-1-methyl-piperidin-5-yl group, a pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, hexahydroazepin-3-yl or hexahydroazepin-4-yl group which is substituted in the 1 position by an amino, alkylamino or di-(C1-3-alkyl)amino group, or an azetidin-2-yl-C1-2-alkyl, azetidin-3-yl-C1-2-alkyl, pyrrolidin-2-yl-C1-2-alkyl, pyrrolidin-3-yl, pyrrolidin-3-yl-C1-2-alkyl, piperidin-2-yl-C1-2-alkyl, piperidin-3-yl, piperidin-3-yl-C1-2-alkyl, piperidin-4-yl or piperidin-4-yl-C1-2-alkyl group, while the above mentioned groups may each be substituted by one or two C1-3-alkyl groups, while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups which may be mono- or disubstituted by R h, while the substituents may be identical or different and R h denotes a fluorine, chlorine, bromine or iodine atom, a trifluoromethyl, cyano, nitro, amino, aminocarbonyl, aminosulphonyl, methylsulphonyl, acetylamino, methylsulphonylamino, C1-3-alkyl, cyclopropyl, ethenyl, ethynyl, hydroxy, C1-3-alkyloxy, difluoromethoxy or trifluoromethoxy group, by the heteroaryl groups mentioned in the definition of the above groups are meant a pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl or isoquinolinyl group, or a pyrrolyl, furanyl, thienyl or pyridyl group, wherein one or two methyne groups are replaced by nitrogen atoms, or an indolyl, benzofuranyl, benzothiophenyl, quinolinyl or isoquinolinyl group, wherein one to three methyne groups are replaced by nitrogen atoms, and the above mentioned heteroaryl groups may be mono- or disubstituted by R h, while the substituents may be identical or different and R h, is as hereinbefore defined, while, unless otherwise stated, the above mentioned alkyl, alkenyl and alkynyl groups may be straight-chain or branched, and the hydrogen atoms of the methyl or ethyl groups contained in the definitions may be wholly or partly replaced by fluorine atoms, the tautomers, enantiomers, diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof.
2. Compounds of general formula I according to claim 1, wherein R1 denotes a methyl group substituted by a group R a, where R a denotes a 3,4-dihydro-quinolinyl group, a 3,4-dihydro-isoquinolinyl group, a 1,4-dihydro-quinazolinyl or 4-oxo-1,4-dihydro-quinazolinyl group, a 3,4-dihydro-quinazolinyl or 4-oxo-3,4-dihydro-quinazolinyl group, a 1H-benzo[d][1,2]oxazinyl or 1-oxo-1H-benzo[d][1,2]oxazinyl group, a 4H-benzo[e][1,3]oxazinyl or 4-oxo-4H-benzo[e][1,3]oxazinyl group, a 4H-benzo[d][1,3]oxazinyl or 4-oxo-4H-benzo[d][1,3]oxazinyl group, a 2H-benzo[1,4]oxazinyl or 2-oxo-2H-benzo[1,4]oxazinyl group, a 4H-benzo[e][1,3]thiazinyl or 4-oxo-4H-benzo[e][1,3]thiazinyl group, a 4H-benzo[d][1,3]thiazinyl or 2H-benzo [1,4]thiazinyl group, a 2-oxo-2H-benzo(e][1,3]oxazinyl or 2,2-dioxo-1H-benzo[c][1,2]thiazinyl group, a 2,3-dihydro-1H-benzo[e][1,4]diazepinyl or 2-oxo-2,3-dihydro-1H-benzo(e][1,4]diazepinyl group, a 4,5-dihydro-3H-benzo[b][1,4]diazepinyl or 4-oxo-4,5-dihydro-3H-benzo[b][1,4]diazepinyl group, a 5-oxo-4,5-dihydro-3H-benzo[e][1,4]diazepinyl group, a 2,3-dihydro-benzo[f][1,4]oxazepinyl or 2,3-dihydro-benzo[b][1,4]oxazepinyl group, a 2,3-dihydro-benzo[f][1,4]thiazepinyl or 2,3-dihydro-benzo[b][1,4]thiazepinyl group, a 5-oxo-4,5-dihydro-benzo[f][1,3,4]oxadiazepinyl group, a 11H-dibenzo[b,e]azepinyl or 11-oxo-11H-dibenzo[b,e]azepinyl group, a 11H-benzo[e]pyrido[3,2-b]azepinyl or a 5H-1,9,10-triaza-dibenzo[a,d]-cycloheptenyl group, a 5H-dibenzo[b,e][1,4]diazepinyl or dibenzo[b,f][1,4]oxazepinyl group, a dibenzo[b,f][1,4]thiazepinyl, 5-oxo-dibenzo[b,f][1,4]thiazepinyl or 5,5-dioxo-dibenzo[b,f][1,4]thiazepinyl group, a 5H-dibenzo[a,d]cycloheptenyl or 5H-dibenzo[b,f]azepinyl group, a phenanthridinyl, benzo[c](1,5]naphthyridinyl, benzo[h][1,6]naphthyridinyl, benzo[c][1,8]naphthyridinyl, benzo[f][1,7]naphthyridinyl or 1,5,9-triaza-phenanthrenyl group, a 1,2,3,4-tetrahydro-phenanthridinyl, 1,2,3,4,4a,10b-hexahydro-phenan-thridinyl, 2,3-dihydro-1H-4-aza-cyclopenta[a]naphthyl or 8,9,10,11-tetrahydro-7H-6-aza-cyclohepta[a]naphthyl group, a 2,3-dihydro-1H-4-oxa-10-aza-phenanthrenyl or 1-oxo-2,3-dihydro-1H-4-oxa-10-aza-phenanthrenyl group, a phenanthrenyl, benzo[h]quinolinyl, benzo[f]quinolinyl or benzo[f]quinoxalinyl group, a 5H-benzo[a]pyrrolo[1,2-a][1,4]diazepinyl, thieno[3,2-b][1,4]benzoxazepinyl, 5H-dibenzo[d,f][1,3]diazepinyl or 5-oxa-7-aza-dibenzo[a,c]cycloheptenyl group, a naphtho[1,2-d]oxazolyl, naphtho[2,1-d]oxazolyl, naphtho[1,2-d]thiazolyl, naphtho[2,1-d]thiazolyl, naphtho[1,2-d]imidazolyl, naphtho[1,2-b]furanyl or naphtho[2,1-b]furanyl group, or a furo[3,2-c]isoquinolinyl, pyrazolo[1,5-c]quinazolinyl or 1H-perimidinyl group, while the benzo groups of the above mentioned radicals R a are substituted by the groups R10 to R13 and the alkylene units of the above mentioned groups R a may be substituted by one or two fluorine atoms or one or two C1-3-alkyl or C1-3-alkyloxy-carbonyl groups and the imino groups of the above mentioned radicals R a may be substituted by a C1-3-alkyl group and R10 denotes a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, a C1-3-alkyl or cyclopropyl group, a hydroxy, C1-3-alkyloxy or cyclopropyloxy group, a nitro, amino, C1-3-alkylamino or di-(C1-3-alkyl)amino group, a C1-3-alkyl-carbonylamino or C1-3-alkyl-sulphonylamino group, a cyano, carboxy, C1-3-alkyloxy-carbonyl, aminocarbonyl, C1-3-alkyl-aminocarbonyl or di-(C1-3-alkyl)-aminocarbonyl group, a mercapto, C1-3-alkylsulphanyl, C1-3-alkysulphinyl, C1-3-alkylsulphonyl or aminosulphonyl group or a difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy group and R11, R12 and R13, which may be identical or different, in each case represent a hydrogen atom, a fluorine, chlorine or bromine atom, a methyl, trifluoromethyl or methoxy group, R2 denotes a hydrogen atom or a C1-3-alkyl, cyclopropyl, trifluoromethyl, cyanomethyl or 2-cyano-ethyl group, Y denotes a nitrogen atom or a group of formula C-R5, while R5 denotes a hydrogen atom or a C1-3-alkyl group, R3 denotes a 2-buten-1-yl or 3-methyl-2-buten-1-yl group, a 1-buten-1-yl group, a 2-butyn-1-yl group or a 1-cyclopenten-1-ylmethyl group and R4 denotes a (3-amino-piperidin-1-yl) group, while, unless otherwise stated, the above mentioned alkyl groups may be straight-chain or branched, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
2. Compounds of general formula I according to claim 1, wherein R1 denotes a methyl group substituted by a group R a, where R a denotes a 3,4-dihydro-quinolinyl group, a 3,4-dihydro-isoquinolinyl group, a 1,4-dihydro-quinazolinyl or 4-oxo-1,4-dihydro-quinazolinyl group, a 3,4-dihydro-quinazolinyl or 4-oxo-3,4-dihydro-quinazolinyl group, a 1H-benzo[d][1,2]oxazinyl or 1-oxo-1H-benzo[d][1,2]oxazinyl group, a 4H-benzo[e][1,3]oxazinyl or 4-oxo-4H-benzo[e][1,3]oxazinyl group, a 4H-benzo[d][1,3]oxazinyl or 4-oxo-4H-benzo[d][1,3]oxazinyl group, a 2H-benzo[1,4]oxazinyl or 2-oxo-2H-benzo[1,4]oxazinyl group, a 4H-benzo[e][1,3]thiazinyl or 4-oxo-4H-benzo[e][1,3]thiazinyl group, a 4H-benzo[d][1,3]thiazinyl or 2H-benzo [1,4]thiazinyl group, a 2-oxo-2H-benzo(e][1,3]oxazinyl or 2,2-dioxo-1H-benzo[c][1,2]thiazinyl group, a 2,3-dihydro-1H-benzo[e][1,4]diazepinyl or 2-oxo-2,3-dihydro-1H-benzo(e][1,4]diazepinyl group, a 4,5-dihydro-3H-benzo[b][1,4]diazepinyl or 4-oxo-4,5-dihydro-3H-benzo[b][1,4]diazepinyl group, a 5-oxo-4,5-dihydro-3H-benzo[e][1,4]diazepinyl group, a 2,3-dihydro-benzo[f][1,4]oxazepinyl or 2,3-dihydro-benzo[b][1,4]oxazepinyl group, a 2,3-dihydro-benzo[f][1,4]thiazepinyl or 2,3-dihydro-benzo[b][1,4]thiazepinyl group, a 5-oxo-4,5-dihydro-benzo[f][1,3,4]oxadiazepinyl group, a 11H-dibenzo[b,e]azepinyl or 11-oxo-11H-dibenzo[b,e]azepinyl group, a 11H-benzo[e]pyrido[3,2-b]azepinyl or a 5H-1,9,10-triaza-dibenzo[a,d]-cycloheptenyl group, a 5H-dibenzo[b,e][1,4]diazepinyl or dibenzo[b,f][1,4]oxazepinyl group, a dibenzo[b,f][1,4]thiazepinyl, 5-oxo-dibenzo[b,f][1,4]thiazepinyl or 5,5-dioxo-dibenzo[b,f][1,4]thiazepinyl group, a 5H-dibenzo[a,d]cycloheptenyl or 5H-dibenzo[b,f]azepinyl group, a phenanthridinyl, benzo[c](1,5]naphthyridinyl, benzo[h][1,6]naphthyridinyl, benzo[c][1,8]naphthyridinyl, benzo[f][1,7]naphthyridinyl or 1,5,9-triaza-phenanthrenyl group, a 1,2,3,4-tetrahydro-phenanthridinyl, 1,2,3,4,4a,10b-hexahydro-phenan-thridinyl, 2,3-dihydro-1H-4-aza-cyclopenta[a]naphthyl or 8,9,10,11-tetrahydro-7H-6-aza-cyclohepta[a]naphthyl group, a 2,3-dihydro-1H-4-oxa-10-aza-phenanthrenyl or 1-oxo-2,3-dihydro-1H-4-oxa-10-aza-phenanthrenyl group, a phenanthrenyl, benzo[h]quinolinyl, benzo[f]quinolinyl or benzo[f]quinoxalinyl group, a 5H-benzo[a]pyrrolo[1,2-a][1,4]diazepinyl, thieno[3,2-b][1,4]benzoxazepinyl, 5H-dibenzo[d,f][1,3]diazepinyl or 5-oxa-7-aza-dibenzo[a,c]cycloheptenyl group, a naphtho[1,2-d]oxazolyl, naphtho[2,1-d]oxazolyl, naphtho[1,2-d]thiazolyl, naphtho[2,1-d]thiazolyl, naphtho[1,2-d]imidazolyl, naphtho[1,2-b]furanyl or naphtho[2,1-b]furanyl group, or a furo[3,2-c]isoquinolinyl, pyrazolo[1,5-c]quinazolinyl or 1H-perimidinyl group, while the benzo groups of the above mentioned radicals R a are substituted by the groups R10 to R13 and the alkylene units of the above mentioned groups R a may be substituted by one or two fluorine atoms or one or two C1-3-alkyl or C1-3-alkyloxy-carbonyl groups and the imino groups of the above mentioned radicals R a may be substituted by a C1-3-alkyl group and R10 denotes a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, a C1-3-alkyl or cyclopropyl group, a hydroxy, C1-3-alkyloxy or cyclopropyloxy group, a nitro, amino, C1-3-alkylamino or di-(C1-3-alkyl)amino group, a C1-3-alkyl-carbonylamino or C1-3-alkyl-sulphonylamino group, a cyano, carboxy, C1-3-alkyloxy-carbonyl, aminocarbonyl, C1-3-alkyl-aminocarbonyl or di-(C1-3-alkyl)-aminocarbonyl group, a mercapto, C1-3-alkylsulphanyl, C1-3-alkysulphinyl, C1-3-alkylsulphonyl or aminosulphonyl group or a difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy group and R11, R12 and R13, which may be identical or different, in each case represent a hydrogen atom, a fluorine, chlorine or bromine atom, a methyl, trifluoromethyl or methoxy group, R2 denotes a hydrogen atom or a C1-3-alkyl, cyclopropyl, trifluoromethyl, cyanomethyl or 2-cyano-ethyl group, Y denotes a nitrogen atom or a group of formula C-R5, while R5 denotes a hydrogen atom or a C1-3-alkyl group, R3 denotes a 2-buten-1-yl or 3-methyl-2-buten-1-yl group, a 1-buten-1-yl group, a 2-butyn-1-yl group or a 1-cyclopenten-1-ylmethyl group and R4 denotes a (3-amino-piperidin-1-yl) group, while, unless otherwise stated, the above mentioned alkyl groups may be straight-chain or branched, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
3. Compounds of general formula I according to claim 2, wherein R1 denotes a methyl group substituted by a group R a, where R a denotes a 3,4-dihydro-quinolin-2-yl group, a 3,4-dihydro-isoquinolin-1-yl group, a 1,4-dihydro-quinazolin-2-yl or 4-oxo-1,4-dihydro-quinazolin-2-yl group, a 3,4-dihydro-quinazolin-2-yl or 4-oxo-3,4-dihydro-quinazolin-2-yl group, a 1H-benzo[d][1,2]oxazin-4-yl or 1-oxo-1H-benzo[d][1,2]oxazin-4-yl group, a 4H-benzo[e][1,3]oxazin-2-yl or 4-oxo-4H-benzo[e][1,3)oxazin-2-yl group, a 4H-benzo[d][1,3)oxazin-2-yl or 4-oxo-4H-benzo[d][1,3]oxazin-2-yl group, a 2H-benzo[1,4]oxazin-3-yl or 2-oxo-2H-benzo[1,4]oxazin-3-yl group, a 4H-benzo(e][1,3]thiazin-2-yl or 4-oxo-4H-benzo[e][1,3]thiazin-2-yl group, a 4H-benzo[d][1,3]thiazin-2-yl or 2H-benzo[1,4]thiazin-3-yl group, a 2-oxo-2H-benzo[e][1,3]oxazin-4-yl or 2,2-dioxo-1H-benzo[c][1,2]thiazin-4-yl group, a 2,3-dihydro-1H benzo[e][1,4]diazepin-5-yl or 2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl group, a 4,5-dihydro-3H-benzo[b][1,4]diazepin-2-yl or 4-oxo-4,5-dihydro-3H-benzo[b][1,4]diazepin-2-yl group, a 5-oxo-4,5-dihydro-3H-benzo[e][1,4]diazepin-2-yl group, a 2,3-dihydro-benzo[f][1,4]oxazepin-5-yl or 2,3-dihydro-benzo[b][1,4]oxazepin-
4-yl group, a 2,3-dihydro-benzo[f][1,4]thiazepin-5-yl or 2,3-dihydro-benzo[b][1,4]thiazepin-4-yl group, a 5-oxo-4,5-dihydro-benzo[f][1,3,4]oxadiazepin-2-yl group, a 11H-dibenzo[b,e]azepin-6-yl or 11-oxo-11H-dibenzo[b,e]azepin-6-yl group, a 11H-benzo[e]pyrido[3,2-b]azepin-6-yl or a 5H-1,9,10-triaza-dibenzo[a,d]-cyclohepten-11-yl group, a 5H-dibenzo[b,e][1,4]diazepin-11-yl or dibenzo[b,f][1,4]oxazepin-11-yl group, a dibenzo[b,f][1,4]thiazepin-11-yl, 5-oxo-dibenzo[b,f][1,4]thiazepin-11-yl or
5,5-dioxo-dibenzo[b,f][1,4]thiazepin-11-yl group, a 5H-dibenzo[a,d]cyclohepten-10-yl or 5H-dibenzo[b,f]azepin-10-yl group, a phenanthridin-6-yl, benzo[c][1,5]naphthyridin-6-yl, benzo[h][1,6]naphthyridin-5-yl, benzo[c][1,8]naphthyridin-6-yl, benzo[f][1,7]naphthyridin-5-yl or 1,5,9-triaza-phenanthren-10-yl group, a 1,2,3,4-tetrahydro-phenanthridin-6-yl, 1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl, 2,3-dihydro-1H-4-aza-cyclopenta[a]naphth-5-yl or 8,9,10,11-tetrahydro-7H-6-aza-cyclohepta[a]naphth-5-yl group, a 2,3-dihydro-1H-4-oxa-10-aza-phenanthren-9-yl or 1-oxo-2,3-dihydro-1H-4-oxa-10-aza-phenanthren-9-yl group, a phenanthren-9-yl, benzo[h]quinolin-6-yl, benzo[f]quinolin-6-yl or benzo[f]quinoxalin-6-yl group, a 5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-11-yl, thieno[3,2-b][1,4]benzoxaze-pin-9-yl, 5H-dibenzo[d,f][1,3]diazepin-6-yl or 5-oxa-7-aza-di-benzo[a,c]cyclohepten-6-yl group, a naphtho[1,2-d]oxazol-2-yl, naphtho[2,1-d]oxazol-2-yl, naphtho[1,2-d]thiazol-2-yl, naphtho[2,1-d]thiazol-2-yl, naphtho[1,2-d]imidazol-2-yl, naphtho[1,2-b]furan-2-yl or naphtho[2,1-b]furan-2-yl group, or a furo[3,2-c]isoquinolin-5-yl, pyrazolo[1,5-c]quinazolin-5-yl or 1H-perimidin-2-yl group, while the benzo groups of the above mentioned radicals R a are substituted by the groups R10 to R13 and the alkylene units of the above mentioned groups R a may be substituted by one or two fluorine atoms or one or two methyl groups and the imino groups of the above mentioned radicals R a may be substituted by a methyl group and R10 denotes a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, a methyl or ethyl group, a hydroxy, methoxy or ethoxy group or a difluoromethyl, trifluoromethyl, difluoromethoxy, or trifluoromethoxy group and R11, R12 and R13, which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom or a methyl, trifluoromethyl or methoxy group, R2 denotes a hydrogen atom or a methyl, cyanomethyl, trifluoromethyl, ethyl, 2-cyano-ethyl, propyl, cyclopropyl or isopropyl group, Y denotes a nitrogen atom or a group of formula C-R5, while R5 denotes a hydrogen atom or a methyl, ethyl, propyl or isopropyl group, R3 denotes a 2-buten-1-yl or 3-methyl-2-buten-1-yl group, a 1-buten-1-yl group, a 2-butyn-1-yl group or a 1-cyclopenten-1-ylmethyl group and R4 denotes a (3-amino-piperidin-1-yl) group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
4. Compounds of general formula I according to claim 1, wherein R1 denotes a 4-oxo-3,4-dihydro-quinazolin-2-ylmethyl group, a dibenzo[b,f][1,4]oxazepin-11-ylmethyl group, a phenanthridin-6-ylmethyl group, a phenanthren-9-ylmethyl group or a naphtho[1,2-d]oxazol-2-ylmethyl or naphtho[2,1-d]oxazol-2-ylmethyl group, R2 denotes a hydrogen atom or a methyl group, Y denotes a nitrogen atom, R3 denotes a 2-butyn-1-yl group and R4 denotes a (3-amino-piperidin-1-yl) group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
5. The following compounds of general formula I according to claim 1:
(1) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (2) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (3) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthren-9-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (4) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (5) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (6) 2-((S)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (7) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (8) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[2,1-d]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (9) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[1,2-d]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (10) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one the enantiomers, the mixtures thereof and the salts thereof.
4. Compounds of general formula I according to claim 1, wherein R1 denotes a 4-oxo-3,4-dihydro-quinazolin-2-ylmethyl group, a dibenzo[b,f][1,4]oxazepin-11-ylmethyl group, a phenanthridin-6-ylmethyl group, a phenanthren-9-ylmethyl group or a naphtho[1,2-d]oxazol-2-ylmethyl or naphtho[2,1-d]oxazol-2-ylmethyl group, R2 denotes a hydrogen atom or a methyl group, Y denotes a nitrogen atom, R3 denotes a 2-butyn-1-yl group and R4 denotes a (3-amino-piperidin-1-yl) group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
5. The following compounds of general formula I according to claim 1:
(1) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (2) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (3) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthren-9-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (4) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (5) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (6) 2-((S)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (7) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (8) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[2,1-d]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (9) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[1,2-d]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (10) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one the enantiomers, the mixtures thereof and the salts thereof.
6. Physiologically acceptable salts of the compounds according to claims 1 to 5 with inorganic or organic acids.
7. Pharmaceutical compositions containing a compound according to at least one of claims 1 to 5 or a salt according to claim 6 optionally together with one or more inert carriers and/or diluents.
8. Use of a compound according to at least one of claims 1 to 5 or a salt according to claim 6 for preparing a pharmaceutical composition which is suitable for the treatment of type I and type II diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis caused by calcitonin.
9. Process for preparing a pharmaceutical composition according to claim 7, characterised in that a compound according to at least one of claims 1 to 5 or a salt according to claim 6 is incorporated in one or more inert carriers and/or diluents by a non-chemical method.
10. Process for preparing the compounds of general formula I according to claims 1 to 6, characterised in that a) a compound of general formula wherein R1, R2, Y and R3 are as hereinbefore defined and R4" denotes one of the groups mentioned for R4 hereinbefore which contain an imino, amino or alkylamino group, where the imino, amino or alkylamino group is substituted by a protective group, is deprotected and subsequently, if desired, a protective group used during the reactions to protect reactive groups is cleaved, and/or a compound of general formula I thus obtained is resolved into its stereoisomers and/or a compound of general formula I thus obtained is converted into its salts, particularly for pharmaceutical use into the physiologically acceptable salts thereof with an inorganic or organic acid.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10327439A DE10327439A1 (en) | 2003-06-18 | 2003-06-18 | Novel imidazopyridazinone and imidazopyridone derivatives, their production and their use as pharmaceuticals |
DEDE10327439.1 | 2003-06-18 | ||
PCT/EP2004/006303 WO2004111051A1 (en) | 2003-06-18 | 2004-06-11 | Imidazo-pyridazinone derivatives and imidazo-pyridone derivatives, production thereof, and use thereof as medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2529729A1 true CA2529729A1 (en) | 2004-12-23 |
Family
ID=33495124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002529729A Abandoned CA2529729A1 (en) | 2003-06-18 | 2004-06-11 | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1641799B8 (en) |
JP (1) | JP2006527717A (en) |
AT (1) | ATE388952T1 (en) |
CA (1) | CA2529729A1 (en) |
DE (2) | DE10327439A1 (en) |
ES (1) | ES2301996T3 (en) |
WO (1) | WO2004111051A1 (en) |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7393847B2 (en) | 2004-03-13 | 2008-07-01 | Boehringer Ingleheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7439370B2 (en) | 2004-05-10 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
US7470716B2 (en) | 2004-06-24 | 2008-12-30 | Boehringer Ingelheim International Gmbh | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7495003B2 (en) | 2004-09-11 | 2009-02-24 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7495002B2 (en) | 2004-09-14 | 2009-02-24 | Boehringer Ingelheim International Gmbh | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7495005B2 (en) | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US7550455B2 (en) | 2003-11-27 | 2009-06-23 | Boehringer Ingelheim International Gmbh | 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition |
US7560450B2 (en) | 2002-11-21 | 2009-07-14 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7566707B2 (en) | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7569574B2 (en) | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7645763B2 (en) | 2004-02-23 | 2010-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition |
US7820815B2 (en) | 2004-11-05 | 2010-10-26 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines |
US8071583B2 (en) | 2006-08-08 | 2011-12-06 | Boehringer Ingelheim International Gmbh | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus |
US8106060B2 (en) | 2005-07-30 | 2012-01-31 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US8232281B2 (en) | 2006-05-04 | 2012-07-31 | Boehringer Ingelheim International Gmbh | Uses of DPP-IV inhibitors |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US8846695B2 (en) | 2009-01-07 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
US8853156B2 (en) | 2008-08-06 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US9149478B2 (en) | 2010-06-24 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
US9155705B2 (en) | 2008-04-03 | 2015-10-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9186392B2 (en) | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9266888B2 (en) | 2006-05-04 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9457029B2 (en) | 2009-11-27 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9486526B2 (en) | 2008-08-06 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
US9526730B2 (en) | 2012-05-14 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9713618B2 (en) | 2012-05-24 | 2017-07-25 | Boehringer Ingelheim International Gmbh | Method for modifying food intake and regulating food preference with a DPP-4 inhibitor |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005051949A1 (en) * | 2003-11-26 | 2007-06-21 | 住友製薬株式会社 | New condensed imidazole derivatives |
DE10359098A1 (en) * | 2003-12-17 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel 2- (piperazin-1-yl) and 2 - ([1,4] diazepan-1-yl) imidazo [4,5-d] pyridazin-4-ones, their preparation and their use as pharmaceuticals |
DE10360835A1 (en) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis |
CA2561210A1 (en) * | 2004-04-10 | 2005-10-20 | Boehringer Ingelheim International Gmbh | Novel 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones, production and use thereof as medicaments |
US7179809B2 (en) | 2004-04-10 | 2007-02-20 | Boehringer Ingelheim International Gmbh | 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions |
DE102004022970A1 (en) * | 2004-05-10 | 2005-12-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel imidazole derivatives, their preparation and their use as intermediates for the manufacture of medicines and pesticides |
DOP2006000008A (en) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1 |
EP1942898B2 (en) | 2005-09-14 | 2014-05-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
KR101368988B1 (en) | 2005-09-16 | 2014-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | Dipeptidyl peptidase inhibitors |
PL1971862T3 (en) | 2006-04-11 | 2011-04-29 | Arena Pharm Inc | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual |
PE20071221A1 (en) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS |
EP2063890A1 (en) * | 2006-09-07 | 2009-06-03 | Nycomed GmbH | Combination treatment for diabetes mellitus |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
CL2008002427A1 (en) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus. |
KR101610005B1 (en) | 2007-08-17 | 2016-04-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Purin derivatives for use in the treatment of FAB-related diseases |
EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
BRPI0917675A2 (en) | 2008-08-15 | 2015-12-01 | Boehringer Ingelheim Int | wound healing organic compounds |
AR075204A1 (en) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | DPP-4 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USEFUL TO TREAT METABOLIC DISEASES IN PEDIATRIC PATIENTS, PARTICULARLY MELLITUS DIABETES TYPE 2 |
EA022349B1 (en) | 2009-02-13 | 2015-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and a further antidiabetic agent and uses thereof |
KR20160143897A (en) | 2009-02-13 | 2016-12-14 | 베링거 인겔하임 인터내셔날 게엠베하 | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
AR077642A1 (en) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME |
JO3257B1 (en) | 2009-09-02 | 2018-09-16 | Novartis Ag | Compounds and compositions as tlr activity modulators |
WO2011039367A2 (en) | 2009-10-02 | 2011-04-07 | Boehringer Ingelheim International Gmbh | Therapeutic uses of pharmaceutical compositions |
US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
BR112012025592A2 (en) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | gpr119 receptor modulators and the treatment of disorders related thereto |
AU2011249771A1 (en) | 2010-05-05 | 2012-11-01 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations comprising pioglitazone and linagliptin |
EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
UY34484A (en) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | BENZOTIENILO-PIRROLOTRIAZINAS DISUSTITUIDAS AND ITS USES |
US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
WO2013174768A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada |
WO2014045266A1 (en) | 2012-09-24 | 2014-03-27 | Ulf Eriksson | Treatment of type 2 diabetes and related conditions |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
EA037712B1 (en) | 2013-03-15 | 2021-05-13 | Бёрингер Ингельхайм Интернациональ Гмбх | Cardio- and renoprotective antidiabetic therapy |
AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11285180B2 (en) | 2016-12-06 | 2022-03-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
JP2020515639A (en) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | PPARγ agonists for the treatment of progressive supranuclear palsy |
JP7025885B2 (en) * | 2017-10-18 | 2022-02-25 | 株式会社日本触媒 | Nitrogen-containing condensed polycyclic complex aromatic ring compound |
WO2024091863A1 (en) | 2022-10-25 | 2024-05-02 | Starrock Pharma Llc | Combinatorial, and rotational combinatorial therapies for obesity and other diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4242459A1 (en) * | 1992-12-16 | 1994-06-23 | Merck Patent Gmbh | imidazopyridines |
DE4339868A1 (en) * | 1993-11-23 | 1995-05-24 | Merck Patent Gmbh | imidazopyridazines |
NZ504452A (en) * | 1997-12-05 | 2002-05-31 | Astrazeneca Uk Ltd | [3,4-d]Pyridazinones, process for their preparation and pharmaceutical compositions containing them |
MXPA02012272A (en) * | 2000-07-04 | 2003-04-25 | Novo Nordisk As | Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv. |
JP3675813B2 (en) * | 2002-06-06 | 2005-07-27 | エーザイ株式会社 | New condensed imidazole derivatives |
UY28103A1 (en) * | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | NEW IMIDAZO-PIRIDINONAS REPLACED, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS |
-
2003
- 2003-06-18 DE DE10327439A patent/DE10327439A1/en not_active Withdrawn
-
2004
- 2004-06-11 EP EP04736644A patent/EP1641799B8/en not_active Expired - Lifetime
- 2004-06-11 JP JP2006515894A patent/JP2006527717A/en active Pending
- 2004-06-11 AT AT04736644T patent/ATE388952T1/en active
- 2004-06-11 DE DE502004006507T patent/DE502004006507D1/en not_active Expired - Lifetime
- 2004-06-11 ES ES04736644T patent/ES2301996T3/en not_active Expired - Lifetime
- 2004-06-11 WO PCT/EP2004/006303 patent/WO2004111051A1/en active IP Right Grant
- 2004-06-11 CA CA002529729A patent/CA2529729A1/en not_active Abandoned
Cited By (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US10023574B2 (en) | 2002-08-21 | 2018-07-17 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9556175B2 (en) | 2002-08-21 | 2017-01-31 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions |
US10202383B2 (en) | 2002-08-21 | 2019-02-12 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8119648B2 (en) | 2002-08-21 | 2012-02-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9321791B2 (en) | 2002-08-21 | 2016-04-26 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9108964B2 (en) | 2002-08-21 | 2015-08-18 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8178541B2 (en) | 2002-08-21 | 2012-05-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8664232B2 (en) | 2002-08-21 | 2014-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7569574B2 (en) | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7495005B2 (en) | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
US7838529B2 (en) | 2002-08-22 | 2010-11-23 | Boehringer Ingelheim International Gmbh | Xanthine derivates, their preparation and their use in pharmaceutical compositions |
US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7696212B2 (en) | 2002-11-08 | 2010-04-13 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7560450B2 (en) | 2002-11-21 | 2009-07-14 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7566707B2 (en) | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
US8034941B2 (en) | 2003-06-18 | 2011-10-11 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7550455B2 (en) | 2003-11-27 | 2009-06-23 | Boehringer Ingelheim International Gmbh | 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition |
US8697868B2 (en) | 2004-02-18 | 2014-04-15 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US7645763B2 (en) | 2004-02-23 | 2010-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition |
US7393847B2 (en) | 2004-03-13 | 2008-07-01 | Boehringer Ingleheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
US7432262B2 (en) | 2004-03-13 | 2008-10-07 | Boehringer Ingelheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
US7667035B2 (en) | 2004-05-10 | 2010-02-23 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
US7439370B2 (en) | 2004-05-10 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
US7906539B2 (en) | 2004-06-24 | 2011-03-15 | Boehringer Ingelheim International Gmbh | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
US7470716B2 (en) | 2004-06-24 | 2008-12-30 | Boehringer Ingelheim International Gmbh | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
US7495003B2 (en) | 2004-09-11 | 2009-02-24 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7495002B2 (en) | 2004-09-14 | 2009-02-24 | Boehringer Ingelheim International Gmbh | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7820815B2 (en) | 2004-11-05 | 2010-10-26 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines |
US8541450B2 (en) | 2004-11-05 | 2013-09-24 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines |
US9499546B2 (en) | 2004-11-05 | 2016-11-22 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US9751855B2 (en) | 2004-11-05 | 2017-09-05 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US8883805B2 (en) | 2004-11-05 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US8637530B2 (en) | 2005-07-30 | 2014-01-28 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US8106060B2 (en) | 2005-07-30 | 2012-01-31 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US11919903B2 (en) | 2006-05-04 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9493462B2 (en) | 2006-05-04 | 2016-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
US11291668B2 (en) | 2006-05-04 | 2022-04-05 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US10080754B2 (en) | 2006-05-04 | 2018-09-25 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US11084819B2 (en) | 2006-05-04 | 2021-08-10 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9815837B2 (en) | 2006-05-04 | 2017-11-14 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9173859B2 (en) | 2006-05-04 | 2015-11-03 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
US10301313B2 (en) | 2006-05-04 | 2019-05-28 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9266888B2 (en) | 2006-05-04 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Polymorphs |
US8673927B2 (en) | 2006-05-04 | 2014-03-18 | Boehringer Ingelheim International Gmbh | Uses of DPP-IV inhibitors |
US8232281B2 (en) | 2006-05-04 | 2012-07-31 | Boehringer Ingelheim International Gmbh | Uses of DPP-IV inhibitors |
US8071583B2 (en) | 2006-08-08 | 2011-12-06 | Boehringer Ingelheim International Gmbh | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus |
US10022379B2 (en) | 2008-04-03 | 2018-07-17 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US10973827B2 (en) | 2008-04-03 | 2021-04-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9155705B2 (en) | 2008-04-03 | 2015-10-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9415016B2 (en) | 2008-04-03 | 2016-08-16 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US8853156B2 (en) | 2008-08-06 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US9486526B2 (en) | 2008-08-06 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US10034877B2 (en) | 2008-08-06 | 2018-07-31 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
US9212183B2 (en) | 2008-12-23 | 2015-12-15 | Boehringer Ingelheim International Gmbh | Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine |
US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
US8846695B2 (en) | 2009-01-07 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
US10092571B2 (en) | 2009-11-27 | 2018-10-09 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9457029B2 (en) | 2009-11-27 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9603851B2 (en) | 2010-05-05 | 2017-03-28 | Boehringer Ingelheim International Gmbh | Combination therapy |
US10004747B2 (en) | 2010-05-05 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9186392B2 (en) | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9149478B2 (en) | 2010-06-24 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US11911387B2 (en) | 2010-11-15 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US8962636B2 (en) | 2011-07-15 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9199998B2 (en) | 2011-07-15 | 2015-12-01 | Boehringer Ingelheim Internatioal Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US10195203B2 (en) | 2012-05-14 | 2019-02-05 | Boehringr Ingelheim International GmbH | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US9526730B2 (en) | 2012-05-14 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US9713618B2 (en) | 2012-05-24 | 2017-07-25 | Boehringer Ingelheim International Gmbh | Method for modifying food intake and regulating food preference with a DPP-4 inhibitor |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
Also Published As
Publication number | Publication date |
---|---|
JP2006527717A (en) | 2006-12-07 |
DE502004006507D1 (en) | 2008-04-24 |
DE10327439A1 (en) | 2005-01-05 |
EP1641799B8 (en) | 2008-10-08 |
ES2301996T3 (en) | 2008-07-01 |
EP1641799B1 (en) | 2008-03-12 |
EP1641799A1 (en) | 2006-04-05 |
WO2004111051A1 (en) | 2004-12-23 |
ATE388952T1 (en) | 2008-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2529729A1 (en) | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | |
US7566707B2 (en) | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | |
CA2505389C (en) | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | |
CA2508233C (en) | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | |
US7482337B2 (en) | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | |
US7109192B2 (en) | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | |
US7560450B2 (en) | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | |
US7393847B2 (en) | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | |
CA2575751A1 (en) | 8-(3-amino-piperidin-1-yl)-7-(but-2-inyl)-xanthines, production thereof and use thereof as medicaments | |
US7569574B2 (en) | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions | |
CA2548323C (en) | Bicyclic imidazole derivatives, the preparation thereof and their use as pharmaceutical compositions | |
US8293735B2 (en) | Thienopyrimidine derivatives as P13K inhibitors | |
US7470716B2 (en) | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions | |
US7217711B2 (en) | Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions | |
AU2002217007B2 (en) | Benzodiazepine derivatives as GABA A receptor modulators | |
CA2543074A1 (en) | Novel 2-(piperazin-1-yl)- and 2-([1,4]diazepan-1-yl)- imidazo[4,5-d]pyridazin-4-one, production and use thereof as medicament for the treatment of diabetes mellitus | |
CA2496325A1 (en) | Phenacyl xanthine derivatives as dpp-iv inhibitor | |
CA2561210A1 (en) | Novel 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones, production and use thereof as medicaments | |
CA2496211A1 (en) | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | |
US20110245291A1 (en) | Tricyclic delta-opioid modulators | |
RO117698B1 (en) | Imidazo-diazepine derivatives and process for preparing the same | |
IL95622A (en) | N-(n-alkyl diazaspiroalkylcarbonyl) substituted tricyclic 1, 4-diazepinones, their preparation andpharmaceutical compositions containing them | |
CA2559444A1 (en) | Imidazopyridazine diones, the production thereof, and the use of the same as a medicament | |
JPWO2006098519A1 (en) | Pyrazolopyrimidine derivatives or medically acceptable salts thereof | |
GB2174695A (en) | Heteroanalogs of imidazobenzodiazepines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |